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The goal of this dissertation was to examine the pathogenic potential of
microglia in globoid cell leukodystrophy (GLD). We determined that psychosine,
the pathogenic lipid toxin that accumulates in GLD, induced microglial
transformation to globoid cells in vitro. Psychosine also induced matrix
metalloproteinase (MMP)-3 in cultured glia. This mirrored the elevated expression
of MMP-3 in the central nervous system (CNS) of twitcher mice, a murine model
of GLD. Pharmacological inhibition or genetic ablation of MMP-3 blocked
psychosine-induced globoid cell formation in vitro. These findings indicate that
MMP-3 mediated psychosine-induced globoid cell formation. These findings were
the first to relate the putative functions of MMPs in the CNS pathogenesis of a
leukodystrophy.
We next determined the effects of the extracellular matrix (ECM) in GLD
pathology. We determined that tenascin-c (TnC), an ECM molecule, was
aberrantly expressed in the brain of murine and human GLD. We determined that
TnC enhances both psychosine-induced MMP-3 expression and globoid cell
formation in microglia. Additionally, TnC altered the phenotype of microglia and
globoid

cells

from

a

protective

toward

a

harmful

phenotype

toward

oligodendrocytes in co-cultures. These findings suggest that TnC modulates
cellular behaviors that may contribute to the GLD pathogenesis.
Overall, results of this thesis determined that microglial responses to
psychosine are a primary event of the pathogenesis in GLD. Overall, the findings
of this dissertation have provided a new level to our understanding of GLD
pathogenesis and provided new potential therapeutic targets to treat GLD.
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PREFACE
Portions of this dissertation have been previously published in the forms of
abstracts and manuscripts.
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General Overview
Globoid cell leukodystrophy (GLD) is a fatal demyelinating disease resulting
from mutations in the galactosylceramindase (GALC) gene. It is most prevalent among
infants. Due to the rapid nature of this disease’s progression, there are presently no
effective long-term therapies for GLD. The precise mechanisms underlying GLD
pathogenesis are not completely understood. This dissertation focused on the molecular
mechanisms of GLD pathogenesis with a particular focus on another poorly characterized
glial pathology of this disease. This dissertation explored how glial pathology arises in
GLD and provided a novel model for study of GLD-associated glial pathology, and
generated a novel hypothesis on the overall pathogenic mechanism of GLD.
Chapter 1 focuses on describing clinical aspects of GLD. The first case of GLD
is discussed, followed by a description of epidemiology, symptoms, and diagnosis of GLD.
The cause of GLD is also briefly discussed, though the detailed information of biological
key players is provided in the following chapter. Then, current therapies for GLD are
discussed, as well as the limitations and need for new therapeutic approaches.
The second chapter centers on pathophysiological aspects of GLD. This
chapter includes spontaneous animal models of GLD, cellular pathologies, psychosine
(the lipid toxin that accumulates in GLD) and a detailed description on the GALC gene
mutations causing GLD. The traditional pathophysiological hypothesis of GLD is
described, followed by emphasis on the emerging need for revision based on new
findings. I, thus, highlight the importance of microglia, and then the rationales of this
dissertation with its focus on microglia and astrocytes. Lastly, the specific aims of this
dissertation are laid out.
Chapter 3 focuses on the first part of specific aims: the involvement of matrix
metalloproteinase (MMP)-3 in GLD. First, changes in MMP-3 levels in GLD are shown.
Also, pathological glial responses to psychosine are described. This chapter ends with
the conclusion that glial responses to psychosine are mediated by MMP-3.
xvii

The main focus of chapter 4 illustrates the effects of the extracellular
microenvironment of glia with respect to the GLD pathogenesis. Elevated expression of
tenascin-c (TnC), an extracellular matrix (ECM) protein, in GLD brains is described. Next,
the effect of TnC on glial responses to psychosine is demonstrated. This chapter
concludes that localized changes in ECM molecules during the disease alter important
cellular behaviors, which likely contributes to GLD pathogenesis.
Chapter 5 begins with a summary of overall findings in this dissertation. Primary
findings include: the MMP-3 involvement in glial responses to psychosine and the
changes in glial functions by local TnC in the context of GLD pathology. A more detailed
discussion on the putative mechanisms by which MMP-3 and TnC regulate glial
responses in GLD, and future directions for research stemming from this work are
discussed. This chapter ends with a discussion on the therapeutic potentials of the results
of this dissertation and the applications of these findings to treat GLD.

xviii

CHAPTER ONE
Introduction to Globoid Cell Leukodystrophy

1

I-1 Globoid Cell Leukodystrophy (GLD)

I-1.1 History of GLD
Globoid cell leukodystrophy (GLD) was first described by a Danish physician,
Knud Krabbe, in 1916 (Krabbe, 1916). In his seminal report, he described five infants,
four of which were from two families in Copenhagen, that presented with violent crying
and extreme irritability starting at an age of four to six months (Krabbe, 1916). These
patients developed progressive muscular rigidity, tonic spasms evoked by auditory, tactile,
or visual stimuli, and an opisthotonic (hypertonic) posture (Krabbe, 1916). In addition,
these children experienced poor feeding, frequent episodes of fever of unknown cause,
and seizures (Krabbe, 1916). These patients became progressively fatigued and
unresponsive by the end stage of their condition. These patients eventually died by 11
months to 1.5 years of age (Krabbe, 1916).
Krabbe and his colleagues performed post-mortem analyses on these five
infant patients, and reported that all cases had hard and rubbery brain matter, unusual for
children of this age (Krabbe, 1916). Microscopic examination revealed that each case
had almost a complete loss of myelin, accompanied by extensive fibrous glial scarring,
which had replaced the damaged tissues (Krabbe, 1916). As well, prominent, large
“scavenger” cells, now referred to as “globoid cells”, were also observed in the brain
tissues of these patients (Krabbe, 1916, Matsuda, 2007). These globoid cells were
described as containing multiple nuclei, with granules, and in some cases had fatty debris
(Krabbe, 1916, Matsuda, 2007). Krabbe described these cases as “familial early infantile
diffuse brain sclerosis” (Krabbe, 1916), which represented a novel category of childhood
neurological disease. On account of this first description, this condition has been named
after him (Matsuda, 2007); thus, GLD is also called “Krabbe disease”.

2

I-1.2 Epidemiology
GLD is a rare disease with a worldwide prevalence. For example, GLD has
been identified in the United States of America (USA; 1/100,000 live births), Netherlands
(1.35/100,000), and Czech Republic (0.4/100,000) (Duffner et al., 2009, Poupetova et al.,
2010). GLD can occur more frequently in certain populations, such as the Druze tribe in
Israel, a religious minority community, where its incidence is 1/170 (Rafi et al., 1996,
Zlotogora et al., 1991, Zlotogora et al., 1985). Interestingly, no cases have been reported
in the Jewish population (Zlotogora, 2010, Zlotogora et al., 1991). In the United States,
GLD has garnered awareness on account of Hunter Kelly, son of Jim Kelly, the former
quarterback of the Buffalo Bills (1986-1996). Hunter was diagnosed with GLD soon after
his birth in 1997. Jim Kelly and his wife established a non-profit organization for GLD,
called "Hunter’s Hope", which has become the world’s largest non-profit center for GLD
research. Hunter's Hope now supports an Institute for GLD research at the Buffalo
Niagara Medical Campus. In 2006, New York State initiated a newborn screening of GLD
for all live birth cases with an expected incidence rate of 1/100,000 (Duffner et al., 2009).
Interestingly, this 4-year screening study, led by Patricia Duffner, a pediatric neurologist
specializing GLD, revealed the incidence of one in 250,000, which was lower than
expected (Duffner et al., 2011). There are no significant differences in the incidence of
GLD between males and females, indicating that the etiology and pathogenesis of GLD is
not gender-specific (Duffner et al., 2009).

I-1.3 Classification and Symptomatology of GLD
There are four forms of GLD classified on the basis of age of onset: infantile
(0-6 months old), late-infantile (7 months to 3 years old), juvenile (4-8 years old), and
adult (over 9 years old) forms (Table 1-1) (Kolodny et al., 1991, Matsuda, 2007, Wenger,
2001). The infantile form is the most common type of GLD representing over 90% of GLD
cases (Duffner et al., 2009, Wenger, 2001).

3

Table 1-1 Clinical Manifestations in four types of GLD

4

The disease course of infantile GLD can be categorized into three clinical phases (I, II,
and III) (Duffner et al., 2009, Hagberg et al., 1963). Phase I includes irritability,
hyperesthesia, episodic idiopathic fever, limb stiffness, seizure, vomiting, and poor
feeding (Duffner et al., 2009, Wenger, 2001). In phase II, rapid and severe motor and
mental retardation become prominent along with hypertonic posture, including extended
and crossed legs, flexed arms, and head bent backward (Wenger, 2001). Optic atrophy
and abnormal pupillary reflex can be also observed (Harris et al., 1996, Wenger, 2001).
The final stage, phase III of infantile GLD, also known as the “burnt-out” stage, can be
reached within only a few months of onset (Wenger, 2001). Patients at this stage of the
disease are blind and deaf, and exhibit no responsiveness to their surroundings. Most
infantile GLD patients die within two years of clinical disease onset (Duffner et al., 2009,
Hagberg et al., 1963).
In late-onset GLD, including late-infant, juvenile, and adult forms, the clinical
symptoms are similar to those seen in infantile GLD (Duffner et al., 2012). However, the
disease course and severity vary greatly among patients compared to infantile forms of
GLD (Duffner et al., 2012, Phelps et al., 1991). For example, one 12-year-old girl
diagnosed with adult-onset GLD developed a progressive hemiplegia with fixed posture
and became intellectually deteriorated over a few years after onset (Phelps et al., 1991).
On the other hand, her 16-year-old brother, who was also diagnosed with an adult variant
of GLD, showed minor difficulty in walking with impaired visual acuity, but remained
intellectually intact and was able to perform social activities for over three year after his
diagnosis (Phelps et al., 1991). Overall, the progression of the disease and the degree of
severity in late-onset GLD are generally milder than in early-onset infantile GLD (Duffner
et al., 2012).
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I-1.4 Causes
For over 50 years after Krabbe’s first report, the pathophysiology and the cause
of GLD were unknown. In 1970, Suzuki and colleagues identified a deficiency in a
lysosomal enzyme, called galactosylceramidase (GALC), in brain, liver, and spleen
samples from GLD patients (Suzuki and Suzuki, 1970). GALC enzymatic activity in all
GLD patients was either non-detectable or significantly lowered by over 90% from normal
(Duffner et al., 2009). Suzuki et al. also demonstrated that the central nervous system
(CNS) of patients with GLD had a significant accumulation of the sphingolipid
intermediate, galactosylsphingosine, a substrate for GALC also known as ‘psychosine’
(Miyatake and Suzuki, 1972). This metabolic association with GLD has lead to a focus on
the study of psychosine as the causal agent in GLD. Psychosine accumulates in multiple
organs in GLD, including the brain, spinal cord, and kidney, without exception (Suzuki,
1998, Wenger, 2000). Additionally, psychosine has been shown to have cytotoxic effects
on multiple cell types from both the CNS and peripheral organs (Castelvetri et al., 2011,
Cho et al., 1997, Galbiati et al., 2007, Taketomi and Nishimura, 1964, Whitfield et al.,
2001, Zaka and Wenger, 2004, Zhang et al., 2013, Zhu et al., 2012). Thus, GLD is
currently thought to arise from the deficiency of GALC leading to a significant
accumulation of psychosine, resulting in the pathology. This notion is now referred to as
the “psychosine hypothesis”, described in more detail in Chapter Two.
In 1993, the complementary deoxyribonucleic acid (cDNA) sequence of GALC
was successfully cloned from human brain and urine samples (Chen et al., 1993, Sakai et
al., 1994). Since then, multiple studies have reported genetic mutations within the coding
region of the GALC gene in GLD patients (Kleijer et al., 1997, Kukita et al., 1997, Luzi et
al., 1995, Luzi et al., 1996, Rafi et al., 1995, Rafi et al., 1996, Selleri et al., 2000). Prior to
the discovery of GALC mutations, it had been speculated that GLD was an inherited
disorder mediated by a genomic defect (Krabbe, 1916, Miyatake and Suzuki, 1972,
Suzuki and Suzuki, 1970).
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Indeed, GLD is now defined as a genetic disorder resulting from GALC mutations that
have an autosomal recessive pattern of inheritance.

I-1.5 Diagnosis
The most definitive diagnostic test for GLD is a genetic mutation analysis,
followed by an enzymatic activity test for GALC. As described above, GALC is a
lysosomal enzyme deficient in GLD patients due to GALC gene mutations (Duffner et al.,
2009). If GALC activity is less than 0.5nmol/h/mg protein in a blood sample, the patient is
considered “at risk” (Duffner et al., 2009). The diagnostic procedure usually requires
multiple neurological and non-neurological diagnostic tests prior to the definitive tests for
GLD. Protein levels in the cerebrospinal fluid (CFS) collected via lumbar puncture are
usually higher in symptomatic patients with GLD (25mg/dL above normal) (Duffner et al.,
2011), suggesting that an abnormal process, such as a tumor, bleeding, or inflammation,
exists within the CNS. Neuroimaging is also a powerful resource, which can be used to
analyze anatomical abnormalities and inflammation in GLD. Neuroimaging examinations
of GLD cases have identified white matter abnormalities in areas such as pyramidal tracts,
cerebellar white matter, and the corpus callosum in magnetic resonance image (MRI;
76.2% of GLD cases) and computer tomography (CT; 66.7% of GLD cases) (Duffner et
al., 2011). Indeed, over half of GLD patients have T2 MRI hyperintensities in the white
matter of periventricular, cerebellar white matter, and/or the corpus callosum (Duffner et
al., 2011). Some exhibit an enlargement of the optic nerve or optic chiasm, atrophy,
and/or delayed myelination (Duffner et al., 2011). Interestingly, scans of some GLD
patients with infantile GLD have been reported not to show any abnormalities (Duffner et
al., 2011); neuroimaging may, therefore, be unreliable for diagnosis of this disease.
Additionally, in pre-symptomatic individuals with GLD, MRI can show non-specific
hyperintensities, which are not definitive for a diagnosis of GLD (Duffner et al., 2009).
These diagnostic results indicate that some neurological exams, including neuroimaging,
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may be more useful for a differential diagnosis rather than an initial diagnosis of GLD
(Wenger, 2001). Importantly, almost all infantile cases exhibit neurophysiologic
aberrations, most notably in their nerve conduction velocity and brainstem auditory
evoked responses, even among pre-symptomatic patients (Duffner et al., 2011, Duffner
et al., 2009). Overall, low GALC activity, identification of GALC mutations, along with
neurological exam abnormalities, are the current standard for establishing a diagnosis of
GLD (Duffner et al., 2009, Wenger, 2001).

I-2 Anatomical Pathology of GLD
Postmortem histological analyses of GLD CNS tissues have provided insights
on tissue and cellular findings. One prominent and remarkable finding is the almost
complete loss of myelin throughout the CNS in GLD, which is almost always
accompanied by extensive fibrillary gliosis around damaged areas. Macrophage
infiltration and the presence of large multinucleated phagocytes referred to as “globoid
cells” are also hallmarks of GLD pathology (Krabbe, 1916, Percy et al., 1994, Sakai,
2009). The demyelinated white matter areas in GLD are frequently replaced with hard,
rubbery, and translucent tissues (Itoh et al., 2002). Most GLD cases present with brain
atrophy and enlargement of the lateral ventricles (Itoh et al., 2002, Krabbe, 1916).
Profound demyelinated lesions are found in the primary white matter tracts of the CNS,
including the corona radiata, corpus callosum, and cerebellar peduncles (Itoh et al.,
2002). Frequently, severe demyelinating loci contain spongy-like microcystic cavitation,
which can also be observed in other leukodystrophies (Cheon et al., 2002, Itoh et al.,
2002). However, the origin and indication of these microcysts in GLD are unknown.
Fibrillary astrogliosis is also evident in both white and grey matter, including cerebral
white matter, the globus pallidus, thalamus, cerebellum, and brain stem (Itoh et al., 2002).
Severe neuronal damage with overt neuronal loss has been reported in the thalamus,
cerebellum, dentate nucleus, and inferior olivary nuclei, whereas cerebral neurons are
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relatively spared (Itoh et al., 2002). Optic nerves are often atrophic, and in some cases
are grossly enlarged due to profound gliosis (Brownstein et al., 1978).
In the peripheral nervous system (PNS), peripheral neuropathy is evident in
both human and murine models of GLD (Hogan et al., 1969, Jacobs et al., 1982).
Histological analyses have revealed that sciatic nerves are enlarged and hardened from
endoneurial fibrosis (Jesionek-Kupnicka et al., 1997, Jones et al., 1999). Cross sections
of peripheral axons exhibit an ‘onion-ring bulb’ morphology, which is suggestive of
repeated de- and remyelination by Schwann cells (Matsuda, 2007, Matsumoto et al.,
1996). Peripheral macrophages are also present in these lesions, with a similar pattern of
association as globoid cells with myelin lesions within the CNS (Bernal and Lenn, 2000).
No structural abnormalities have been reported for other organs; thus, GLD is considered
a neurological disease (Hagberg et al., 1963, Krabbe, 1916, Sakai, 2009, Suzuki, 2002,
Wenger, 2001).
Interestingly, recent studies have indicated potential pathologic abnormalities in
other organs, suggesting that GALC deficiency may impact physiological functioning of
other organ systems in conjunction with the CNS. For example, it has been reported that
in twitcher mice, an authentic murine model of GLD, there is abnormal development of
femurs (Contreras et al., 2010). This study also reported alterations in hepatic function of
twitcher mice (Contreras et al., 2010). Another study reported atrophy of the thymus with
reduced numbers of immature T cells and mature lymphocytes in twitcher mice (Galbiati
et al., 2007). These findings, although they have not been confirmed in human GLD
cases, suggest that GLD may impact multiple organ systems.

I-3 Current Treatments for GLD
Our current understanding on the etiology and pathogenesis of GLD is based
upon the function of genetic mutations in the GALC gene, all of which result in a loss of
GALC function. This loss of GALC function leads to psychosine accumulation that is
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credited for the cellular damage, including oligodendrocyte death and demyelination.
Thus, the primary focus of therapies for GLD has been administering functional GALC.
Early studies using twitcher mice reported that intravenous or intraperitoneal
administration of GALC, or liposomes containing GALC, was unsuccessful; this was due
to failure of the administered GALC to reach or become incorporated into the CNS
(Kobayashi and Suzuki, 1982, Umezawa et al., 1985). However, Hoogerbrugge and
colleagues demonstrated that bone marrow transplantation (BMT), which increased
GALC activity by 7-8 fold, effectively reduced psychosine accumulation, lowered the
prevalence of globoid cells, and yielded some evidence of remyelination in the CNS of
twitcher mice (Hoogerbrugge et al., 1988). In addition, BMT increased lifespan by over 60
days in twitcher mice (Hoogerbrugge et al., 1988). BMT has also been shown to have
beneficial effects in patients with other lysosomal storage diseases, including
mocopolysaccharidosis and Gaucher’s disease, in which the pathology resembles
aspects of GLD (Gasper et al., 1984, Rappeport and Ginns, 1984). Thus, enzyme
replacement therapy via cell transplantation has become a major therapeutic strategy for
treating GLD.
Currently, the only effective treatment available for GLD patients is
hematopoietic stem cell transplantation (HSCT). This transplant approach can include
BMT or umbilical cord stem cell transplantation. The first HSCT for a GLD patient was
performed in 1989 at the University of Minnesota (Krivit et al., 1998). This first patient
showed a moderate to significant improvement, including reduced ataxia, hyperextended
limbs, and increased head control, with improvement in gait, language development,
cognition, and school performance (Krivit et al., 1998). After this report, HSCT became a
primary therapy for GLD patients.
The stem cells used for HSCT can be obtained from either bone marrow or
umbilical cord blood donation, where human leukocyte antigens (HLAs) match those of
the recipient (Escolar et al., 2005). After immuno-suppression of the recipient by
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chemotherapy or radiation, donor stem cells are then transplanted to a host intravenously
(Escolar et al., 2005, Yagasaki et al. , 2011). Chimerism of bone marrow cells is usually
confirmed about one month after HSCT (Yagasaki et al., 2011). To prevent
graft-versus-host disease, immunosuppressant agents, such as cyclosporin A, must be
administered for the life of the patient (Escolar et al., 2005).
As mentioned above, a primary objective of transplantation of hematopoietic
stem cells in GLD is for enzyme replacement therapy; that is to restore functional GALC
in GLD individuals. Donor stem cells, which reconstitute the bone marrow of the recipient,
are capable of producing functional GALC. When these cells proliferate and infiltrate into
the host CNS, they function to degrade the accumulated psychosine, thereby decreasing
the tissue damage and potentially promoting regeneration of myelin (Hoogerbrugge et al.,
1988). After one year of HSCT, hyperintensity signals by MRI have been reported to
decrease in the CNS white matter of some GLD patients (Krivit et al., 1998). Additionally,
protein levels in CSF have been reported to decline, and nerve conductive velocity
increases in some cases (Krivit et al., 1998). After several years of HSCT, some patients
have also shown improvement in cognition, gait, motor coordination, verbal learning, and
overall academic performance in school (Krivit et al., 1998). HSCT can also extend a
patient’s lifespan by decades (Duffner et al., 2012). Thus, currently HSCT is the primary
treatment option for GLD, although it may only provide limited benefit to some patients
and it is not readily available to all GLD patients. GLD patients who are not candidates for
HSCT may only receive symptom management and palliative care, such as
administration of anti-convulsion agents for seizures, rigorous physical therapy, and
assisted ventilation; however, these generally do not increase the lifespan of GLD
patients (Duffner et al., 2009).
Although the effectiveness of HSCT after diagnosis of GLD is usually greater in
patients with the late-onset variant than infantile GLD (Duffner et al., 2012, Krivit et al.,
1998), HSCT can be effective in both forms, when administered during the
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pre-symptomatic period (Escolar et al., 2005, Yagasaki et al., 2011). Disease onset of
infants is typically early in life, when HSCT would need to be implemented. Newborn
screening for GLD is not widespread and not mandatory in many locales; thus, it is rare
that HSCT can be provided to infantile GLD patients within the effective therapeutic
window (Duffner et al., 2011). Additionally, due to the need for sustained
immuno-suppression following HSCT, this therapy comes with a high risk for those prone
to infections (Escolar et al., 2005), making it common for family members to refuse HSCT
for their pre-symptomatic children (Duffner et al., 2011). Therefore, HSCT may be a
therapeutic option for some, but there is a need for safer long-term therapies for GLD
patients.
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CHAPTER TWO
Pathophysiology of GLD
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II-1 Animal Models of GLD

II-1.1 The Twitcher Mouse
In 1976, at the Jackson Laboratories, several mice of the inbred CE/J strain
presented with generalized tremor, low body weight, progressive weakness in limbs
around postnatal day (P)20, and then succumbed to premature death by P45 (Duchen et
al., 1980, Matsuda, 2007) (Table 2-1). Duchen and colleagues reported these cases and
named them, the “twitcher mouse” line (Duchen et al., 1980). Detailed analyses of
twitcher mice revealed a severe demyelination both in the CNS and PNS, extensive
gliosis, and the presence of multinucleated globoid cells with periodic acid Schiff (PAS)positive material inclusions (Duchen et al., 1980). All of these pathological findings are
comparable to human GLD pathology. When the GALC gene was cloned from the
twitcher mouse liver, a genetic analysis was performed and determined that the basis for
this murine form of GLD was a missense mutation of guanine (G)1017 adenine(A) in the
GALC gene (Sakai et al., 1996) (Table 2-1). Now, the twitcher mouse line is recognized
as an authentic mouse model of GLD resulting from a spontaneous mutation in the GALC
gene (Sakai et al., 1996, Suzuki and Taniike, 1995). Since the report by Duchen et al.,
numerous studies have used these twitcher mice to study the pathogenesis of GLD
(Hoogerbrugge et al., 1988, Kobayashi et al., 1980, Matthieu and Omlin, 1984, Scaravilli
and Suzuki, 1983, Suzuki, 1995, Suzuki, 1998, Suzuki et al., 2003). Although pathology
of the nervous systems in twitcher mice is similar to that of humans with GLD, several
additional defects observed in these mice are yet to be corroborated with the human
condition of GLD; these include retarded femur growth and atrophy of lymphoid organs
(Contreras et al., 2010, Galbiati et al., 2007). Overall, the twitcher mouse is a very useful
and valuable animal model to study GLD.
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Table 2-1 Animal models of GLD
Table adapted from (Wenger, 2000).
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II-1.2 Other Animals with GLD
The first animal case of GLD was described by Fankhauser and colleagues in
1963, before the discovery of the twitcher mouse model (Fankhauser R., 1963, Wenger,
2000). Cairn and West Highland terriers presented with a lack of movement coordination,
muscle weakness, and tremor between 1-3 months of age (Fankhauser R., 1963,
Wenger, 2000) (Table 2-1). Although the disease course and severity varied between
individual animals, all died prematurely (Wenger, 2000). Terriers are the most reported
canine strain to develop GLD-like illness (Fletcher et al., 1966, Victoria et al., 1996,
Wenger et al., 1999, Zaal et al., 1997). Other canine strains have also been reported to
develop spontaneous GLD, including miniature poodles, hound dogs, beagles, Irish
setters, and Australian Kelpies (Boysen et al., 1974, Fletcher et al., 2010, Johnson et al.,
1975, McGraw and Carmichael, 2006, Zaki and Kay, 1973). In all canine cases,
symptoms are comparable to those seen in murine GLD; these include low weight gain,
hind leg weakness, and tremor (Wenger, 2000) (Table 2-1).
Among these animal models, spontaneous genetic mutations in GALC
dramatically reduce enzymatic activity (<10% of normal) (Wenger, 2000) (Table 2-1).
Analyses of GALC mutations have been performed on several strains and all have
determined that terriers carry an A473 cytosine (C) mutation, and Irish setters have a 78nucleotide insertion between positions 790 and 791 (McGraw and Carmichael, 2006,
Wenger, 2000).
GLD has also been observed in other animals, including rhesus monkeys,
domestic longhaired cats, and Pulled Dorset sheep (Johnson, 1970, Luzi et al., 1997,
Pritchard et al., 1980, Sigurdson et al., 2002). All of these animals present with low weight
gain, lack of coordinated movement, tremor, hindlimb weakness, and succumb to
premature death. GALC activity in these GLD animals, except cats, was measured and
revealed that it was only 2% (rhesus monkey) and 6% (sheep) of GALC activity of healthy
cohorts (Luzi et al., 1997, Pritchard et al., 1980). Mutation analyses of GALC were only
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available in rhesus monkey cases, but this determined that there was a deletion of A387
and C388, which caused a frame shift resulting in a premature stop codon (Luzi et al.,
1997) (Table 2-1).
Postmortem analyses in all animal cases revealed similar pathological findings
to human and the murine model of GLD. Key findings include severe demyelination,
widespread astrogliosis, and the presence of globoid cells (Johnson, 1970, Luzi et al.,
1997, Pritchard et al., 1980, Sigurdson et al., 2002). Animals without GALC activity tests
or mutation analyses were diagnosed with GLD largely based on their observable
symptoms and an identification of globoid cells within the CNS in postmortem analyses
(Wenger, 2000). Overall, GLD is not a human-specific disease, but is a phylogenetically
conserved disorder in mammals. Although many animal cases with GLD have been
reported, the twitcher mouse is the most useful and practical animal model for the study
of GLD pathogenesis, as it is an available means for study of genetic alteration with lower
maintenance costs and shorter cycles of breeding with larger litter sizes (Wenger, 2000).

II-2 Cellular Abnormalities of GLD

II-2.1 Cellular Pathology
Cytological analyses and in vitro studies have revealed that accumulated
psychosine can impact multiple cell types in GLD. For example, at the end stage of GLD
in twitcher mice, there are no oligodendrocytes and/or oligodendrocyte progenitor cells
(OPCs) present in the CNS parenchyma (Itoh et al., 2002, Krabbe, 1916). However,
before reaching the clinical end stage, OPCs are present and capable of proliferating in
twitcher mice (Taniike and Suzuki, 1995). Additionally, glial fibrillary acidic protein
(GFAP)-positive astrocytes are found throughout the brain and the spinal cord of twitcher
mice (Itoh et al., 2002, Krabbe, 1916) (Figure 2-1).
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Figure

2-1

Astrocytosis

in

the

brains

of

twitcher

mice.

Representative

immunohistochemical images show that glial fibrillary acidic protein (GFAP)-positive
astrocytes (red) are found throughout the brains (cortex, corpus callosum, and
cerebellum) of twitcher mice at postnatal day (P)10-40. Note that GFAP+ astrocytes are
observed in cerebellum and corpus callosum, as early as P10. Scale bar= 500um. (Ijichi
& Crocker, unpublished data)
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Figure 2-2 Globoid cells in the brains of twitcher mice. Globoid cells were identified
in the corpus callosum and cerebellum of twitcher mice at P30 by immunohistochemistry
using Iba-1 (red, microglial marker), MHCII (green, monocyte marker), DAPI (nuclear
marker). Note that all globoid cells were positive for Iba-1 with multiple DAPI positive
nuclei, but only some show MHCII immunoreactivity. Scare bar= 30µm. (Ijichi & Crocker,
unpublished data)
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Multinucleated globoid cells are also present in demyelinated sites throughout the GLD
brain (Itoh et al., 2002, Krabbe, 1916) (Figure 2-2). T cells are also found in areas close to
vasculature, identified by their expression of cluster of differentiation (CD)45 and CD3 cell
surface marker (Itoh et al., 2002). However, the infiltration of hematopoietic-origin cells,
including T cells and macrophages, occurs only after clinical onset, suggesting a later
pathogenic contribution to GLD (Wu et al., 2000). In the sciatic nerves of twitcher mice,
axonal damage can be found well before the onset of symptoms and overt demyelination
(Castelvetri et al., 2011, Smith et al., 2011). This axonopathy in twitcher mice may be
attributed to an inhibition of neurofilament phosphorylation in axons by the accumulation
of psychosine during development (Cantuti-Castelvetri et al., 2012). Schwann cells, the
myelinating cells of the PNS, show a significantly lower proliferative rate in GLD and fail
to respond normally to growth factors, including basic fibroblast growth factor (bFGF)
(Yamada et al., 1996). These phenomena may be mediated by dysfunctions of protein
kinase C (PKC) signaling resulting from exposure to excessive levels of psychosine
(Yamada et al., 1996).
The cellular pathology of GLD is also evident outside of the nervous systems.
For instance, twitcher splenic natural killer (NK) cells have been found to be apoptotic,
which agrees with findings of an in vitro study reporting that psychosine treatment can
induce apoptosis in cultured NK cells (Al-Falahi et al., 2009). Stromal/stem cells derived
from twitcher adipose cells have also been reported to have less proliferation with
impaired osteogenic differentiation capacity. These defects could underlie femur
maldevelopment in the twitcher mouse model of GLD (Contreras et al., 2010, Zhang et al.,
2013). A recent study has also revealed that the endothelial architecture in
microvasculature in twitcher mice are also altered (Belleri et al., 2013). This is likely a
result of accumulated psychosine inducing rearrangement of the actin cytoskeleton
and/or inhibition of proliferation, migration, and responsiveness of endothelial cells to
growth factors (Belleri et al., 2013). In the liver of twitcher mice, hepatocytic pexisomes
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are also known to have irregular membrane structure, resulting in reduced catalase
activity (by 43% compared to age-matched wildtype controls) (Contreras et al., 2008).
Spermatozoa in twitcher mouse testes were reported to have a swollen acrosome, which
is a cap-like structure in the head portion of a sperm cell, due to the production of
excessive membrane (Luddi et al., 2005). Overall, GLD has multiple cellular malfunctions
in various organs. Clearly, a better understanding of disease mechanisms, what cell
types are most responsible, and how these changes contribute to the pathogenesis of
GLD, requires further study.

II-2.2 Globoid Cells
Globoid cells, or multinucleated phagocytes, are a hallmark of GLD pathology.
From the initial postmortem microscopic analysis of the GLD brain performed by Krabbe,
these globoid cells were notable due to their large size (Krabbe, 1916). Other studies
have shown that globoid cells are typically 15µm in diameter (Duchen et al., 1980,
Norman et al., 1961), can contain up to 20 nuclei, and have fatty filamentous inclusions
that are frequently positive for PAS (Martin et al., 1981, Suzuki, 1971, Yunis and Lee,
1970). These fatty substances in globoid cells are thought to be phagocytized myelin
debris (Itoh et al., 2002, Yunis and Lee, 1970). Multinucleated globoid cells in GLD are
often found in the corpus callosum and cerebellar peduncles, sites where demyelination
is prominent (Itoh et al., 2002).
Globoid cells are thought to originate from CNS resident microglia and/or
infiltrating peripheral macrophages. This is based on their immunoreactivity to MAC-1
(alpha M integrin chain-1), ferrin, and KP-1 (CD68), markers of phagocytes (Itoh et al.,
2002, Kobayashi et al., 1985). Currently, there are no reliable means by which to
distinguish between these two types of phagocytes (Kondo et al., 2011). Some studies
have suggested that globoid cells can be found in the PNS, where microglia do not reside,
but only at the later stages of the disease (Kobayashi et al., 1985). This observation
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might suggest a potential macrophage-origin of globoid cells, or indicate migration of
microglia-originated globoid cells from the CNS into the PNS. On the other hand, others
have reported a total absence of globoid cells within the PNS (Wenger et al., 1999).
Additionally, one study demonstrated that ablation of a key factor of macrophage
infiltration, keratinocyte chemoattractant factor or its receptor CXCR2 (CXC chemokine
receptor 2), in twitcher mice did not eradicate globoid cell formation, suggesting that
globoid cells are of microglial origin (Reddy et al., 2013). Overall, the origin of globoid
cells has remained elusive.
Multinucleated phagocytes, also known as giant cells, are observed in several
neurological diseases, including human immunodeficient virus (HIV)-encephalopathy and
CNS sarcoidosis (Masliah et al., 1996, Trombley et al., 1981). In general, the presence of
giant cells is believed to be a secondary response of phagocytes to prolonged
inflammation (McNally and Anderson, 2011). Globoid cell formation in GLD, therefore,
has been thought to be a result of chronic demyelination and inflammation (Reddy et al.,
2013). However, globoid cells can be found in the fetal spinal cord of GLD considerably
earlier than demyelination and/or damage-associated inflammation (Ida et al., 1994,
Martin et al., 1981), suggesting that globoid cell formation precedes demyelination and
inflammation.
Globoid cells can be induced by psychosine in vitro in immortal cell lines, such
as the monocyte cell line, U937, or the cervical cancer line, HeLa cells (Kanazawa et al.,
2000). Additionally, Im and colleagues demonstrated that psychosine could induce
multinucleation of human embryonic kidney (HEK)293 or RH7777 hepatoma cells in
culture (Im et al., 2001). They also determined that this action of psychosine was
mediated, in part, by a receptor protein called T cell death associated gene 8 (TDAG8)
(Im et al., 2001). Time-relapse microscopic analyses revealed that psychosine induced
multinucleation via cytokinesis failure of U937 cells (Kanazawa et al., 2000). This
mechanism underlying multinucleation in response to psychosine is in contrast to the
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mechanism of giant cell formation reported in other disaeses, where cellular fusion of
macrophages is thought to mediate the development of syncytia (Huerta et al., 2009).
Thus, globoid cells found in GLD may be a different multinucleated cell type from the
giant cells found in other neurodegenerative diseases.

II-3 Galactosylceramidase (GALC) and Psychosine

II-3.1 GALC
Galactosylceramidase, galactosylcerebrosidase, or GALC, is a galactolipid
hydrase that resides in the lysosome. GALC is known to hydrolyze galactolipids, such as
psychosine and galactosylceramide, into galactose and lipids. One of GALC substrates,
galactosylceramide, also known as cerebroside, is abundant in myelin; thus, expression
of GALC was initially thought to be exclusive to myelinating cells in the nervous systems
(Suzuki and Suzuki, 1970). However, accumulating evidence now suggests that GALC is
also expressed in other tissues, including the placenta, kidney, intestines, thymus, skin,
and the hematopoietic stem cell population (Beier and Gorogh, 2005, Chen et al., 1993,
Chen and Wenger, 1993, Galbiati et al., 2007, Martino et al., 2009, Visigalli et al., 2010).

II-3.1.1 GALC gene:
The GALC gene is located on the long arm of chromosome 14 (q31) in humans
(Cannizzaro et al., 1994, Oehlmann et al., 1993). The human GALC gene is
approximately 58 kilobases (Kb) containing 17 exons and 16 introns (Figure 2-3) (Luzi et
al., 1995, Wenger et al., 1997). The initiation codon follows 200 nucleotides of a 5' UTR
(Luzi et al., 1995). The 5’ end of intron 1 contains a GC- rich sequence with 13 copies of
GGC (Luzi et al., 1995, Wenger et al., 1997).
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Figure 2-3 Schematic gene structure of human GALC gene. Schematic drawing
represents human GALC gene consists of 17 exons (Ex). Cross-hatched box represents
leading sequence. Open boxes represent coding region of 50kb fragment, and lined
boxes are coding region for 30kb fragment. Black boxes are untranslated regions (UTR).
Mutation nomenclatures are based on cDNA sequence except some large deletions.
Figure adapted from (Wenger et al., 1997).

24

The 5’ flanking region contains a YY1 element (Yin Yang 1: transcription factor binding
site) and one potential SP1 (Specificity Protein 1: transcription factor) binding region (Luzi
et al., 1995), which are widely found in other genes. Also, four GC boxes, which are
known as general transcription factor binding sites, and two AP-2 (Activator Protein-2:
transcription factor) binding sites have been identified at the beginning of intron 1 (Luzi et
al., 1995). There is no thymine (T)ATA box (TATAAA) or CAAT box (GGCCAATCT) found
within 800 nucleotides preceding the initiation codon, ATG (Luzi et al., 1995). There is a
high promoter activity at nucleotide -172 to -24 (Luzi et al., 1995). Also there is another
potential initiation sequence found 48 base pairs (bp) upstream of exon 1; however, there
is no evidence that this alternate start site is used (Luzi et al., 1995). These analyses of
transcription factor binding sites in the GALC gene have not provided any evidence for
tissue-specific expression (Matsuda, 2007, Schug et al., 2005).

II-3.1.2 GALC Protein and Functions:
Chen and colleagues successfully cloned and characterized the cDNA of
human GALC from brain and urine samples of GLD patients (Chen et al., 1993, Sakai et
al., 1994). They determined that the full length GALC cDNA consisted of 3795 bp,
resulting in the full GALC protein with 669 amino acids (Chen et al., 1993). GALC is an
80kD protein that undergoes glycosylation in endoplasmic reticulum-Golgi complex
(Nagano

et

al.,

1998).

GALC

is

then

transported

into

a

lysosome

via

a

mannose-6-phosphate receptor-mediated process and functions as a lysosomal hydrase
for sphingolipid degradation (Nagano et al., 1998).
GALC consists of a signaling peptide sequence, triosephosphate isomerase
(TIM) barrel, !-sandwich domain, and lectin domain (Deane et al., 2011). N-linked
glycosylation has been implicated as a critical modulation of GALC trafficking to
lysosomes (Deane et al., 2011). Both the galactose-specific recognition site [threonine
(T)93] and catalytic sites [glutamic acid (E)182 and E258] reside in TIM barrel (Deane et
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al., 2011). Based on these structural studies, GALC does not have a lipid-tail binding site;
thus, GALC recognizes its substrates by a galactose moiety of the galactolipid (Deane et
al., 2011). GALC protein has been thought to have several isoforms due to the proteolytic
cleavage of the “precursor” (80kD) into two subunits (50 kD of N terminus and 30kD C
terminus) by a yet-to-be-identified enzyme (Chen et al., 1993, Nagano et al., 1998, Sakai
et al., 1994, Wenger et al., 2000) (Figure 2-3). This event is thought to occur in
lysosomes (Hasilik, 1992, Nagano et al., 1998). However, a recent structural analysis of
GALC has indicated that there may be a possible molecular cleavage site located within
the !-sandwich domain, which unlikely causes a physical segregation of GALC into two
fragments; thus, cleavage may not influence the catalytic activity of GALC (Deane et al.,
2011).
It has been suggested that GALC may require a co-activator, saposin, when
GALC catalyzes a glycolipid that resides within a membrane (Sandhoff, 2012, Schulze et
al., 2009). Saposin, a lysosomal lipid-binding protein, either obtains the galactolipid from
the membrane bilayer or distorts the bilayer to expose galactolipids, which enables GALC
to access its enzymatic substrates, such as galactosylceramide (Deane et al., 2011,
Sandhoff, 2012). Thus, both GALC and saposin may be important to allow for the proper
function and maintenance of membrane homeostasis.

II-3.1.3 GALC in GLD -Gene Mutations-:
The most common mutation identified among cases of infantile GLD in the
United States and Europe is a 30Kb deletion at position 502 (502/del) within intron 10
(Figure 2-3) (Luzi et al., 1995, Rafi et al., 1995). In fact, this allele is found in nearly 75%
of all GLD patients in Sweden and Europe (Kleijer et al., 1997). Interestingly, point
mutations including C1538T and A1652C are more common among Japanese
populations (Furuya et al., 1997, Kukita et al., 1997, Satoh et al., 1997, Tatsumi et al.,
1995, Xu et al., 2006), whereas the Israeli population tend to have different point
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mutations, such as G1582A (Rafi et al., 1996, Wenger et al., 2000). While some
mutations are limited to certain GLD populations, polymorphisms at other loci, such as
C502T and A865G, are common to all GLD populations (Kleijer et al., 1997, Luzi et al.,
1995, Rafi et al., 1995, Rafi et al., 1996, Tatsumi et al., 1995, Wenger et al., 2000).
Interestingly, there have been no mutations identified in exon 12 where proteolytic
cleavage of the GALC precursor occurs (Tappino et al., 2010, Wenger et al., 2000). To
date, over 70 mutations in the GALC gene have been identified in human GLD (Tappino
et al., 2010, Wenger, 2000, Wenger, 2001, Wenger et al., 2000). These mutations
represent several possible mechanisms of dieases, including protein misprocessing and
alterations in GALC secretion or GALC reuptake (Lee et al., 2010). These findings also
point to a variety of modes through which mutations(s) can lead to a loss of GALC
function. Regardless of the type of mutations, all individuals with GLD have considerably
lower levels of functionally active GALC. If GALC activity in blood samples, for example,
is lower than 0.5nmol/hr/mg of protein, the individual is considered “at risk” for developing
GLD. In patients with the infantile variant of GLD, GALC activity is often below
0.15nmol/hr/mg, which is considered to be the threshold value for a HSCT candidate
(Jalal et al., 2012). Interestingly, the level of GALC activity does not always correlate with
disease severity, but it does correlate with the age of onset of GLD (Jalal et al., 2012).
Overall, functional loss of GALC is an important and pathogenic characteristic of GLD
that underlies the etiology of GLD itself.

II-3.2 Psychosine
II-3.2.1 Synthesis of Psychosine:
Psychosine is a galactolipid also known as galactosylsphingosine. As the name
denotes, psychosine is composed of a galactose moiety and a sphingosine backbone
comprised of 18 carbons (Figure 2-4). Psychosine was first described in 1876 and named
by Johann L. W. Thudichum, a German chemist (Rosenheim, 1907, Thudichum, 1876).
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Figure 2-4 Structure of psychosine and its degradation by GALC. Schematic
chemical structure shows that psychosine consists of 18-carbon sphingosine backbone
with a galactose moiety. Galactosylcerebrosidase (GALC) hydrolyzes psychosine into
galactose and sphingosine.
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non-phosphorous fraction of human brain matter and a mixture of galactose, cerebronic
acid and sphingosine (Thudichum, 1876). Thudichum obtained a lipid substance
composed of C23H45NO7 and called it “psychosine” (Thudichum, 1876); though his
rationale for this name remains unclear. Thudichum also demonstrated that psychosine
can be further degraded into galactose and sphingosine by acid treatment (Thudichum,
1876). Sphingosine is an important lipid serving as a precursor for ceramide, an essential
component of lipid membranes; thus, psychosine is synthesized during the process of
lipid membrane synthesis.
It is now known that psychosine (C24H47NO7) is produced within a cell by the
binding of uridine diphosphate (UDP)-galactose to sphingosine (Cleland and Kennedy,
1960). This binding process may be catalyzed by an enzyme, UDP-galactose:ceramide
galactosyltransferase (CGT). This binding is also known as the Cleland and Kennedy
reaction (Cleland and Kennedy, 1960). The importance of CGT in the production of
psychosine is supported by studies on the effects of genetic ablation of CGT in twitcher
mice (Ezoe et al., 2000). Cross-breeding of CGT knockout (KO) mice, which lack the
synthetic enzyme for psychosine, with twitcher mice resulted in a significant reduction in
psychosine accumulation (Ezoe et al., 2000). This result suggested that CGT is a major
contributor to psychosine production in vivo.
Expression of CGT is higher in myelinating cells and other cells of the CNS,
including oligodendrocytes, astrocytes, and neurons, than cells in other organ systems;
therefore, the nervous system is more liable to accumulate psychosine in GLD
(Schaeren-Wiemers et al., 1995, Zoller et al., 2005). However, it should be noted that
accumulation of psychosine in GLD has been identified in other organs outside of the
nervous system, including the kidneys, lever, adipose cells, thymus and also blood
(Galbiati et al., 2007, Ichioka et al., 1987, Stahl et al., 1994, Whitfield et al., 2001, Zhang
et al., 2013, Zhu et al., 2012).
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These data suggest that psychosine may be efficiently synthesized in CGT-independent
manner.

II-3.2.2 Function of Psychosine:
Psychosine is considered as a natural byproduct during membrane lipid
synthesis (Miyatake and Suzuki, 1972, Vanier, 1976). A recent study has also proposed a
potential natural physiological function for psychosine in oligodendrocyte development,
albeit at low concentrations (<100nM) (Zhu, 2013). In general, psychosine is known as a
lipid that is cytotoxic to many cell types (Castelvetri et al., 2011, Cho et al., 1997, Galbiati
et al., 2007, Sugama et al., 1990, Taketomi and Nishimura, 1964, Whitfield et al., 2001,
Zaka and Wenger, 2004, Zhang et al., 2013, Zhu et al., 2012). The naturally occurring
level of psychosine in healthy individuals is extremely low (less than 10pmol/mg wet
tissue) (Miyatake and Suzuki, 1972).
Interestingly, TDAG8, an orphan receptor, has been identified as a potential
extracellular binding target of psychosine (Im et al., 2001, Wang et al., 2004). However,
this receptor-mediated pathway is not widely accepted as the toxic mechanism of
psychosine since other glycolipids can also act as ligands of this G-protein coupled
receptor (Tomura et al., 2005). Overall, the natural physiological function of psychosine in
homeostasis is not well studied, perhaps due to the conventional belief that it is potently
cytotoxic and produced at very low levels only as a natural byproduct of metabolism.
However, when considered together, regulation of the physiological levels of psychosine
and normal GALC activity are critical for healthful development.

II-3.2.3 Psychosine in GLD:
Psychosine is a major pathogenic player of GLD, as it significantly accumulates
in the cells and tissues of GLD. In the healthy CNS, the level of psychosine is extremely
low (less than 10pmol/mg wet tissue) (Miyatake and Suzuki, 1972). In GLD brain,
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however, more than 100 fold increase of psychosine concentration has been detected in
the CNS tissue (White et al., 2009). The psychosine level is increased in other organs,
such as the kidney, liver, blood, and thymus of GLD (Galbiati et al., 2007, Zhu et al.,
2012); thus, psychosine may have a pathogenic effect in multiple organ systems. This
accumulation has also been evidenced in prenatal tissues of GLD (Ida et al., 1994).
At higher concentrations (>1µM, in vitro), psychosine becomes cytotoxic for
oligodendrocytes and neurons (Castelvetri et al., 2011, Cho et al., 1997, Zaka and
Wenger, 2004). It is estimated that the in vivo concentration of psychosine in the GLD
tissue is much higher (>120µM) than experimentally used in vitro (Shinoda et al., 1987,
Svennerholm et al., 1980). Therefore, psychosine may have a broader impact on cells
than observed in vitro. It is thought that in GLD psychosine accumulates in lipid rafts, a
membrane domain that is responsible for many signaling pathways (White et al., 2009). It
has also been suggested that psychosine can accumulate both intracellularly and
extracellularly, which can result in both cell-autonomous and non-cell autonomous effects
(White et al., 2009). As mentioned above, psychosine has cytotoxic effects on multiple
cell types, including red blood cells, thymocytes, stromal stem cells, and CNS cells
(Castelvetri et al., 2011, Cho et al., 1997, Galbiati et al., 2007, Sugama et al., 1990,
Taketomi and Nishimura, 1964, Whitfield et al., 2001, Zaka and Wenger, 2004, Zhang et
al., 2013, Zhu et al., 2012). However, the precise mechanism by which accumulated
psychosine contributes to the pathology of GLD remains unclear.

II-4 The Psychosine Hypothesis
The psychosine hypothesis was first proposed by Miyatake and Suzuki in 1972
(Miyatake and Suzuki, 1972). In 1970, Suzuki and his colleagues had discovered that
there was a deficiency of GALC in patients with GLD. GALC, as mentioned above, is an
important lysosomal enzyme that regulates a myelin lipid, called galactosylceramide.
Surprisingly, however, detailed biochemical analyses revealed that there was not a
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significant accumulation of galactosylceramide in GLD. Miyatake and Suzuki then
determined that there was an exceptionally high level of another galactolipid, called
psychosine, present in the CNS tissues from GLD patients. Thus, they hypothesized that
this abnormal accumulation of psychosine in GLD was the likely candidate toxin for GLD
pathophysiology.
The psychosine hypothesis has become the primary focus of GLD research,
with particular attention to the direct effect of psychosine on the death of
oligodendrocytes as its primary pathological action leading to demyelination (Miyatake
and Suzuki, 1972). Indeed, many studies have now confirmed that psychosine can elicit
cytotoxic effects on oligodendrocytes by inducing apoptosis in vitro (Cho et al., 1997, Giri
et al., 2008, Giri et al., 2006, Haq et al., 2003, Zaka and Wenger, 2004). Thus, the
psychosine hypothesis has become the tenet of GLD pathogenesis.
Although psychosine is an enzymatic substrate of GALC, other substrates can
also be hydrolyzed by GALC, including the myelin lipid, galactosylceramide. However, in
GLD, the level of galactosylceramide is unchanged, suggesting an alternate pathway for
degrading this myelin lipid and for the maintenance of myelin homeostasis (Eto and
Suzuki, 1970). Recently, it had been reported that only the carbon (C)-18 short chain
isoform of galactosylceramide accumulates in the brains of twitcher mice, but this C-18
form does not accumulate to the same extent as psychosine (Esch et al., 2003). The
levels of long chain galactosylceramides, including the C-22 and C-24 isotypes, are
similar in both twitcher and wildtype tissue samples (Esch et al., 2003). Changes in these
isotypes have not been confirmed in human GLD tissues. Despite these reports, a
potential connection between accumulated short chain galactosylceramides and
demyelination in GLD has not been identified. On the other hand, the accumulation of
psychosine and its toxicity in GLD are well documented by numerous studies across
multiple species and cellular models (Castelvetri et al., 2011, Cho et al., 1997, Galbiati et
al., 2007, Taketomi and Nishimura, 1964, Whitfield et al., 2001, Zaka and Wenger, 2004,
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Zhang et al., 2013, Zhu et al., 2012). To date, psychosine accumulation remains the most
plausible primary driving force underlying GLD pathogenesis. Although it has been over
40 years since the psychosine hypothesis was first proposed (Suzuki, 1998), the exact
mechanism by which psychosine accumulation accounts for all aspects of GLD pathology
remains an area of intensive study.

II-5 A Microglial Hypothesis of GLD Pathogenesis

II-5.1 Shortcomings of the Psychosine Hypothesis
The psychosine hypothesis, as mentioned above, has garnered the reputation
as a dogma for the pathogenesis of GLD. Indeed, multiple in vitro studies have
determined that psychosine is cytotoxic to oligodendrocytes (Cho et al., 1997, Giri et al.,
2006, Haq et al., 2003, Zaka and Wenger, 2004). However, there are many pathological
aspects of GLD that are not explained by this hypothesis. For example, psychosine also
has direct cytotoxic effects on neurons in vitro (Castelvetri et al., 2011, Sugama et al.,
1990). This finding agrees with axonal swelling observed prior to demyelination in the
twitcher mouse (Castelvetri et al., 2011). Psychosine also induces apoptosis of human
lymphocytes obtained from blood samples (Formichi et al., 2007). In addition, psychosine
application in non-CNS cell line cultures, such as U937 and HeLa cells, has also been
reported to induce multinucleation - a cardinal feature of globoid cells (Kanazawa et al.,
2000). Thus, it is likely that the pathogenic effects of psychosine are not limited to
oligodendrocytes, and that psychosine impacts multiple cell types that together culminate
in the pathology of GLD.
Oligodendrocyte death in GLD has been attributed to the intracellular
accumulation of psychosine that induces cellular apoptosis (Giri et al., 2008). This
cell-autonomous theory contradicts observations from the study by Kondo and
colleagues where they examined the myelinating potential of oligodendrocytes isolated
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from twitcher mice by transplanting them into the shiverer mouse CNS (Kondo et al.,
2005). Shiverer mice are a mutant mouse line in which myelination is absent because of
a lack of myelin basic protein (MBP)(Gumpel et al., 1989). The Kondo study
demonstrated that transplanted oligodendrocytes from twitcher mice survived and were
able to appropriately myelinate axons in the shiverer mouse CNS (Kondo et al., 2005).
Thus, the notion that intracellular accumulation of psychosine is soley responsible for the
loss of oligodendrocytes in GLD does not explain why twitcher mouse oligodendrocytes
can myelinate in the shiverer brain. When considered from another perspective, these
findings also suggest that the extracellular environment may be an important contributor
to the survivial and function of oligodendrocytes in GLD. In fact, this disease does not
start with demyelination, but rather, the presence of multinucleated globoid cells can be
found in the fetal spinal cord at a time well before overt myelin pathology is even
observed in GLD (Martin et al., 1981). Thus, GLD is likely a multifactorial disease with a
complex pathophysiology involving many cell types. Moreover, in light of these findings,
the current oligodendrocyte-centered psychosine hypothesis may require revision.

II-5.2 Importance of Microglia in GLD
Microglia are CNS-resident phagocytes. Microglia constitute about 5% and
12% of CNS cell population in the white matter and grey matter, respectively (Lawson et
al., 1990). Microglia originate from primitive macrophage precursors, entering the
developing neuroepithelia from the circulation around embryonic day (E)8.5-9.5 in mice
(Ginhoux et al., 2010). From the time of this CNS colonization by precursors, microglia
and peripheral macrophages reside in distinct tissue compartments without contact
(Ginhoux et al., 2013). The primary role of microglia is surveillance since they function as
a first line of defense against pathogen invasion, and are primary responders to traumatic
CNS injuries (Nimmerjahn et al., 2005). Additionally, microglia facilitate maintenance of
CNS tissue homeostasis where they contribute to the development of CNS by
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contributing to the differentiation and proliferation of neuronal precursors (Cunningham et
al., 2013). Microglia have also been associated with synapse formation and synaptic
plasticity mediated by physical contact with pre- and post-synaptic neurons and
peri-synaptic astrocytes (Schafer et al., 2013, Tremblay et al., 2010). Thus, tight
regulation of microglial activity is a necessary component of health and aberrant
microglial activity has many recognized negative consequences for tissue repair and
disease.
Microglia have not been a primary focus of pathology in GLD. This may be due
to the severe demyelination in GLD, which is the most prominent pathological finding of
this disease. However, several studies have shown strong evidence that microglia may
play an important role in the pathogenesis of GLD. For example, it was reported that sites
of demyelination almost always co-exist with astrogliosis and highly activated microglia in
the twitcher CNS (Ohno et al., 1993). Also, the CNS of twitcher mice expresses high
levels of proinflammatory cytokines, including interleukin (IL)-6, tumor necrosis factor
(TNF)-", macrophage inflammatory protein (MIP)-1", MIP-1!, monocyte chemoattractant
protein-1, and regulated on activation normal T cell expressed and secreted (RANTES),
all of which are associated with activated microglia (LeVine and Brown, 1997, Wu et al.,
2000). Additionally, Mohri and colleagues demonstrated that microglia can communicate
with astrocytes via prostaglandin (PG)D2 production during the pathogenesis of GLD,
and inhibition of PGD2 synthesis in twitcher mice resulted in a substantial reduction in
astrogliosis and demyelination (Mohri et al., 2006). This report supports microglial
activation as an early and therefore upstream event, which triggers astrocyte activation
and precedes demyelination. Also, globoid cells, the aberrant form of activated microglia
in GLD, have been observed in fetal tissues from genetically determined GLD cases
(Martin et al., 1981). This is particularly relevant because the presence of these globoid
cells occurs before initial myelination of the CNS (Martin et al., 1981). Finally, it has been
previously proposed that uncontrolled activation of microglia may limit the long-term
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efficacy of HSCT for treating GLD (Pellegatta et al., 2006).
Despite the ample evidence for microglial involvement in GLD pathogenesis,
the contribution of microglia toward GLD pathology has not been studied in detail. We
hypothesized that microglia may be primary mediators of GLD pathogenesis. Our studies
on the role of microglia in the context of GLD may provide impetus to revise the
psychosine hypothesis. Toward this objective, we have studied the role of matrix
metalloproteinases (MMPs,), a family of extracellular proteases implicated in CNS
demyelination and microglial activation in the context of GLD pathology and
pathogenesis (Kim et al., 2010, Kouwenhoven et al., 2001, Ozenci et al., 1999).

II-5.3 Matrix Metalloproteinase (MMP)-3
II-5.3.1 MMP Family:
MMPs are extracellular endopeptidases that play important roles in tissue
remodeling, regeneration, and homeostasis (Candelario-Jalil et al. , 2009). MMPs cleave
all known components of the extracellular matrix (ECM) and tightly regulate extracellular
environment (Rodriguez et al., 2010). MMPs are zinc (Zn)-dependent extracellular
proteases that are synthesized as a zymogen that contains a ‘cysteine switch’, an
interaction between a cysteine residue and Zn2+ within the catalytic domain of the
enzyme (Van Wart and Birkedal-Hansen, 1990). Disruption of this bond by
organomercurial agents, heavy metals, oxidants, or proteases, results in conformational
changes, which expose the catalytic site leading to enzyme activation (Lijnen et al., 1998,
Van Wart and Birkedal-Hansen, 1990). To date, there are over 100 human MMPs
identified (Overall, 2002) and seven different subclasses of MMPs based on their
domains; collagenases, gelatinases, matrilysins, stromelysins, membrane-type MMPs,
metalloelastases, and enamelysins (Kim and Hwang, 2011). The activity of MMPs is also
tightly regulated by small endogenous inhibitor proteins called tissue inhibitor of
metalloproteinases (TIMPs). There are four mammalian TIMP proteins that largely share
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structural and functional domains. TIMPs non-covalently bind MMPs in a 1:1
stoichiometry ratio. Imbalance of MMP/TIMP ratios or elevated activation or expression of
MMPs has been implicated in a wide range of CNS diseases including Alzheimer’s
disease, Parkinson’s disease, Huntington’s disease, stroke, amyotrophic lateral sclerosis
(ALS) and multiple sclerosis (MS) (Kim et al., 2010, Lim et al., 2011, Lorenzl et al., 2003,
Mandler et al., 2001, Miller et al., 2010, Moore and Crocker, 2012, Mun-Bryce and
Rosenberg, 1998, Niebroj-Dobosz et al., 2010). Thus, MMPs are important regulators of
tissue homeostasis in the CNS.

II-5.3.2 MMP-3:
MMP-3, also known as stromelysin-1, is a member of the stromelysin MMP family,
which has a relatively simple structure containing a catalytic domain, hemepexin domain,
and furin recognition site (Cao et al., 2005, Lijnen et al., 1998, Van Wart and
Birkedal-Hansen, 1990). Like other MMPs, MMP-3 is produced as a zymogen with a
pro-peptide domain that contains the cysteine switch that masks the catalytic site. Upon
breakage of this cysteine-zinc bond by activators such as plasminogen and serine
proteases, the catalytic domain is then exposed and the pro-peptide region is removed by
auto-cleavage (Lijnen et al., 1998, Van Wart and Birkedal-Hansen, 1990). Activation of
MMP-3 is believed to be an intracellular event (Kim et al., 2005); however, the exact
mechanism by which MMP-3 is secreted by cells is still a topic of intense study (Kim and
Hwang, 2011).
In the healthy CNS, basal levels of MMP-3 are very low (Kim and Hwang, 2011,
Maeda and Sobel, 1996). However, in response to injury or inflammation, MMP-3 is
dramatically upregulated by multiple cell types (Sole et al., 2004).
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Table 2-2 Catalytic targets of MMP-3 in the CNS
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Major cellular sources of MMP-3 in the CNS include the astrocyte (Crocker et al., 2008,
Deb and Gottschall, 1996, Keene et al., 2009, Kim et al., 2008, Savarin et al., 2011),
stressed neurons (Kim et al., 2005, Nishida et al., 2008) and microglia (Rosenberg et al.,
2001).
Proteolytic substrates of MMP-3 include many constituents of the extracellular
matrix (ECM), such as proteoglycans, gelatin, collagen, laminin, fibronectin (Okada et al.,
1986), and tenascins (Imai et al., 1994, Siri et al., 1995, Stegemann et al., 2013) (Table
2-2). Accumulating evidence suggests that MMP-3 has additional non-ECM substrates
that can include the protelytic activation of other MMPs (Kim and Hwang, 2011, Ogata et
al., 1992, Ramos-DeSimone et al., 1999), which activates signaling molecules such as
tumor growth factor (TGF)-!1 (Maeda et al., 2002), and even prevents cell death by
shedding the surface molecule Fas-L (Matsuno et al., 2001) (Table 2-2). Overall, MMP-3
has diverse functions in intracellular, intercellular, and extracellular regulations within the
CNS. MMP-3 gene expression can be induced by a variety of factors, including cytokines
(Bond et al., 1999, Crocker et al., 2006, Fleenor et al., 2003), growth factors (Kirstein et
al., 1996, Witek-Zawada and Koj, 2003), and cellular interactions with the ECM (Werb et
al., 1989). Aberrant MMP-3 expression has been implicated in the pathogenesis of many
CNS diseases, including Parkinson’s disease (Choi et al., 2008, Kim et al., 2010),
Alzheimer’s disease (Deb and Gottschall, 1996, Horstmann et al., 2010, Yoshiyama et al.,
2000), traumatic brain injury (Grossetete et al., 2009, Kim et al., 2005), stroke
(Rosenberg et al., 1996) and MS (Kouwenhoven et al., 2001, Ozenci et al., 1999).

II-5.3.3 MMP-3 and Neuroinflammation:
While the functions of MMP-3 are known to be important for CNS homeostasis, its
dysregulation has also been linked to many aforementioned neurodegenerative diseases.
Accumulating evidence points to an important role for MMP-3 in regulating
neuroinflammation (Kim and Hwang, 2011). Specifically, an important aspect of MMP-3
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has been its expression from activated glia in association with neurodegeneration in the
CNS (Bonneh-Barkay and Wiley, 2009, Kim and Hwang, 2011). Recent evidence
suggests that MMP-3 is released from stressed neurons, and then activates microglia.
This proteolytic activation of microglia can then initiate an inflammatory cascade that can
culminate in neuronal death (Kim et al., 2007, Kim et al., 2005).
One aspect of MMP-3 pathophysiology relevant to this thesis is its association
with demyelination. Indeed, elevated levels of MMP-3 in the CNS were reported in
several demyelinating disease models, including the mice, which develop spontaneous
demyelination resulting from overexpression of the proteolipid protein (PLP) isoform
DM20, infection with Theiler’s murine encephalomyelitis virus (TMEV), and secondary
demyelination resulting from stroke (D'Souza et al., 2002, Jalal et al., 2012, Kumnok et al.,
2008, Rosenberg et al., 2001, Ulrich et al., 2006). These data suggest an association
between MMP-3 and CNS demyelination.
MMP-3 has also been described as an inducer of microglial cytokine release in
response to cellular stress (Mun-Bryce et al., 2002, Woo et al., 2008). In addition to
MMP-3 proteolytically targeting inflammatory cytokines, such as TNF-" and IL-1! (Black
et al., 1996, Ito et al., 1996), MMP-3 has been implicated to directly cleave MBP, a critical
myelin protein (D'Souza and Moscarello, 2006). Moreover, activated microglia can induce
apoptosis of oligodendrocytes via reactive oxygen species production (Yeo et al., 2012).
As mentioned above, MMP-3 is also capable of activating microglia; thus, MMP-3 may
play an important role in the demyelinating process of GLD via activation of microglia.
Overall, there are many lines of evidence to suggest MMP-3 may play a role in
demyelination in GLD.
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MMPs have not been previously implicated in the pathogenesis of any
leukodystrophy. MMP-3 was of particular interest to us because it had a strong
association with demyelination. Many features of GLD, including the robust activation of
microglia, also suggested a potential role for MMP-3 in this disease. Therefore, one focus
of this thesis was to investigate the role of MMP-3 in GLD.

II-5.4 Tenascin-C (TnC)
II-5.4.1 Extracellular Matrix (ECM) in the CNS:
The extracellular matrix (ECM) is an intricate macromolecular network that
occupies the extracellular space. It provides cells direct structural support and also
mediates intercellular signaling. Furthermore, the ECM has been implicated in cellular
differentiation, lineage fate, and growth (Goetz et al., 2006). The main constituents of the
ECM in the CNS include laminin, fibronectin, vitronectin, and proteoglycans, which
include agrins, aggrecans, brevicans, neurocans, perlecans and tenascins (Bandtlow and
Zimmermann, 2000, Franco and Muller, 2011, Liesi and Silver, 1988, Rogers et al., 1987,
Welser-Alves et al., 2011). All proteoglycans found in the ECM of the CNS contain either
heparin sulfate or chondroitin sulfate chains, which are important glycosaminoglycan
domains for binding to a wide array of interacting proteins (Bandtlow and Zimmermann,
2000). ECM constituents bind to each other to produce an intricate mesh-like structure
occupying the extracellular space. The ECM can also bind to the cell surface and/or
cellular membranes by means of transmembrane domains that can mediate cellular
development and migration through signaling (Bandtlow and Zimmermann, 2000).
Indeed, ECM molecules such as laminin, fibronectin, and proteoglycans containing
glycosaminoglycan domains, have been implicated in neurite outgrowth, axon sprouting,
neuronal and glial migration, and oligodendrocyte differentiation (Alvarado and Castejon,
1986, Ard and Bunge, 1988, Calof et al., 1994, Czopka et al., 2010, Gates et al., 1995,
Giftochristos and David, 1988, Gil et al., 2009). Additionally, the ECM is capable of
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binding to multiple secreted extracellular molecules to influence their biological signaling
properties (Bandtlow and Zimmermann, 2000, Bonneh-Barkay and Wiley, 2009, Dityatev
and Schachner, 2003, Yamaguchi, 2000). For instance, fibronectin binds to
heparin-binding growth factor-1 to promote growth of endothelial cells (Kan and Shi,
1990). Also, tenascin-C (TnC) has been reported to bind to multiple growth factors,
including epidermal growth factor (EFG), FGFs, and platelet-derived growth factors
(PDGFs), all of which have diverse effects on cellular growth and differentiation in the
CNS (De Laporte et al., 2013, Garcez et al., 2009, McKinnon et al., 1990). Laminin can
also bind to brain-derived neurotrophic factor (BDNF), which participates in
neuroprotection during ischemic injury (Han et al., 2011). This latter study also
emphasized the importance of laminin binding to BDNF as a mechanism to prolong the
neuroprotective effect of BDNF (Han et al., 2011). Thus, the biological activity of growth
factors may rely on binding to ECM molecules (Bandtlow and Zimmermann, 2000).
The distribution and expression of ECM constituents are tightly regulated, not only
at the transcriptional and the translational levels, but also by many extracellular
modulators, including the MMP family of extracellular proteases (Cahoy et al., 2008,
Ethell and Ethell, 2007, Galtrey et al., 2008). Imbalance or dysregulation of ECM
components has been observed in many diseases, including Alzheimer’s disease, stroke,
HIV encephalopathy, and MS (Bonneh-Barkay and Wiley, 2009). Especially in the MS
brain, the levels of different ECM constituents have been reported to be dramatically
altered at sites of myelin injury. For example, in acutely demyelinated lesions, TnC levels
are strikingly decreased relative to unlesioned or healthy tissues, whereas in chronically
demyelinated areas, levels of TnC are elevated (Back et al., 2005, Gutowski et al., 1999).
Also, several ECM molecules have been suggested to modulate the responses of
immune cells and glia at lesion sites within the MS brain (Mohan et al., 2010). Thus,
changes in the composition of the ECM may contribute to disease pathology.

42

II-5.4.2 Tenascin-C (TnC):
Tenascin-C (TnC) is a large matrix glycoprotein that forms a mono- or
hetero-hexamer by disulfide bonding that connects N-termini of six subunits (Erickson
and Bourdon, 1989, Taylor et al., 1989). Each subunit consists of four domains; an
assembly domain, an EGF-like repeats domain, a fibronectin-type III like repeats (FNIII)
domain, and a C-terminal fibrinogen-like globe domain (Taylor et al., 1989). Each domain
can be alternatively spliced, resulting in a wide range of potential isoforms (Nies et al.,
1991, Spring et al., 1989). Thus, it is not surprising that TnC is known to have a wide
variety of interacting proteins, including ECM receptors, integrins (Yokosaki et al., 1998,
Yokoyama et al., 2000), signaling receptors including EGF receptor and toll-like receptor
4 (TLR4) (Midwood et al., 2009, Swindle et al., 2001), growth factors such as EGF, FGF,
PDGF (De Laporte et al., 2013), and other ECM molecules, such as fibronectin and
aggrecan (Day et al., 2004, Ingham et al., 2004). Among many molecules of the ECM,
TnC is an interesting matrix protein because it has paradoxical functions on cellular
adhesion by promoting cell growth/maturation while also having the potential to evoke
local cellular detachment (Jones and Jones, 2000, Spring et al., 1989). Indeed, TnC is
capable of binding to cell adhesion molecules (CAMs) and annexins, which are known
components involved in both cell adhesion and detachment (Chung and Erickson, 1994,
Chung et al., 1996, Hasan et al., 1998, Mai et al., 2000). The dual functionality of TnC
has been thought to arise from its multidomain structure (Jakovcevski et al., 2013),
although the precise mechanism regulating its diverse effects on cellular behavior are still
unknown.
Tenascin-C is widely expressed in many organs, including the thymus, liver,
pancreas, kidney, bladder, muscle, skin, placenta, and the CNS (Borsi et al., 1993, Saga
et al., 1991). It was hypothesized that genetic ablation of TnC in mice would have had a
significant impact on their development (Mackie and Tucker, 1999). However, the first
TnC KO mouse line exhibited normal weight, fertility, and tissue architecture (Saga et al.,
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1992). This finding was unexpected and was subsequently determined to be due to the
failure to completely ablate TnC messenger ribonucleic acid (mRNA) (Mitrovic and
Schachner, 1995). It is important to note that there are likely compensatory mechanisms
resulting from expression of other tenascins, such as tenascin-R, -X, and –W, that may
have also provided a degree of functional redundancy in the TnC KO mice (Mackie and
Tucker, 1999). Interestingly, other studies revealed that while the TnC KO mice did not
have a remarkable basal phenotype, they did exhibit abnormal behaviors, including
hyperactivity throughout the circadian cycle (Fukamauchi et al., 1996). In the PNS, TnC
KO mice were also found to have significantly more unmyelinated axons in their sciatic
nerves than in age-matched wildtype mice (Cifuentes-Diaz et al., 1998). Additional
physiological differences have since been identified in TnC KO mice, particularly in their
responses to pathological challenges. For instance, glial scarring in the cerebral cortex of
TnC KO mice has been reported to contain more astrocytes in response to a cortical stab
wound than was observed in wildtype mice (Steindler et al., 1995). Also, wound healing
following a corneal incision has been reported to be delayed in TnC KO mice as a result
of altered gene expression in the local fibroblasts (Sumioka et al., 2013). TnC deficiency
also resulted in impaired regeneration of hematopoietic stem cells following bone marrow
ablation in vivo, although TnC KO mice exhibited developmentally normal hematopoiesis
(Nakamura-Ishizu et al., 2012). These studies on TnC KO mice have now identified many
pathological functions of TnC; however, the effect of TnC ablation was not as profound as
may have been expected at the outset of these studies (Mackie and Tucker, 1999).

II-5.4.3 TnC in the CNS:
Several salient functions of TnC in the CNS have been revealed by studies on
TnC KO mice. Recent studies have also identified severe deficits in neuronal activity and
plasticity both in vivo and in vitro from ablation of TnC (Geissler et al., 2013, Sekeljic and
Andjus, 2012). Detailed histological analyses of TnC KO mice have also determined that
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these mice have a significantly higher density of cortical neurons than in wildtype animals
(Irintchev et al., 2005). Also, oligodendrocytes isolated from TnC deficient mice exhibit
lower rates of proliferation, likely due to their lack of integrin-mediated signaling (Garcion
et al., 2001). This reduced oligodendrocyte proliferation is though to underlie the lower
ratio of oligodendrocytes to neurons also observed in the TnC KO mice (Irintchev et al.,
2005).
The expression of TnC is also dynamically resgulated by CNS injury and
inflammation. For instnace, TnC accumulates in the demyelinated lesions of mice
infected with TMEV, a virus that evokes immune-mediated CNS demyelination (Haist et
al., 2012). Elevated TnC expression has also been identified as a feature of demyelinated
lesions in MS (Gutowski et al., 1999). However, based on the variety of potential
functions of TnC, the impact of TnC on demyelinating lesions could be reasonably
interpreted to either promote or hamper the remyelination process. For instance, at lesion
sites, increased level of TnC could benefit cell growth based on the cell adherence
properties of TnC. Conversely, it is also possible that elevated TnC may hamper the
migration of progenitor cells, which would be promoting cellular detachment necessary
for mediating myelin repair (Frost et al., 1996, Garcion et al., 2001). Thus, increased TnC
within myelin lesions may be an important factor limiting the process(es) of endogenous
regeneration needed for tissue repair. Also, TnC is known to modulate glial responses. It
was reported that TnC deficiency leads to astrogliosis in vivo, although the potential
mechanisms by which aberrant increases in the density of GFAP+ astrocytes in
unchallenged TnC KO brain remain unclear (Irintchev et al., 2005). The presence of TnC
is also known to modify the behavior of astrocytes, which can result in a dominating
inhibitory effect on oligodendrocyte growth and differentiation (Nash et al., 2011).
Activated astrocytes are recognized as a prominent source of TnC during development
and in response to demyelination in the adult CNS (Cahoy et al., 2008, Grierson et al.,
1990, McKeon et al., 1991).
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It has also been reported that astrocytic tenascin expression can be regulated
by microglia, although the mechanisms by which astrocytic tenascin-c may regulate
microglia remain elusive (Smith and Hale, 1997). Deposition of TnC has been implicated
as a potential inducer of MMP-3 expression in non-glial cell types (Thomasset et al., 1998,
Tremble et al., 1994, Yang et al., 2004). Yet, prior to my thesis experiments, changes in
ECM constituents had not been previously explored as an aspect of GLD
neuropathology.

II-6 Specific Aims

II-6.1 Goal and Rationale
The goal of this thesis was to characterize the non-myelinating glial
contributions to the pathogenesis of GLD and to determine whether MMP-3 was a
regulator of glial activation in this disease. As outlined in the preceeding discussion,
MMP-3 is a potent activator of microglia that has been associated with several
demyelinating conditions and diseases, including MS (Kouwenhoven et al., 2001, Ozenci
et al., 1999). However, the potential involvement of MMPs had not been previously
studied in any leukodystrophy. As well, we explored the potential role of ECM changes in
GLD as potential mediators of pathological glial functions.

Hypothesis: MMP-3 induces microglial activation that contributes to the
pathogenesis of GLD.
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II-6.2 Specific Aim 1: To examine the effect of psychosine in glial cells and
expression of MMP-3 (Chapter 3)
Accumulating evidence supports a role for MMP-3 in neuroinflammation and
demyelination in the CNS. First, MMP-3 expression and activity are elevated in multiple
demyelinating conditions (D'Souza et al., 2002, Jalal et al., 2012, Kumnok et al., 2008,
Rosenberg et al., 2001, Ulrich et al., 2006). Secondly, proteolytic targets of MMP-3
include inflammatory cytokines and ECM proteins (Table 2-2). Third, MMP-3 has been
implicated in the pathogenesis of myelin lesions. Lastly, MMP-3 is known to activate
microglia, which are also present in GLD. Thus, we hypothesized that the GLD toxin,
psychosine, would induce globoid cells from microglia that would be mediated by MMP-3.
This hypothesis was tested by addressing the following questions:
Aim1.1) Is MMP-3 expression elevated in GLD? This part of aim 1 examined if the level of
MMP-3 was elevated during the disease course of GLD. Using brain tissues from twitcher
mice at different postnatal ages, the level of MMP-3 expression was determined using
quantitative real-time-polymerase chain reaction (qRT-PCR). Additionally, the source of
MMP-3 in vivo was examined using immunohistochemical analyses. We also examined
whether psychosine transcriptionally induced MMP-3 expression in glial cultures, as
astrocytes have been implicated as a major source of MMP-3 in the CNS. The cellular
source of MMP-3 in vitro was also determined by immunocytochemistry.
Aim1.2) Does psychosine induce globoid cells from microglia in vitro?: In this set of
experiments, we determined whether psychosine induced globoid-like cells from
microglia. Using a primary glial culture system, we employed immunocytochemistry to
visualize, identify, and quantify the degree of multinucleation among psychosine-treated
microglia in culture. The number of "globoid cells" was determined using manual counting,
while the function of psychosine-induced globoid cells was also characterized using a
phagocytic activity assay.
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Aim1.3) Does MMP-3 mediate psychosine-induced globoid cells?: The experiments in
this sub-aim examined whether MMP-3 mediates psychosine-induced "globoid cell"
formation in vitro. This was tested using the same quantitative approach in Aim 1.2 but
using mixed glial cultures derived from MMP-3 KO mice and wildtype mixed glial cultures
that were also treated with chemical inhibitors specific to MMPs or MMP-3 [e.g.
N-isobutyl-N-(4-methoxyphenylsulfonyl)-glycylhydroxamic acid (NNGH)].

II-6.3 Specific Aim 2: To examine how changes in ECM influence glial responses to
psychosine (Chapter 4)
A factor limiting the long-term efficacy of BMT to treat GLD patients may be the
persistent presence of reactive microglia in the CNS (Pellegatta et al., 2006). Importantly,
the extracellular environment surrounding glial cells can significantly contribute to glial
reactivity in disease. In GLD, there have not, as yet, been any reports investigating
changes in ECM expression and composition. Thus, we hypothesized that changes in
ECM components in the GLD brain may contribute to glial activation in this disease and
microglial activity in particular. Specifically, we hypothesized that signals from ECM
molecules differentially produced in the GLD brain could modulate psychosine-induced
glial behaviors. Lastly, we examined whether globoid cells were toxic to oligodendrocytes,
and tested the influence of ECM on this potential toxicity. The following questions were
addressed:
Aim2.1) Are levels of ECM components different in the GLD brains?: The level of several
ECM constituent macromolecules was measured. ECM components examined were
laminin, fibronectin, vitronectin, and TnC. Expression of these components were
examined using immunohistochemsitry on twitcher mouse brain tissues at different
postnatal ages and human brain tissue samples from individuals who had GLD.
Age-matched wildtype littermates and age-matched human control samples were used
as a basis for comparison.
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Aim2.2) How does altered ECM composition influence glial responses to psychosine?:
We prepared mixed glial cultures on different ECM substrates and then treated these
cultures with psychosine to determine how changes in the ECM impacted the glial
responses; as measured by MMP-3 expression, globoid cell formation and phenotype
(M1/M2) marker expression profiles.
Aim2.3) Are psychosine-induced globoid cells toxic to oligodendrocytes?: In this aim, we
tested the potential toxicity of globoid cells to oligodendrocytes in vitro using a co-culture
system of psychosine-activated microglia/globoid cells that were then placed in culture
with primary oligodendrocytes. Microglia were grown on either laminin or TnC substrates,
exposed to psychosine, and then co-cultured with oligodendrocytes. The effect of various
microglial conditions was then evaluated on the number and survival of oligodendrocytes
and OPCs, as determined by immunocytochemistry and a lactose dehydrogenase (LDH)
assay to measure cell death.

II-7 Significance
GLD is a rare, yet fatal pediatric disease with a rapid progression of
demyelination and neurodegeneration. More than 90% of GLD cases are of an infantile
type, in which the patients die by the age of two. Presently, the only effective therapy for
GLD patients is a HSCT such as umbilical cord blood transplantation and BMT. However,
the efficacy of HSCT in GLD is limited by the high-risk nature of this procedure and its
narrow therapeutic window, where this treatment is effective only when applied during
pre-symptomatic period. Thus, a discovery of alternative or additional therapeutic
target(s) for GLD is essential for the development of new treatment for GLD. Our current
knowledge of the precise mechanisms of pathophysiology and cellular pathogenesis in
GLD are limited by a lack of understanding on the sequence of cellular events. Therefore,
in this thesis, I focused on the microglial contribution toward GLD pathogenesis. Results
described in this dissertation provide novel insights into the overall understanding of GLD
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pathogenesis, which may lead us to novel therapeutic targets and treatment strategies for
this devastating disease.
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Chapter Three
Matrix Metalloproteinase (MMP)-3 Mediates Psychosine-induced
Globoid Cell Formation
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III-1 Summary

Globoid cell leukodystrophy (GLD), or Krabbe disease, is a fatal demyelinating disease
attributed to mutations in the galactocerebrosidase (GALC) gene.
mutations

in

GALC

result

in

accumulation

of

the

Loss-of-function

glycolipid

intermediate,

galactosylsphingosine (psychosine). Due to the cytotoxicity of psychosine, it has been
hypothesized that accumulated psychosine underlie the pathophysiology of GLD.
However, the cellular mechanisms of GLD pathophysiology remain unclear. Globoid cells,
multinucleated microglia/macrophages in the central nervous system (CNS), are a
defining characteristic of GLD. Here we report that an exposure of primary glial cultures
to psychosine induces the expression and the production of matrix metalloproteinase
(MMP)-3 that mediated a morphological transformation of microglia into a multinucleated
globoid cell type. Additionally, psychosine-induced globoid cell formation from microglia
was prevented by either genetic ablation or chemical inhibition of MMP-3. These effects
are microglia-specific as peripheral macrophages exposed to psychosine did not become
activated or express increased levels of MMP-3. In the brain from twitcher mice, a murine
model of human GLD, elevated MMP-3 expression relative to wildtype littermates was
contemporaneous with disease onset and further increased with disease progression.
Further, bone marrow transplantation (BMT), currently the only therapeutically beneficial
treatment for GLD, did not mitigate the elevated expression of MMP-3 in twitcher mice.
Hence, elevated expression of MMP-3 in GLD may promote microglial responses to
psychosine that may represent an important pathophysiological process in this disease
and its treatment.
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III-2 Introduction
Leukodystrophies are rare genetic diseases affecting CNS white matter.
Globoid Cell Leukodystrophy (GLD), also known as Krabbe disease (Krabbe, 1916), is a
commonly-pediatric de/dysmyelinating disease with an incidence of about 1 in 100,000
(Duffner et al., 2009). GLD has been attributed to a deficiency of the lysosomal enzyme,
galactocerebrosidase (GALC), resulting from loss of function mutations in the GALC gene
(Wenger, 2001). These loss of function mutations in GALC result in a metabolic defect
and an accumulation of a sphingolipid intermediate, galactosylsphingosine (psychosine)
(Suzuki

and

Suzuki,

1970).

The

excessive

accumulation

of

psychosine

in

oligodendrocytes coupled with the toxicity of this metabolite has led to the “psychosine
hypothesis” of GLD (Miyatake and Suzuki, 1972, Suzuki, 1998). This hypothesis
proposes that elevated levels of psychosine cause the death of oligodendrocytes, which
results in the prominent white matter pathology of GLD. However, when oligodendrocytes
from the twitcher mouse model of this disease are transplanted into dysmyelinating
shiverer mice, these oligodendrocytes differentiate and myelinate (Kondo et al., 2005).
Thus, oligodendrocyte cell death and demyelination in GLD are not a cell-autonomous
process.
Microgliosis and infiltration of peripheral macrophages into the CNS
parenchyma are notable pathologic changes in GLD. Robust microglial activation in the
brains of GLD patients provide a unique and defining feature of this disease: they
transform into highly active, multinucleated phagocytes referred to as 'globoid cells'.
These globoid cells are also observed in animal models of this disease (Kobayashi et al.,
1985). Globoid cells are known to develop from phagocytes during the course of this
disease; however, it is not clear whether these giant multi-nucleated cells arise from
resident CNS microglia and/or infiltrating macrophages. Discerning which cell types
contribute to the formation and activation of these highly activated phagocytes is
expected to provide new insights into the pathogenesis of GLD.
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In a variety of demyelinating diseases, there is a well-established role for matrix
metalloproteinases (MMPs), a family of extracellular endopeptidases that play significant
roles in tissue remodeling and regeneration (Yong et al., 2001). MMPs are known to
cleave all components of the extracellular matrix (ECM) and thereby serve important
homeostatic functions. Particularly relevant to a potential role in GLD, dysregulated
activities of MMPs have been associated with a wide variety of neurodegenerative and
demyelinating diseases, including multiple sclerosis. A role for MMPs in a leukodystrophy
has not been previously reported. In multiple sclerosis, elevated expression of MMPs by
leukocytes facilitates the extravasation of autoreactive T cells into the CNS parenchyma
(Gijbels et al., 1994). Increased expression of MMPs within the CNS is also thought to
promote tissue degeneration (Pagenstecher et al., 1998). In an animal model of
Parkinson's disease, for instance, MMP-3 in particular, has been shown to be a potent
activator of microglia leading to neurodegeneration (Kim et al., 2005). Since microgliosis
and invasion of peripheral macrophages into the CNS represents a primary pathology in
GLD, we hypothesized a role for MMP-3 in GLD.
Herein, we report that psychosine-induced expression of MMP-3 is responsible for
microglial activation and development of multi-nucleated globoid-like cells in primary
murine glial cultures. Elevated expression of MMP-3 in the CNS of twitcher mice, which
was not mitigated by bone marrow transplantation (BMT), the only therapeutically
beneficial treatment for GLD, suggests a role for MMP-3 in the pathology of GLD.
Together these data provide the first demonstration of MMP involvement in a
leukodystrophy.
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III-3 Materials and Methods
III-3.1 Mice
All protocols were performed in accordance with animal use and care protocol
approved by Institutional Animal Care and Use Committees (IACUC). For cell culture
experiments, all procedures using wildtype C57BL/6 and MMP-3 knockout (KO) neonates
were performed at the University of Connecticut Health Center. Bone marrow transplant
experiments were performed at the University of Illinois at Chicago.

III-3.2 Preparation of Primary Mixed Glial Cultures
Cultures were prepared from postnatal day (P) 0-3 wild-type C57BL/6 or
MMP-3 KO mouse pups. Briefly, forebrains were stripped of meninges, chopped into fine
pieces and dissociated using a neural tissue dissociation kit (papain) according to the
manufacturer’s protocol (Miltenyi Biotec, Auburn, CA). The single cell suspension was
then cultured in T75 tissue culture flasks (Grenier Bio-One, Germany) in Dulbecco’s
modified eagle media (DMEM, Gibco, Carlsbad, CA) supplemented with 10% fetal calf
serum (FBS; Atlanta Biologicals, Lawrenceville, GA), penicillin (100U/mL: Sigma Aldrich,
St. Louis, MO) and streptomycin (100mg/mL, Sigma Aldrich). After 12-16 hours, all
non-adherent cells were removed and fresh media was added to the adherent cells.
Mixed glial cultures were utilized experimentally when the confluent astrocytic monolayer
was established.

III-3.3 Purified Glial Cultures
Primary mixed glial cultures were established, as described above. For purified
microglial cultures, confluent mixed glial cultures were shaken using orbital shaker at
110rpm at 37oC 3-4 hrs to allow the loosely adhered microglia to detach from the
astrocytic

monolayer.

Media

was

supplied

with

25mM

2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES, Invitrogen, Grand Island,
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NY) and 25mM sodium bicarbonate (Invitrogen) to buffer pH changes in the absence of
CO2. Following the shaking, media containing detached microglia was collected and
manually counted using a hemacytometer. Cells were re-plated into 6-well plates in
mixed glial conditioned media, and used experimentally as a purified microglial culture
after 2-3 days of incubation at 37oC. Enriched astrocyte cultures were acquired by
culturing the remaining adherent cells following 3-4 hrs shaking and collection of
detached microglia, as described above. Fresh media was added to these cultures and
incubated for 3-5 days at 37oC prior to any experimental manipulation.

III-3.4 Psychosine Treatment & Characterization of Globoid Cells in Culture
Mixed glial cell cultures were established from P0-P3 C57BL/6 or MMP-3 KO
mice, as described above. When confluent, culture media was removed and cells were
washed once in 1x phosphate buffer solution (PBS), then detached using a 0.25%
Trypsin solution (Invitrogen). Cells were spun, washed with 1X PBS, then re-suspended
in culture media, counted and plated at a density of 5.0 x 104/ml on circular glass
cover-slips (Fisher Scientific, Pittsburgh, PA) coated in 5µg/ml laminin (Sigma Aldrich).
Six replicates were performed per treatment. Cells were allowed to adhere for 4-5 days at
37oC with 5% CO2, and treated with either culture media (untreated control); psychosine
(10#M, Sigma Aldrich) (Im et al., 2001); psychosine + the broad-spectrum MMP inhibitor,
GM6001 (12.5#M, Calbiochem, Billerica, MA); psychosine + GM6001i (inactive GM6001
analogue: 12.5#M, Calbiochem); or vehicle control (0.13% of DMSO, Sigma Aldrich; and
0.02% ethanol, Sigma Aldrich). For study using MMP-3 specific inhibitor, NNGH (0.1µM,
Enzo Life Sciences, Farmingdale, NY) was used in the same paradigm of GM6001.
Treatments were supplemented every 48hrs, at the same concentrations, over seven
days of the experiment. We defined globoid cell by immunocytochemistry (see below) as
Iba-1+ with a rounded amoeboid-like morphology and multi-nucleated. Representative
images were taken using an Olympus IX71 fluorescent microscope and Eclipse imaging
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software (empix.com). Numbers of globoid cells were quantified by counting the number
of Iba-1+ cells in four separate areas per coverslip (n=3 replicates totaling 12 images per
treatment group were counted).

III-3.5 Immunocytochemistry (ICC)
Cells were fixed on laminin-coated circular glass cover-slips in freshly prepared
4% paraformaldehyde (PFA, Sigma Aldrich) for 10 min. at room temperature for 15min.,
then blocked and permeabilized with 0.2% Triton X-100 (Sigma Aldrich) in PBS with 5%
normal goat serum (Invitrogen) for 1hr. Fixed cells were incubated at 37oC using the
microglial marker Iba-1 (1:500; Wako, Richmond, VA), glial fibrillary acidic protein
(GFAP)-Cy3 (1:1000; Sigma Aldrich) or GFAP (1:1000; Dako, Carpinteria, CA), and
MMP-3 (Calbiochem; 1:500) primary antibodies in 5% normal goat serum for 1hr.
Following incubation, cells were washed three times in PBS for 10min. each. Cover-slips
were then incubated at 37oC with 1:500 Alexa Fluor® 594 and/or 488 (Invitrogen) and
1:1000 4',6-diamidino-2-phenylindole (DAPI, Invitrogen) for 45min followed by three
washes in 1x PBS for 10min. each. Finally, coverslips were mounted in Fluoromount-G™
(SouthernBiotech, Birmingham, AL).

III-3.6 Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)
Total RNA was isolated from cultured cells, as described previously (Moore et
al., 2011), and reverse transcribed into complementary DNA (cDNA) (iScript cDNA
synthesis kit, Bio-Rad, Hurcules, CA) according to the manufacturer’s protocol.
Synthesized cDNA samples were amplified using PCR primers specific to mmp-3 and
TNF mRNA (Integrated DNA Technologies, Coralville, IA), as employed previously (Chen
et al. , 2009); [MMP-3: forward 5' - GGA AAT CAG TTC TGG GCT ATA CGA-3', reverse,
5'- TAG AAA TGG CAG CAT CGA TCT TC-3'; TNF: forward 5' - GAC CCT CAC ACT
CAG ATC ATC TTC T -3', reverse 5' - CCT CCA CTT GGT GGT TTG CT -3'] and
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SsoFastTMEvaGreen® Supermix (Bio-Rad), according to the manufacturer’s protocol.
Amplification of target cDNA was analyzed by a Mastercycler® ep realplex (Eppendorf,
Hauppauge, NY). Primers for GAPDH were used to assess general expression level of
housekeeping gene among samples; Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH): forward 5' -ACC ACC ATG GAG AAG GC-3', reverse, 5' GGC ATG GAC TGT
GGT CAT GA-3'. For peripheral blood and macrophage sample, ribosomal unit 18S was
targeted as a housekeeping gene (18S: forward: 5’- AGT TGG TGG AGC GAT TTG-3',
reverse: 5’ - TTG CTC AAT CTC GGG TG - 3'). Relative expression of mRNA was
calculated using the comparative cycle threshold analysis (!!CT), as previously
described (Livak and Schmittgen, 2001). Briefly, the difference of cycle threshold (CT)
values between target and housekeeping genes within each sample (!CT) was calculated,
and then the difference of !CT between control or wildtype and experimental groups
(!!CT) was derived by substraction. Finally, relative quantification values (RQ) for each
sample were calculated using the following equation: RQ = 2-!!CT (Livak and Schmittgen,
2001). The RQ reflects the normalized values of target mRNA expression (i.e. MMP-3) in
fold change with reference to control or wildtype samples, which are expressed as 1 fold
change in graphs, within the same experiment.

III-3.7 Microglial Phagocytosis Assay
Primary mixed glial cultures were prepared, as described above, from
P0-P3 wild-type C57BL/6 mice. Cultures were plated at a density of 1 x 105 cells/mL on
laminin-coated glass coverslips and treated for 7 consecutive days with PBS, psychosine
(10#M), or psychosine and GM6001 (12.5#M). At 48hrs prior to fixation, fluorescein
isothiocyanate (FITC)-labeled latex beads (Cayman Chemical Company; Ann Arbor, MI)
were added to all treatment groups. Cells were then incubated at 37oC for the duration of
the experiment and then fixed using 4% PFA in PBS. Immunocytochemistry was then
performed for Iba-1 and numbers of Iba-1+/FITC+ labeled cells were counted to
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determine the numbers of microglia that took up the beads for each treatment group
(n=3/group; replicates of 9).

III-3.8 Peripheral Blood Cell Assay
Peripheral blood was collected from wildtype mice by intracardial needle
puncture and treated for 4 hrs (37˚C, 5% CO2) with either psychosine (10µM) or
lipopolysaccharide (LPS; 100µg/ml; Sigma Aldrich). To lyse the red blood cells, the
treated samples were immediately incubated on ice with ammonium chloride (0.72%, pH
7.2; STEMCELL technologies) for 10min. Samples were spun at 1000Xg for 10min.,
followed by aspiration of ammonium chloride. The pellet was washed with 1mL of Roswell
Park Memorial Institute media (RPMI; Gibco), spun at 1000Xg for 5min, and supernatant
was aspirated. The pellet was re-suspended in TRIzol (invitrogen) and total RNA from
peripheral blood white cells was isolated, as previously described (Moore et al., 2011).

III-3.9 Peripheral Macrophage Collection
Peripheral macrophages were collected from the peritoneal cavity of adult mice,
as described previously (Ray and Dittel, 2010) with slight modifications. Briefly, adult
wildtype C57BL/6 mice were anesthetized and 4-5mL of ice cold PBS with 3% FBS was
injected intraperitoneally to each animal. Filled peritoneum was massaged well to detach
the tissue-adhered macrophages into the cavity, followed by collection of injected PBS
through 25G needle inserted into the peritoneal cavity. Collected cell suspension was
centrifuged at 1500rpm for 7min, and collected cell pellet was resuspended in RPMI with
5% FBS. Cells were plated in the plastic dish overnight (37˚C, 5% CO2) to allow
macrophages to adhere at the bottom of dish. Media was then removed and adhered
macrophages were plated at 5x106 cells/ml. The purity of differentially adhered
macrophages was enumerated by flow cytometry (Supplemental Figure 1). Plated
macrophages were then treated with psychosine or LPS in the same regimen as

61

described in peripheral blood cells assay (see above).

III-3.10 Twitcher Mice
Twitcher mice (GALCtwi Mice) are a well-characterized murine model of GLD,
which is caused by a spontaneous mutation in the GALC gene. Mice were housed and
bred at the Sanford-Burnham Institute (La Jolla, CA) where tissues were collected from
homozygous GALCtwi/GALCtwi mice and wildtype littermates at different time points
following birth P0, 10, 20, 31, and 40, as previously described (Taylor et al., 2006).
Twitcher mice for BMT experiment were housed and bred at the University of Illinois at
Chicago (Chicago, IL).

III-3.11 Immunohistochemistry (IHC)
Twitcher mice and age-matched littermate control mice were transcardially
perfused with PBS and 4% PFA, and their brain was removed. Collected brains were
immersed in 4% PFA overnight and then in 30% sucrose solution. Brain tissue was
paraffin-embedded and sectioned 15µm in thickness. Tissue sections mounted on slide
glass were deparaffinized and dehydrated by series of xylene and ethanol,
antigen-retrieved by heated citric acid buffer (0.01M, pH6.0), and blocked with 5% normal
goat serum in PBS for 1 hour. Immunohistochemistry was then performed using primary
antibodies against GFAP (1:1000, Dako), ionized calcium-binding adapter molecule 1
(Iba-1; 1:2000, Wako), and MMP-3 (1:100, CalBioChem), diluted in PBS with 2% normal
goat serum and incubated tissues in antibodies overnight at 4˚C, followed by PBS wash.
Immunoreactivity for each target was visualized by using fluorescent secondary
antibodies, including Alexa Fluor® 594 and 488 (1:500; Invitrogen), followed by PBS wash.
The tissues were then coversliped using FluoroMount G (SouthernBiotech).
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III-3.12 Bone marrow transplantation (BMT) in Twitcher mice
Bone marrow cells were obtained from C57BL/6J CD45.1 (8-12 weeks) as
previously described (Galbiati et al., 2009). Briefly, tibiae and femora were flushed with
0.9% saline and the cells filtered (44-#m strainer; BD, San Diego, CA). The cellular eluent
was then centrifuged at 1,500 rpm (5 min) and cell pellets incubated in lysis buffer to
eliminate all red blood cells (10 min at 48oC; 155 mM ammonium chloride, 10 mM
potassium bicarbonate, 0.1 mM ethylenediaminetetraacetic acid, EDTA, pH 8).
Mononuclear cells were washed in saline and counted using a hemocytometer and then
re-suspended (30 X 106 cells/20 #l saline) for intravenously infusion. Cells were injected
in newborn Twitcher pups (1-2 days after birth) through the parietal vein, as previously
described (Billingham et al., 1956, Sands and Barker, 1999). Transplanted mice were
returned to their mothers without any other treatment.

III-3.13 Statistical Analyses
Data are presented as mean ± standard error of mean (SEM). A one-way
analysis of variance (ANOVA) with Tukey's post hoc tests or unpaired Student's t test was
used to determine group differences. For all tests, p < 0.05 was considered significant.
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III-4 Results
III-4.1 Age-dependent increase in the CNS expression of MMP-3 in twitcher mice
Spontaneous mutations in GALC in C57/BL6 mice have been found to limit
lifespan and produce neuropathology resembling human GLD. These 'twitcher' mice are
now established as an authentic model of GLD. To determine whether expression of
MMP-3 was altered during the lifespan of twitcher mice, total RNA was isolated from
whole brains of twitcher mice and wildtype littermates from time of birth (P0) through P40,
at which >95% mortality was observed among homozygous mutant mice. qRT-PCR
evaluation of mmp-3 mRNA revealed a significant increase in expression in twitcher mice
compared to wildtype counterparts (Figure 3-1A). This increase of MMP-3 expression
coincided with the onset of clinical disease in twitcher mice, which is approximately P20
(Figure 3-1A). Additionally, the increase of MMP-3 expression in twitcher mice showed a
temporal correlation (Figure 3-1A). The increase in MMP-3 expression in twitcher mouse
brain relative to wildtype age-matched controls was 7.5 fold by P40. To identify the
cellular source of increased MMP-3 in the twitcher mouse brain, we performed
immunohistochemistry for MMP-3 on brain tissue sections from P40 twitcher mice, a time
point with the highest MMP-3 expression. Immunoreactivity of MMP-3 in twitcher mouse
brain at P40 was frequently co-localized with GFAP+ astrocytes (Figure 1B-D). Only a
small portion of Iba-1+ microglia in twitcher mouse brain was co-localized with MMP-3
immunostaining (data not shown). Although neurons have also been implicated as a
source of MMP-3 in other neurodegenerative disease models (Kim et al., 2005), our data
support glia as a prominent source of MMP-3 production in GLD.
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Figure 3-1 Elevated astrocytic MMP-3 expression in twitcher mouse brain. (A)
MMP-3 expression level in the brain of wildtype (WT) and twitcher (TWI) mice at various
ages was quantified by qRT-PCR. (B-D) MMP-3 protein expression (red) was visualized
by immunohistochemistry from the brain section of P30 twitcher mouse. Note that MMP-3
immunoreactivity is co-localized (white arrows) with the astrocyte-specific marker, glial
fibrillary acidic protein (GFAP; green). Data represent mean ± SEM. N=3/age/genotype,
scale bar = 50µm
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III-4.2 Psychosine regulates MMP-3 expression from glia, but not peripheral
immune cells.
The increase of MMP-3 in twitcher mice and its correlation with disease
progression prompted us to examine if psychosine is a regulator of this response. To test
this, mouse primary mixed glial cultures were treated with psychosine (10µM) at a dose
previously reported to activate a macrophage cell line (Im et al., 2001). qRT-PCR analysis
of RNA isolated from cultures treated with psychosine for 2, 4 or 20 hours determined that
there was a time-dependent increase of mmp-3 mRNA expression (Figure 3-2, ANOVA,
**P<0.01, ***P<0.001). In a second set of experiments, we tested whether the level of
mmp-3 expression induced by psychosine was concentration-dependent. Psychosine
concentration less than 10µM did not influence glial cells with respect to MMP-3
transcription (data not shown). Additionally, analysis of increasing concentrations of
psychosine (10-100µM) did not uncover a further enhancement of mmp-3 expression
above that observed with 10µM (data not shown). At the highest concentration of
psychosine tested (100 µM) we observed significant cytotoxicity in the glial cultures (data
not shown). Hence, we determined that psychosine transcriptionally induced mmp-3
expression in primary cultured glia.
In a previous study, we determined that MMP-3 is predominantly expressed by
astrocytes in response to inflammatory stimuli (Crocker et al., 2006). To determine
whether psychosine-induced mmp-3 expression in glial cultures was derived from
astrocytes or microglia, or both, we next examined the cellular source of increased
mmp-3 mRNA expression. Mixed glial cultures, enriched astrocyte cultures, or purified
microglial cultures were treated with psychosine (10 #M) for 20 hours, and the level of
mmp-3 mRNA expression was analyzed using qRT-PCR.
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Figure 3-2 Psychosine transcriptionally regulates MMP-3 expression in primary
glial cultures. Primary mixed glial cultures from wildtype mouse were treated with
psychosine (10µM) for 2, 4, 24hrs and MMP-3 mRNA expression level was quantified by
qRT-PCR. Data represent mean ± SEM. N=3-4/treatment/timepoint. ** P<0.01, ***
P<0.001
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In our mixed glial cultures, which we have previously characterized, are comprised of
approximately 95% astrocytes and 5% microglia at 25 days in vitro (Crocker et al., 2006,
Milner and Campbell, 2002), can be grown and then mechanically sorted to enrich for
astrocytes and separate purified microglial populations. Importantly, these culture
conditions are not conducive to oligodendrocyte progenitor cell growth or maturation.
Psychosine treatment of enriched astrocyte cultures significantly increased mmp-3
mRNA expression compared to untreated enriched astrocyte cultures (p<0.01,
psychosine vs. untreated in mixed glia; p<0.05, psychosine vs. enriched astrocytes;
Figure 3-3a). However, application of psychosine to purified microglial cultures did not
significantly increase mmp-3 expression when compared with either untreated purified
microglia cultures or untreated mixed glial cultures (t-test, p=0.247; Figure 3-3c). These
results indicated that astrocytes were the primary source of mmp-3 expression in our
cultures.
Because macrophages infiltrate the CNS during GLD, and macrophages have
been implied in the formation of globoid cells in this disease, we next sought to determine
whether peripheral immune cells, including macrophages specifically, could be induced to
express MMP-3 in response to psychosine. Whereas psychosine treatment in primary
purified microglial cultures moderately induced MMP-3 expression, treatment of
peripheral blood or purified macrophages with equivalent concentrations of psychosine
did not induce MMP-3 expression (Figure 3-3 b,d,f,h). qRT-PCR analysis of mmp-3
mRNA expression also revealed that LPS did not induce mmp-3 mRNA expression in
peripheral blood samples (Figure 3-3e). Since whole blood contains a myriad of cell types
that may also regulate macrophage responsiveness, and peripheral blood samples
contain only a small population of macrophages, we also isolated unstimulated peritoneal
macrophages and challenged these purified cells with either psychosine or LPS. Flow
cytometry determined that the proportion of macrophages in our preparations from
peritoneal cavity were over 95% (Figure 3-4).
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Figure 3-3 Psychosine regulates MMP-3 expression differently in CNS microglia
and peripheral blood cells/macrophages. Mixed glial culture, purified microglia, whole
blood white cells, and peritoneal macrophages were treated with psychosine (10µM) or
LPS (10µg/mL) for 4hrs, and MMP-3 mRNA expression level was analyzed by qRT-PCR
(a,c,e,g). Also, to ensure the cellular responsiveness to stimulus, TNF mRNA expression
level was also quantified (b,d,f,h). Note that CNS cells with psychosine treatment had
increased MMP-3 expression (a,c), but not peripheral cells (e,g), although peripheral cells
had increased TNF expression in response to LPS (f,h). N=3-4/treatment/cell type. Data
represent mean ± SEM. *P<0.05, **P<0.01
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Figure 3-4 Differential adherence highly enriches macrophages from peritoneal
exudates. Isolated macrophages from peritoneal cavity of adult wildtype mice were
adhered on plates overnight and yielded higher number of macrophages, determined by
flow cytometry. CD11b+ cells within the CD45+ live cell population (blue) were >97% in
adherent cell samples. CD11b positivity was determined by the negative control of mouse
blood cell sample (red).
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Treatment of purified peritoneal macrophages for 4 hours with either psychosine or LPS
revealed that neither psychosine nor LPS induced mmp-3 expression in peritoneal
macrophages (Figure 3-3g).
However, analysis of tumor necrosis factor (TNF) expression in these same
culture preparations determined that TNF expression was robustly induced by LPS
(Figure 3-3h; ANOVA, P<0.05), suggesting that the peritoneal macrophages were healthy
and capable of responding to stimulation. These results indicate that microglia and
peripheral macrophage populations markedly differ in their responses to psychosine and
regulation of mmp-3 expression.

III-4.3 Psychosine induces 'globoid'-like cells in primary glial cultures.
A hallmark pathology of GLD is the formation of globoid cells. Based on our
finding that psychosine regulated MMP-3, an extracellular activator of microglia (Kim and
Hwang, 2011), and previous work by Im and colleagues reported the development of
multinucleated cells following psychosine treatment of BV2 and HEK293 cell lines (Im et
al., 2001), we hypothesized that psychosine may induce a globoid-like phenotype in
primary cultured glia. We next treated primary mixed glial cultures with 10µM psychosine
for seven consecutive days. Cultures were then analyzed by immunostaining for the
microglial marker, Iba-1, the astrocyte marker, GFAP, and nuclear counterstain with DAPI.
Control, untreated mixed glial cultures exhibited Iba-1+ cells with short-branched
morphology that is typical of cultured microglia (Figure 3-5A). In contrast, Iba-1+ glia
exposed to psychosine exhibited an amoeboid-shaped phenotype, which was frequently
multinucleated (Figure 3-5C). These enlarged multinucleated cells resembled what would
be referred to as 'globoid' cells in the CNS pathology of GLD specimens. Indeed, the
number of polynucleated Iba1+ cells in psychosine-treated cultures was increased 5.5
fold compared to control conditions (p<0.001; Figure 3-5 C&D).
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Figure 3-5 Psychosine induces globoid cell formation in a primary mixed glial
culture. (A-D) Addition of psychosine (10µM) for 7 days significantly increases numbers
of Iba-1+ (green) multi-nucleated globoid cells compared to both controls [No treatment
(No/T)] and vehicle in a primary mixed glial culture. Data represent mean ± SEM.
***p<0.001 relative to No/T. Scale bar= 20µm.
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III-4.4 Psychosine does not induce globoid-like cells in MMP-3KO glia.
To determine whether MMP-3 specifically was the mediator of globoid cell
formation in response to psychosine treatment, we prepared primary mixed glial cultures
from MMP-3 knockout (KO) mice in addition to wildtype littermates, and applied
psychosine (10µM) for 7 consecutive days, as outlined above. In MMP-3 KO cultures,
psychosine did not induce mmp-3 expression, as we expected (data not shown).
Moreover, globoid cells were not induced in MMP-3KO cultures by psychosine treatment
(Figure 3-6C,D), but were readily and robustly produced in wildtype cultures (Figure 3-5).
Microglial morphology in psychosine-treated MMP-3KO cultures was similar to untreated
cultures (Figure 3-6A,C). Thus, genetic ablation of MMP-3 prevented psychosine-induced
globoid cell formation in vitro, suggesting that MMP-3 is required for psychosine-induced
globoid cell formation.

III-4.5 Globoid cell formation in primary glial cultures is blocked by chemical
inhibition of MMPs.
To determine whether increased expression of MMP-3 in response to
psychosine exposure was directly related to the morphological transformation of
microglia, we treated primary mixed glial cells with the broad-spectrum MMP inhibitor,
GM6001, in conjunction with psychosine treatment for seven days. Microglial morphology
was examined using immunostaining with Iba-1 as a microglial marker. Psychosine
treatment in mixed glial culture induced the morphological change of Iba-1+ cells toward
globoid-like cells (Figure 3-7B,J). However, this morphological alteration in microglia was
hampered when an MMP inhibitor was concomitantly added in the treatment (Figure 3-7C,
J). Next, we sought to determine whether morphological alterations in Iba-1+ microglia
induced by psychosine were also associated with functional changes in phagocytosis.
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Figure 3-6 Psychosine-induced “globoid-like cell” formation in vitro requires
MMP-3. Primary mixed glial cultures were prepared from MMP-3 KO and WT littermates
and then treated with psychosine (10µM) for 7 days. ICC was performed using Iba-1
antibody (green) and DAPI (blue) and the number of multi-nucleated microglia were
quantified. The numbers of Iba-1+ cells did not differ between untreated wt of KO cultures.
The prevalence of globoid-like cells observed in wt cultures treated with psychosine was
elevated 6 fold over vehicle treatment (A-D) but were absent from the MMP-3 KO cultures
(D). Data represent n=8/treatment; **, P<0.01, t-test vs. WT. Scale bar = 20µm.
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Figure 3-7 Metalloproteinase inhibition impairs psychosine-induced globoid cell
formation and phagocytic activity of microglia. (A-C) Following a 7d treatment with
psychosine (10µM), the presence of Iba-1+ globoid cells (green; nuclei-blue) were
significantly increased (A) compared to control (B), while this effect was reversed with the
addition of a pan-MMP inhibitor (MMPi; GM6001, 12.5µM) (C,J). Panel B demonstrates
the large amoeboid shape of Iba-1+ cells treated with psychosine, which was reversed
with the MMPi. (D-F) Primary mixed glial cultures (Iba-1+ cells-red; FITC+ beads-green;
nuclei-blue) incubated for last 48hrs of 7d psychosine treatment with latex FITC-labeled
beads (white arrows) demonstrates that psychosine treatment significantly increased the
phagocytic activity Iba-1+ cells, which was also significantly decreased by addition of the
MMPi (K). Primary mixed glial culture from wildtype mouse (G) was treated with
psychosine (10µM) alone (H), or psychosine and NNGH (0.1µM) concomitantly (I) for 7d.
Immunocytochemistry study revealed that psychosine induced Iba-1+ (green) globoid
cells containing multiple nuclei (DAPI, blue) (H), but failed to induce globoid cells when
NNGH was added together (I). Number of globoid cells was quantified (L). Data represent
mean ± SEM. ***p<0.001, *p<0.05. Scale bar Top= 30µm; Middle=20µm; Bottom=18µm.
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To test this, we cultured primary mixed glia, treated them with psychosine for seven days
but applied fluorescent latex beads to the cultures for the last 48 hours of the experiment.
Immunostaining for Iba-1+ cells that also contained fluorescent beads was quantified as
a functional index of phagocytosis in response to psychosine (Figure 3-7D-F,K).
Psychosine induced a four-fold increase in phagocytosis over basal levels observed in
untreated, control cultures (ANOVA; p<0.0001). Treatment with the MMP inhibitor,
GM6001, significantly reduced psychosine-induced phagocytosis (Figure 3-7F,K). These
data indicate that psychosine-induced activation of microglia in culture was mediated by
MMPs.

III-4.6 Globoid cell formation in primary glial cultures is blocked by a peptide
inhibitor of MMP-3.
Because GM6001 is a non-selective, broad spectrum MMP inhibitor, we wanted
to ascertain whether selective inhibition of MMP-3 may also attenuate globoid cell
formation in primary cultures treated with psychosine. To test this, we used the small
peptide NNGH (Ki=130nM for MMP-3), which exhibits greater specificity for MMP-3 than
other MMPs. Co-application of NNGH to psychosine-treated cultures resulted in a
marked reduction in the number of globoid cells compared to cultures treated with
psychosine alone (Figure 3-7G-I,L). Thus, inhibition of MMPs including specific inhibition
of MMP-3 attenuated the transformation of primary microglia into the highly activated
globoid-like cell type.
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Figure 3-8 Increased mmp-3 mRNA expression in twitcher mouse brain is not
attenuated by bone marrow transplantation. qRT-PCR was performed on cDNA
derived from mRNA isolated from whole brain homogenates from P40-50 WT, untreated
twitcher, and bone marrow transplanted (BMT)-twitcher mice. Data are presented as fold
change of mmp-3 mRNA relative to the expression of GAPDH within each sample
(N=3-4/timepoint/genotype). Data represent mean ± SEM.
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III-4.7 Bone marrow transplantation does not dampen elevated MMP-3 levels in
twitcher mice.
Currently, the only treatment option for GLD cases is bone marrow
transplantation (BMT) (Krivit et al., 1998). Recent clinical follow-up studies have
determined that although BMT for GLD can alleviate symptoms, it does not prevent
disease progression and eventually most patients succumb to ongoing progressive
deterioration (Duffner et al., 2009). The clinical benefit of BMT is also observed in twitcher
mice (Luzi et al., 2009, Yeager et al., 1984). Indeed, analysis of glial pathology in twitcher
mice following BMT has reported reduced microgliosis and enhanced numbers of foamy
macrophages that correlated with improved clinical outcome (Hoogerbrugge et al., 1988).
We hypothesized that BMT may dampen the elevated mmp-3 expression within the CNS
in GLD and this may be a contributing factor to the therapeutic benefit of BMT. To
determine whether elevated mmp-3 expression in the twitcher CNS was affected by BMT,
we next examined mmp-3 mRNA expression in twitcher mice that received BMT in the
early postnatal period. A detailed characterization of these transplanted mice has been
reported (Galbiati et al., 2009). Consistent with our previous analyses, symptomatic
twitcher mice exhibited higher levels of mmp-3 mRNA than wildtype (control) mice (Figure
3-8). However, expression of mmp-3 among twitcher mice that had received BMT,
although exhibiting more inter-subject variability (range: 1.5 - 21 fold over wildtype) did
not differ from non-BMT treated twitcher mice (Figure 3-8). Hence, the sustained
expression of mmp-3 in BMT-recipient twitcher mice may reflect a persistent disease
process within the CNS that is not ameliorated by BMT.
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III-5 Discussion
In this study we have determined that psychosine regulates expression of MMP-3,
which mediates the activation and proliferation of microglia toward a multi-nucleated
globoid cell phenotype. Psychosine-induced increase in phagocytic activity and globoid
cell formation were prevented by inhibition of MMP-3. Elevated MMP-3 expression was
also identified in twitcher mice, an authentic animal model of GLD, and this elevation was
not reversed by BMT. Hence, elevated MMP-3 expression in GLD may represent an
important mediator of microglial activation in GLD.
The roles of microglia and macrophages in GLD are not currently well defined.
Evidence for beneficial and detrimental functions for both of these phagocytic populations
in GLD and twitcher mice have been provided in several previous studies by others
(Kagitani-Shimono et al., 2005, Kondo et al., 2011, Matsushima et al., 1994). We
hypothesize that sustained induction of MMP-3 by accumulated psychosine in the CNS of
individuals with GLD promotes microglial activation and globoid cell formation, but not
macrophage activation, which may promote myelin degeneration through the robust
phagocytic activity of these microglia-derived cells. Our in vitro experiments would
indicate that macrophages and microglia are functionally distinct cell types that respond
in distinctly different ways to psychosine exposure. These results support an ontogenic
separation of these related yet specialized phagocytic cell types (Ginhoux et al., 2010)
and our findings provide a potentially unique distinction between microglia and
macrophages in this disease through their differential propensity to be activated by
psychosine.
While we hypothesize that the highly activated nature of globoid cells in vitro
may reflect a pathogenic form of microglia that contribute to neuropathology in GLD, it is
also plausible that highly activated phagocytes could represent an endogenous protective
response to clear dead or dying cells to foster remyelination (Neumann et al., 2009). For
instance, remyelination in a chemical lesion model of focal demyelination is impaired
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when microglia/macrophages are inhibited (Kotter et al., 2005, Li et al., 2005). When
interpreted in the context of our results, the highly activated microglia in response to
psychosine could represent a mode of myelin debris clearance that would allow for
removal of growth inhibiting molecules and promote oligodendrocyte progenitor cell
proliferation and differentiation (Neumann et al., 2009). Although these previous studies
were not examined in the context of the twitcher mouse brain, recent work by Kondo et al.
describes a possible protective function of microglia/macrophages in GLD (Kondo et al.,
2011). Thus, it is plausible that psychosine-induced MMP-3-mediated microglial
activation could be a robust but ultimately insufficient attempt to foster brain repair in the
GLD CNS.
Our results may also indicate that globoid cells in GLD may be exclusively derived
from resident microglia and provides an explanation for why globoid cells are not
observed in association with demyelinating peripheral neuropathy in GLD (Siddiqi et al.,
2006, Tanaka et al., 1988). Globoid cell formation in the CNS of human and animal GLD
is traditionally believed as a secondary consequence followed by a primary
oligodendrocyte death due to the accumulation of psychosine in oligodendrocytes
(Takahashi and Suzuki, 1984). Our data demonstrate that microglia transformed toward a
globoid cell-like morphology in response to psychosine treatment in vitro, however our
glial culture systems used in this study did not contain oligodendrocytes. Moreover,
microglial activation and globoid cell formation are effects of psychosine on microglia that
can occur independently of oligodendrocytes in culture. Thus, based on these data,
microglial activation and globoid cell formation in GLD, rather than being a secondary
response to CNS demyelination, may instead be a primary response to psychosine. In
fact, it was previously reported that globoid cells were observed prior to the onset of
disease and/or demyelination (Martin et al., 1981).
Overall, this work indicates that psychosine initiates changes in many cell types;
including, microglia, astrocytes and oligodendrocytes. In this context, our globoid cell
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assay using primary glial culture may be a practical model to test and understanding the
pathological process of microglial activation by psychosine. For instance, identifying the
proteolytic target(s) of MMP-3 on microglia may provide a novel strategy to better
understand the specific actions of activated microglia and/or formation of globoid cells in
GLD. While the pathogenic contribution of microglia can only be inferred from previous
work, the contribution of MMP-3 toward GLD pathology was not directly addressed in this
study. Future studies will be required to examine the specific contribution of MMP-3 in
GLD neuropathology and elucidate whether this process impacts microglial activation,
inflammatory profiles and globoid cell formation in vivo.
The proteolytic actions of MMPs are regulated by the tissue inhibitors of
metalloproteinases (TIMPs) (Crocker et al., 2004). In a course of disease in twitcher mice,
we examined the expression of TIMP-1, a timp gene that is robustly expressed during
CNS demyelination that is also well-characterized endogenous inhibitor of MMP-3
(Gomis-Ruth et al., 1997). Our qRT-PCR analysis determined that expression of TIMP-1
increased only modestly over the same time frame relative to the robust increase in
MMP-3 expression (data not shown). Moreover, expression of MMP-2 and -9 in the CNS
of twitcher mice did not differ from the levels of expression in wildtype littermates
throughout their postnatal development (data not shown). Hence, in the CNS of twitcher
mice there is a dysregulation of certain MMPs, namely MMP-3, during the course of
disease. Elevated expression of MMP-3 has been reported in a variety of CNS white
matter disorders including multiple sclerosis and experimental models of spontaneous
demyelination (D'Souza et al., 2002, Pagenstecher et al., 1998, Toft-Hansen et al., 2004).
On the basis of previous studies, pathological actions of elevated MMP-3 expression in
GLD could contribute to GLD pathology in two ways. First, we have shown that MMP-3 is
important for the phenotypic activation of microglia (Kim et al., 2005), as we have also
demonstrated in response to psychosine. Secondly, previous studies have shown that
many myelin proteins are proteolytic targets of MMPs (Chandler et al., 1996, Milward et
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al., 2008), including MMP-3 (Shiryaev et al., 2009). Hence, elevated MMP-3 production in
the CNS of twitcher mice may contribute to destabilization of CNS myelin and
oligodendrocyte death as well.
Currently, the primary therapy for GLD patients is BMT. The effectiveness of this
stem cell-based therapy in GLD has been reported to be highly variable among human
cases with limited long-term benefit for some patients (Duffner et al., 2009,
Hoogerbrugge et al., 1988, Kobayashi et al., 1988). Among twitcher mice, BMT increases
lifespan

and

improves

neuropathology

but

these

mice

still

die

prematurely

(Hoogerbrugge et al., 1988, Yagi et al., 2005, Yeager et al., 1984). Previous discussions
on the limited efficacy of the stem cell transplantation in GLD have indicated that
microglial activity in twitcher mice remains high, even after neural stem cell
transplantation (Pellegatta et al., 2006). Our data in this study may shed light on this
pathology, namely that elevated MMP-3 expression in the CNS of twitcher mice was
unaltered by BMT, although there is a possibility of delayed induction in MMP-3
expression by BMT. Thus, sustained induction of MMP-3 may represent an inherent
limitation of BMT treatment for GLD. Abrogation of microglial activation, perhaps through
MMP-3-targeted strategies may be a mode for controlling microglial activation that could
enhance the therapeutic efficacy of BMT in GLD. Hence, persistent expression of MMP-3
in the GLD brain may represent a limitation of long-term prognosis for this treatment
approach. In future, experiments designed to address the issue of the limited therapeutic
window for BMT (Krivit et al., 1998) could potentially include adjunct MMP inhibiting
therapy to address the excessive production of MMP-3 in the CNS compartment in this
disease. Nevertheless, whether as a potential therapeutic target for GLD treatment, or as
a source of basic understanding on MMP-3 regulation of microgliosis in GLD, additional
study is expected to provide new information on the innate inflammatory response in GLD,
how it may be regulated by MMP-3, as shown in this study, and potentially provide
additional insights into MMP-3 in other diseases as well.
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Formation of multinucleated giant cells are pathological hallmarks of many
neurological diseases including amyotrophic lateral sclerosis (ALS) (Fendrick et al.,
2007), HIV encephalitis (Budka, 1986), Alzheimer's disease, acute disseminated
encephalomyelitis, giant cell angiitis [associated with vasculitis in the CNS (Ciappetta et
al. , 2010)], gliomas and neuroepithelial tumors (Adamek et al., 2008) and other
leukodystrophies as well (Budka, 1986, Elleder, 1984). Among these other diseases in
which giant multinucleated microglia are found, elevated expression of MMP-3 has been
reported in Alzheimer’s disease (Yoshiyama et al., 2000). Although a pathological
association between MMP-3 and formation of giant cells in these diseases has not been
previously reported, our study would support this line of future investigation. Moreover,
the mechanism by which multinucleated microglial cells are formed in response to
psychosine, and mediated by MMP-3, may have an application toward the pathogenesis
of these other neurodegenerative diseases. Future studies will explore the actions of
MMP-3 on microglial cytokinesis, for instance (Kanazawa et al., 2000), in response to
psychosine and other pathological stimuli that results in formation of multinucleated giant
cells. The importance in pathogenic contribution of these multi-nucleated phagocytes
toward neuropathology and disease progression will be required to fully understand the
mechanism of these disease-associated changes in microglial phenotypes.
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Chapter Four
Aberrant Production of Tenascin-C in Globoid Cell
Leukodystrophy Alters Psychosine-induced Microglial
Functions
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IV-1 Summary
Globoid Cell Leukodystrophy (GLD), also known as Krabbe disease, is a rare
and often fatal genetic demyelinating disease, for which there is no reliable or effective
long-term treatment. GLD results from mutations in the galactocerebrosidase (galc) gene.
Reduced or nullified GALC activity results in a pathological accumulation of
galactosylsphingosine (psychosine) in GLD. The pathological impact of psychosine
accumulation in GLD is likely manifold; dys/demyelination, lipid raft disruption, perturbed
neuronal function, microglial activation and formation of globoid cells are all known
consequences of psychosine toxicity. We recently reported that the extracellular protease,
matrix metalloproteinase (MMP)-3, was specifically elevated in GLD and is a principal
regulator of psychosine-induced microglial activation. Well-known substrates of MMP-3
include many components of the extracellular matrix (ECM), which are increasingly
recognized for their influence on glial responses in neurodegenerative diseases. Elevated
production of MMP-3 and its plausible role in GLD led us to examine whether ECM
components were altered in their expression in the CNS of GLD patients or its animal
model, the twitcher mouse. Herein, we determined that the ECM glycoprotein tenascin-c
(TnC) was expressed at significantly higher abundance in GLD than age-matched
controls. TnC-positive immunostaining displayed a pattern of intensely labeled foci
resembling plaques that were also frequently thioflavin-S positive. This unique pattern of
TnC positive staining was evident in brain specimens from both human and the twitcher
mouse model of GLD. Expression of other ECM components, including vitronectin,
laminin, and fibronectin were unaltered in these tissues. We then examined the effect of
TnC on glial function and found that formation of 'globoid-like' cells in psychosine-treated
primary glial cultures grown on TnC was increased in association with dramatically higher
MMP-3 mRNA expression. Co-culture of 'globoid-like' cells grown on a TnC substrate
with primary oligodendrocyte cultures resulted in a marked increase in cytotoxicity when
compared with cells grown on a laminin substrate. Microglia exposed to psychosine
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grown on TnC also exhibited increased expression of M1 microglial phenotype markers,
whereas without TnC exposure grown microglia exhibited predominantly M2 phenotype
markers. Thus, we hypothesize that the elevated expression of TnC in GLD contributes to
neuropathology in this disease, at least in part, through the modification of the microglial
responses to psychosine. These data offer a novel perspective on the role of the ECM
microenvironment in the pathology of GLD, and provide additional insight into our
emerging understanding on the microglial contribution to the pathogenesis of this
disease.
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IV-2 Introduction
Globoid cell leukodystrophy (GLD), also known as Krabbe disease, is a fatal
demyelinating disease with an incidence of 1 in 100,000 in the United States (Duffner et
al., 2009, Wenger et al., 2000). The cause of GLD is attributed to genetic loss-of-function
mutations in the galactosylceramidase (GALC) gene (Zlotogora et al., 1990). The natural
function of this lysosomal enzyme, GALC, is to hydrolyze galactolipids, including the toxic
lipid galactosylsphingosine, ‘psychosine’. Hydrolysis of psychosine is thought to prevent
cellular damage (Svennerholm et al., 1980). Thus, its mutation in GLD results in
supraphysiological accumulation of psychosine (Miyatake and Suzuki, 1972). It is widely
accepted that abnormal accumulation of psychosine drives GLD pathology through its
pathophysiological effects on multiple cell types (Miyatake and Suzuki, 1972). However,
the exact mechanism of action of psychosine and the sequence of events that occur at
the cellular level culminating in GLD pathology remain unclear.
The neuropathological hallmarks of GLD include severe demyelination of the
central nervous system (CNS), extensive astrogliosis, and the presence of large,
multinucleated phagocytes called ‘globoid cells’. It had been suggested that formation of
globoid cells in GLD was a secondary response to profound CNS demyelination; however,
we recently determined that globoid cells are likely a primary microglial response to
psychosine (Ijichi et al., 2013). These data support an emerging hypothesis that
psychosine induces widespread pathological changes in many cell types. Moreover, the
response of microglia to psychosine provides a new model to study the unique formation
and specific function(s) of globoid cells found within the CNS in GLD.
The extracellular matrix (ECM) is an intricate macromolecular network that
occupies the extracellular space to provide a structural framework and homeostatic
signaling environment for tissues. Differential production of ECM components has been
reported in many CNS diseases, including Alzheimer’s disease (Morawski et al., 2012),
stroke (Ji and Tsirka, 2012), human immunodeficiency virus encephalitis (Belichenko et
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al., 1997), and multiple sclerosis (MS) (Bonneh-Barkay and Wiley, 2009). One widely
studied implication of altered ECM composition includes dysregulation of cellular growth,
differentiation and cell fate (Eyermann et al., 2012, Goetz et al., 2006, Lathia et al., 2007,
Lei et al., 2012). For instance, in acutely demyelinated lesions in MS, tenascin-C (TnC)
levels have been reported to be decreased relative to unlesioned or healthy tissues
(Gutowski et al., 1999), whereas in chronically demyelinated lesions elevated production
of TnC from astrocytes has been observed (Back et al., 2005, Gutowski et al., 1999).
These changes in TnC levels associated with myelin lesions have lead to the suggestion
that TnC may negatively influence the remyelinating potential of oligodendrocyte
progenitor cells in and around myelin lesions (Back et al., 2005, Gutowski et al., 1999).
Increased production of fibronectin in MS has also been reported to pathologically alter
glial responses. Recently Stoffels et al. reported that astrocyte-derived fibronectin can
prevent oligodendrocyte differentiation, therein contributing to the chronicity of
demyelinated lesions in MS (Stoffels et al., 2013). In addition, excessive fibrillar collagen
production around actively demyelinating lesions in MS has been suggested to impair the
expression of potentially beneficial chemokines from infiltrating monocytes (Mohan et al.,
2010). Thus, changes in ECM composition are closely associated with the pathology of
demyelination and may represent important mediators of disease-related cellular
responses in CNS diseases.
The distribution and expression of ECM constituents are tightly regulated, not
only at the transcriptional and translational level, but also through extracellular proteolysis
by matrix metalloproteinases (MMPs). Most ECM components are enzymatic substrates
of MMPs, and degradation of ECM by MMPs can have profound effects on cellular
signaling (Rodriguez et al., 2010). We had previously determined that MMP-3
(Stromelysin-1) was highly expressed in human and mouse GLD brain (Ijichi et al., 2013).
We also determined that MMP-3 mediated psychosine-induced multinucleation of
microglia with increased phagocytic activity (Ijichi et al., 2013). Since we have determined
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that psychosine induced MMP-3-dependent formation of multi-nucleated microglia, or
"globoid cells", this finding led us to hypothesize that changes in ECM may contribute to
the neuropathology of microglia in GLD. Moreover, as the precise role of globoid cells in
GLD is currently unclear, we also sought to determine whether 'globoid cells' had a direct
effect on the survival of oligodendrocytes. In this study, we determined that expression of
TnC was specifically elevated in GLD and it fostered the pathogenic transformation of
microglia in response to psychosine by promoting their cytotoxic potential toward
oligodendrocytes.

93

IV-3 Materials and Methods
IV-3.1 Animals for primary cultures
All procedures involving animals were conducted according to the approved
procedures that comply with guidelines set forth by the Institutional Animal Care and Use
Committee (IACUC) at the University of Connecticut Health Center.

IV-3.2 Mixed glial cultures
Primary mixed glial cultures were established from postnatal day (P)0-3 pups of
C57/BL6 wildtype mice, as previously described (Crocker et al., 2008, Ijichi et al. , 2013).
Briefly, cortices were manually dissected in cold HBSS, followed by mechanical and
enzymatic dissociation using a papain-based neural dissociation kit, per manufacture’s
protocol (Miltenyi Biotec, Auburn, CA). Dissociated cells were plated in DMEM (Gibco,
Carlsbad, CA) with 10% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA),
penicillin (100U/mL, Sigma Aldrich, St Louis, MO) and streptomycin (100 mg/mL, Sigma
Aldrich) in T175 culture flask (Grenier Bio-One, Germany). After 16 hrs, culture media
was replaced with fresh media to remove non-adherent cells. Adhered cells were
incubated in the flask at 37oC for 2 to 3 weeks until an astrocytic monolayer was
established.

IV-3.3 Primary microglial cultures
Pure microglial cultures were established by detaching microglia from mixed
glial cultures, as previously described (Ijichi et al., 2013, Welser-Alves et al., 2011). Briefly,
established mixed glial cultures with 100% confluency were shaken by orbital shaker at
110 rpm at 37oC for 4 hours to detach microglia from the astrocytic monolayer.
Supernatants containing detached microglia were spun at 300 Xg for 10 min, followed by
resuspension of the microglia in astrocyte-conditioned media, and then plated onto
coverglass coated with either laminin (10 µg/ml, Sigma) or TnC (1 µg/ml, EMD Millipore)
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or into 6-well UltraLow adherence culture plates (Corning, Tewksbury, MA). Cells were
acclimated for 2-3 days prior to experiments. Chemical inhibitors used were: GM6001
(12.5 µM, Calbiochem, Billerica, MA), NNGH (0.1 µM, Enzo Life Sciences, Farmingdale,
NY), psychosine (10 µM, Sigma), and dimethylsulfoxide (0.13% "DMSO", Sigma Aldrich).

IV-3.4 Primary oligodendrocyte cultures
Pure oligodendrocytes cultures were established from postnatal (P)0-3 rat pups,
as described previously (McCarthy and de Vellis, 1980) with modifications. Briefly, brains
from rat pups were dissected out and meninges were removed. After removal of the
cerebellum, the brain tissue was mechanically dissociated by mincing with scissors and
passing through fire-polished Pasteur-pipet. The single cell suspension was then plated
in T75 flask in maintenance medium composed of DMEM/F12 (Gibco), 10% FBS (Atlanta
Biologicals), penicillin (100 U/mL, Sigma Aldrich), and streptomycin (100 mg/mL, Sigma
Aldrich). Cells were incubated at 37oC for 3 weeks or until monolayer was formed.
Cultures were shaken for 30 min at 37oC at 55 rpm to remove microglia and large debris
from monolayer. Oligodendrocyte progenitor cells (OPCs) were removed by shaking in an
orbital shaker at 225 rpm at 37oC for 16 hrs. Medium containing detached cells was
collected and centrifuged at 300 Xg for 10 min. Cells were resuspended in maintenance
media and plated in Petri dish for 3 to 4 hours at 37oC to eliminate microglia by differential
adhesion. Non-adhered cells were collected and plated on poly-ornithine (0.1% Sigma
Aldrich)-coated coverglass, and incubated for 1 to 2 hrs at 37°C. Media was replaced with
oligodendrocytes differentiation medium, composed of Neurobasal medium (Gibco),
L-glutamine (1X, Life Technologies, Grand Island, NY), B-27 supplement (1X, Life
Technologies), and Triiodothyronine (T3, 10 ng/mL, Sigma Aldrich).
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IV-3.5 Co-cultures of microglia and oligodendrocytes
Primary microglial cultures in 6-well UltraLow adherence culture plates and
oligodendrocytes cultures on poly-ornithine-coated coverslips were established as
described above. To induce globoid cells in microglia, psychosine, psychosine +TnC, or
vehicle treatments were applied for consecutive 7 days; then treated microglia were
collected by gentle pipetting to detach loosely adhered cells at the bottom of wells.
Collected cells were spun at 300Xg for 10 min, and cells were carefully resuspended in
oligodendrocytes differentiation media (see above). Number of microglia in single cell
suspension was counted by hemacytometer and seeded at 0.5-1x105 cells/mL onto
oligodendrocyte cultures, resulting in approximately 1:1-2 microglia/oligodendrocyte ratio.
Co-cultures were incubated for 3 days, and media were collected for cytotoxicity assay
(see below), and cells were fixed for immunocytochemistry (see below).

IV-3.6 Primary neuronal cultures
Primary cortical or hippocampal neuronal cultures were established from rat
pups at P1 (Shan et al., 2003). Briefly, brains from rat neonates were dissected out and
meninges were stripped off. Cortices and hippocampi were isolated in HBSS, followed by
incubation for 15min at 37°C in trypsin (0.25%). Tissues settled at the bottom of conical
tubes were washed with HBSS 3 times and triturated 10 times with a fire-polished
Pasteur pipette in plating media (Neurobasal media with 10% FBS). Single cell
suspensions were passed through a 70µm filter, and then plated on poly-L-lysine-coated
plates. Media was replaced with maintaining media A (Neurobasal media, 2% B-27, 2%
FBS, 0.5mM L-glutamine, 25µM L-glutamic acid, 1X antibiotic/antimycotic solution) 3
hours after plating. Half of media in cultures was replaced with media B (Neurobasal
media, 2% B-27, 0.5mM L-glutamine, 1X antibiotic/antimycotic solution) every 3-5 days.
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IV-3.7 Human brain tissues
Brain specimens from GLD and age-matched control patients (1-2 years old)
were obtained from the National Institute of Child Health and Human Development
(NICHD) Brain and Tissue Bank for Developmental Disorders (Baltimore, MD). Brain
tissues were paraffin-embedded, cut into 15µm thick sections, and then processed for
immunostaining (see IHC description, below).

IV-3.8 Mouse brain tissues
Twitcher mice were bred and housed at the Sanford-Burnham Institute (La Jolla,
CA), at which the brain specimen from twitcher mice and age-matched littermate control
mice were collected. Mice were deeply anesthetized in accordance with IACUC-approved
protocols and transcardial perfusion with phosphate buffer saline (PBS) followed by 4%
paraformaldehyde (PFA). Brain tissues were collected at the ages of P0, 10, 20, 31, 40,
as previously described (Taylor et al., 2006).

IV-3.9 Immunohistochemistry (IHC)
Collected brain and spinal cord tissues were paraffin-embedded, and 15 µm
sagittal sections were made, as described previously (Crocker et al., 2006, Moore et al.,
2011). Tissue sections were subjected to antigen retrieval using 95°C citric acid buffer
(0.01 M, pH 6.0), followed by blocking non-specific binding site with 5% normal goat
serum (NGS; Life Technologies) in PBS-T for 1 hr at room temperature. Sections were
then incubated with primary antibodies against Tenascin-C (N-19, Santa Cruz
Biotechnology, Dallas, Tx), Laminin ["-2 (6D580), Santa Cruz], Vitronectin [10/65/75
(H-202), Santa Cruz], and Fibronectin (C-20, Santa Cruz), followed by PBS wash and 1
hr incubation with Alexa® 594- or 488- conjugated secondary antibodies (Life
Technologies) against appropriate species from which primary antibodies were raised. To
identify nuclei, tissues were counter-stained with 4',6-diamidino-2-phenylindole (DAPI,
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Life Technologies) and then coverslipped using Fluoromount-GTM (SouthBiotech,
Birmingham,

AL).

Immunoreactivity

was

visualized

and

analyzed

using

computer-assisted image analysis software (Eclipse, Empix Imaging) on an Olympus
IX71 microscope. Two to four different specimens were analyzed.

IV-3-10 Thioflavin-s staining
Following labeling of TnC using primary and secondary antibodies in IHC (see
IHC section), tissues were then incubated with 0.1% thioflavin-s (Sigma Aldrich) in
PBS:EtOH (1:1, v:v) for 5 min at room temperature. Tissues were then washed with 80%
EtOH several times, rehydrated with PBS, and then analyzed.

IV-3.11 Quantitative real-time polymerase chain reaction (q-RT-PCR)
Total RNA was isolated from cultured cells as described previously (Ijichi et al.,
2013) and converted into complementary DNA (cDNA) via reverse transcription (iScript
cDNA synthesis kit, BioRad, Hercules, MA), according to the manufacturer’s protocol.
Synthesized cDNA samples were amplified for q-RT-PCR using primer pairs specific to
mmp-3 and tenascin-c mRNA (Integrated DNA Technologies, Coralville, IA), as described
previously (Chen et al., 2009), and SsoFastTMEvaGreen® Supermix (BioRad) according
to the manufacturer’s protocol. Target cDNA were amplified and analyzed by a
Mastercycler® ep realplex (Eppendorf, Hauppauge, NY). Primers for GAPDH were used
to assess the general expression level of the housekeeping gene among samples.
Relative expression of target RNA was calculated using the comparative cycle threshold
analysis ($$CT), as previously described (Ijichi et al., 2013).
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IV-3.12 Immunocytochemistry (ICC)
Cells plated and grown on laminin-coated or poly-ornithin-coated glass
coverslips were fixed using 4% PFA and processed for ICC using antibodies against Iba-1
(Wako, Richmond, VA), CD11b (eBioscience, San Diego, CA), Olig2 (EMD Millipore),
Myelin Basic Protein (MBP; aa82-87, EMD Millipore), CD206 (C-20, Santa Cruz), and
major histocompatibility class II (MHCII; Y-Ae, Santa Cruz), following blocking by 5%
NGS (Life Technologies), as previously described (Moore et al., 2011). Immunoreactivity
was visualized using fluorescently conjugated secondary antisera against the species of
the primary antibodies (Alexafluor" 488 or 594, Life Technologies). Positive
immunostaining results were viewed and analyzed using computer-assisted image
analysis software on an Olympus IX71 microscope. DAPI staining was used to label
nuclei in order to determine cellular densities per field and perform multinucleated cell
analyses, as previously described (Ijichi et al., 2013). Four to six visual fields containing
50-70 DAPI+ nuclei were randomly chosen per coverslip and number of cells with single
and/or multiple immunoreactivities were manually counted using ImageJ software (NIH).

IV-3.13 Lactose dehydrogenase (LDH) assay
Media from cell cultures were collected at the end of treatment time course.
The level of LDH contained in collected media was measured using a commercial LDH
assay kit, as per manufacture’s protocol (BioVision, Milpitas, CA).

IV-3.14 Enzyme-linked immunosorbant assay (ELISA)
Media were collected from cell cultures at the end of experiments. The level of
tumor necrosis factor alpha (TNF") released into media was analyzed using a
commercially available TNF" ELISA DuoSet kit per manufacture’s instructions (R&D,
Minneapolis, MN).
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IV-3.15 Statistical Analyses
Data are presented in Mean +/- SEM. Statistical significance was tested by
one-way analysis of variance (ANOVA) with Tukey’s post hoc analysis, or two-way
ANOVA with Bonferroni’s post hoc test, using Prism software (Graphpad, San Diego, CA).
For all comparisons, p<0.05 was considered statistically significant.
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IV-4 Results
IV-4.1 TnC expression is elevated in the GLD brain.
The emerging significance of ECM molecules on glial cell functions led us to
consider whether differential expression of ECM molecules occurred in GLD. To explore
this idea, we performed IHC for four prominent ECM molecules; laminin (Lm), fibronectin,
vitronectin, and TnC on brain tissue sections from human brain from validated GLD cases
and age-matched control subjects. Expression of the ECM components, Lm, fibronectin,
or vitronectin, revealed no significant differences between GLD and control brains in
terms of their expression patterns or staining intensities (Fig. 4-1A). However, there were
significant TnC-positive deposits in the brain of GLD patients compared to age-matched
control subjects (Fig. 4-1A). Next, we examined whether TnC was a generalized feature
of GLD brain pathology across species. To address this question, TnC immunoreactivity
was analyzed in brain tissues from twitcher mice, an authentic mouse model of GLD
(Duchen et al., 1980). Similar to the human GLD cases and control brains, there were no
significant differences in staining for Lm, fibronectin, or vitronectin between the two
genotypes. However, elevated TnC positive (TnC+) deposits were frequently observed in
twitcher brains when compared to age-matched controls (Fig. 4-1B). Interestingly, the
high TnC immunoreactivity in twitcher mouse was frequently observed in plaque-like
patterns, resembling the staining observed in human GLD. This pattern also exhibited
similarities to #-amyloid deposits observed in Alzheimer's disease; in fact, TnC+ plaques
were frequently co-localized with thioflavin-s, a marker for amyloid fibrils [(Kelenyi, 1967),
Fig. 1C]. Together, these data indicate that the intensity and pattern of TnC was altered in
the CNS of GLD.
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Figure 4-1 Tenascin-C is highly expressed in GLD. (A, B) Immunohistochemical
analysis of the extracellular matrix (ECM) proteins laminin, fibronectin, vitronectin, and
tenascin-C in the midbrain of human infantile GLD patients (A, bottom row), age-matched
control human subjects (A, top row). Immunohistochemical analysis of ECM proteins in
the midbrain of the P30 twitcher mouse model of GLD (B, bottom row), and age-matched
littermate wildtype control mice (B, top row). Note that intense punctate pattern of
tenascin-c immunoreactivity in human and murine GLD tissues when compared to control
subjects. (C) Tenascin-C immunoreactivity co-localizes with Thioflavin-S positive staining
in the hippocampus of P30 twitcher mouse brain as visualized by immunohistochemistry
for Tenascin-C and thioflavin-s histological staining. Nuclei are stained with DAPI (blue).
2-4 specimens were analyzed. Scale bar: A= 250µm, B= 150µm, C= 100µm.
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IV-4.2 TnC enhances glial responses to psychosine in vitro.
ECM proteins have the potential to potently modulate glial functions. Based on the
high expression of TnC in GLD brain, and previously reported effects of TnC on glia
(Battisti et al., 1995, Nash et al., 2011, Smith and Hale, 1997), we next examined whether
TnC influenced the microglial response to psychosine. We have previously reported that
psychosine induced globoid cell formation in glial cultures (Ijichi et al., 2013). Using this in
vitro model system, we prepared primary mixed glial cultures that were grown on either
TnC or laminin (Fig. 4-2). Cultures were then exposed to psychosine (10 µM) for 7
consecutive days. Immunocytochemical analyses indicated that globoid cells formed in
response to psychosine when grown on either ECM substrate (Fig. 4-2A-D). However, in
glial cultures grown on TnC, there were significantly more psychosine-induced globoid
cells formed than in glial cultures grown on Lm (Fig. 4-2E). These data suggest that TnC
enhanced globoid cell formation in response to psychosine in vitro.
To address how TnC potentiated globoid cell formation, we examined MMP-3
expression since we had previously determined that induction of globoid cells by
psychosine required MMP-3 (Ijichi et al., 2013). To determine whether TnC modified
psychosine-induced MMP-3 expression by glia, we grew mixed glial cultures on either
TnC or Lm, and treated with psychosine for 4, 24 hours, or 3 days. We then quantified
MMP-3 mRNA expression by qRT-PCR. At earlier time points, there was no significant
difference in psychosine-induced MMP-3 expression on either substrate. However,
MMP-3 mRNA expression by psychosine-treated glia on TnC reached a 92 fold change
by day 3 of psychosine treatment when compared with controls (Fig. 4-3A). These data
suggest that microglia grown on TnC exhibit a more robust transcriptional response to
psychosine.

103

Figure 4-2 Tenascin-C promotes globoid cell formation. Primary glial cell cultures
(mixture of astrocytes and microglia) grown either on laminin (A, B) or Tenascin-C (TnC;
C, D) were treated with either vehicle (A, C) or psychosine (B, D) for 7 consecutive days.
Cells were fixed and immunostained for the microglial marker, Iba-1 (green) and
counter-stained with DAPI (blue; nuclei). 7-9 visual fields generally containing 50-70 total
DAPI+ nuclei under 20X magnification were randomly chosen and numbers of
multinucleated

cells

were

manually

counted.

Psychosine

treatment

induced

multinucleation of Iba-1+ cells regardless of ECM substrate although glia grown on TnC
produced significantly more "globoid-like" cells when compared to laminin-grown cultures.
(E). Scale bar= 20µm. Two-way ANOVA; ***, p<0.0001 with N=3/condition. Data are
provided as mean+/-SEM.
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Figure 4-3 MMP-3 mediates globoid cell formation in response to psychosine. (A)
Primary glial cell cultures, which consisted of astrocytes and microglia exclusively, grown
on either laminin- or TnC-coated plates were challenged with psychosine for 4, 24 hrs, or
3 days. Total RNA were isolated, reverse-transcribed into cDNA, and MMP-3 mRNA
expression was analyzed by qRT-PCR. Data represent mean+/-SEM of fold change
normalized to laminin-treated 4hr samples. (B) Primary glial cultures grown on
TnC-coated coverslips were treated with either psychosine (Psy; black bar), psychosine
with the pan-MMP inhibitor, GM6001 (12.5 µM; gray bar) or the MMP-3 specific inhibitor,
NNGH (0.1 µM; striped bar) for consecutive 7 days. Cells were fixed and immunostained
for microglial marker, Iba-1 and DAPI for nuclei. 4-6 visual fields under 20X magnification
were randomly chosen and the number of globoid cells was manually counted. The
number of globoid cells was significantly decreased when GM6001 or NNGH was applied
in culture in conjunction with psychosine treatment (Two-way ANOVA; interaction: **
p<0.0099; treatment: ***, p<0.0002). Data represent mean+/-SEM. N=3/condition.
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We next tested whether the enhanced formation of globoid cells grown on TnC
was also mediated by MMP-3. TnC-grown glial cultures were challenged with psychosine
in combination with a pan-MMP inhibitor (GM6001), MMP-3-specific inhibitor (NNGH), or
vehicle (DMSO) for 7 consecutive days. Immunocytochemical analysis determined that
treatment with either GM6001 or NNGH significantly attenuated the psychosine-induced
globoid cell formation in TnC-grown microglial cultures (Fig. 4-3B). These data confirmed
that psychosine-induced globoid cell formation was mediated by MMP-3, but also
revealed that this process was enhanced by recapitulating the ECM environment of the
GLD brain (e.g. TnC).

IV-4.3 TnC modifies microglial phenotype in response to psychosine.
Globoid cells originate from microglia (Ijichi et al., 2013). Our previous study
had determined that psychosine induced phagocytic activity of microglia, but we had not
fully characterized the phenotype of these cells. Because microglia can have detrimental
or beneficial effects, based on their phenotypes, known as M1 and M2, respectively
(Chhor et al., 2013, Miron et al., 2013), we next determined the phenotypes of both
mononuclear and polynucleated microglia following treatment with psychosine or
psychosine and TnC. Microglial phenotypes were determined by ICC using expression of
MHCII or CD206 on Iba-1+ microglia as indicators of the classic M1 and M2 phenotypes,
respectively. Mononuclear Iba-1+/MHC+ microglia in co-culture showed relatively similar
expression

levels

in

all

conditions

(Fig.

4,

A-E),

whereas

co-cultures

with

psychosine-treated microglia contained significantly more CD206+ mononuclear
microglia (Fig. 4F). Interestingly, in co-cultures with psychosine- and TnC-treated
microglia, the number of CD206+ mononuclear microglia was significantly decreased (Fig.
4F). These data suggest that the presence of TnC during psychosine exposure switches
the phenotype from beneficial to harmful in mononuclear microglia.
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Figure

4-4

Tenascin-C

changes

M1/M2

phenotype

in

psychosine-treated

microglia/globoid cells. Isolated microglial culture were treated with psychosine (+Psy
microglia, black bar), psychosine + TnC (+Psy+TnC microglia, stripe bar), or vehicle
(+Microglia, white bar) for 7 days, then co-cultured with oligodendrocytes for 3 days.
(A-D) Cultures were fixed and expression of M1, M2 markers (MHCII, CD206,
respectively; green) in mononuclear microglia (Iba-1, red) was visualized using
immunocytochemistry. Pictures are representative images showing that +Psy microglia
express MHCII (A) and CD206 (C), and +Psy+TnC treated microglia express MHCII (B)
but not CD206 (D). (E, F) 4-6 visual fields containing 50-70 DAPI+ nuclei were randomly
chosen and the number of mononuclear Iba-1+ cells was counted. Manual counting of
Iba-1+ mononuclear cells revealed that microglia treated with Psy alone expressed
higher proportion of CD206 when compared to psychosine-treated microglia grown on
TnC or vehicle-treated microglia. Data represent percent of marker positive staining of
total cell number/field. N=5-8. (G-J) Representative images of psychosine-induced
polynucleated globoid cells (DAPI; blue/Iba-1; red) that expressed high CD206 (I; green)
but low MHCII (G; green). In contrast multinucleated "globoid cells" grown on TnC
expressed high MHCII (H) and low CD206 (J). (K, L) Manual counting of
psychosine-induced "globoid cells" grown on TnC identified an increase in MHCII cell
surface staining (K), while CD206 expression was significantly decreased (L), when
compared with globoid cells induced by psychosine alone. Data represent Mean+/-SEM.
F: one-way ANOVA; N=3-4/treatment where *** p<0.0001; and L: one-way ANOVA: **,
p<0.0014; where * P<0.05, ** P<0.01, *** P<0.001 for intergroup comparisons. Scale bar
=20µm.
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We then analyzed the phenotype of the polynucleated microglia (globoid cells)
induced by psychosine when grown either in the presence or absence of TnC (Fig.
4-4G-J). The number of MHCII+ globoid cells in psychosine-treated microglia grown on
TnC was slightly higher than those in microglia grown without TnC, albeit without a
statistically significant difference (Fig. 4-4K). Conversely, the number of CD206+ 'globoid
cells' from psychosine treated microglia was significantly greater than those from
psychosine-treated microglia exposed to TnC (Fig. 4-4L). These data provide support for
a distinct M1-microglial phenotype of microglia in response to psychosine when grown on
TnC, whereas microglia without TnC tended to exhibit an M2 phenotype. We reasoned
that this difference in M1/M2 phenotype marker expression may reflect an important
functional difference of GCs with respect to their potential role in demyelination in GLD.

IV-4.4 TnC determines the cytotoxicity of globoid cells for oligodendrocytes.
We had previously reported that when microglia were treated with psychosine in
vitro they transformed into large, highly-phagocytic multinucleated cells (Ijichi et al., 2013).
Also, globoid cells in the brains of human GLD, twitcher mice, or other animal models of
GALC deficiency have often been found close to myelin lesion sites and to contain
tubulous myelin debris (Figols et al., 1992). Thus, we hypothesized that globoid cells
phagocytize myelin and possibly accelerate disease process(es) of GLD by promoting
demyelination and oligodendrocyte death. To test this hypothesis, isolated microglia were
grown on low adherence plates either with or without TnC and then treated with
psychosine (10 µM) or vehicle. Microglia were then detached, collected and co-cultured
with primary oligodendrocyte cultures. The impact of psychosine-induced activation of
microglia grown on TnC was then assessed by lactate dehydrogenase (LDH) assay for
cell death. Psychosine-treated microglia exhibited less cytotoxicity to oligodendrocytes
than observed in control-treated microglia (Fig. 4-5A). In contrast, psychosine-treated
microglia grown on TnC evoked a 2.9 fold increase in cytotoxicity to oligodendrocytes
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over psychosine-treated microglia without TnC, or compared with control microglia (Fig.
4-5A).
We measured TNF$ production in these co-cultures by ELISA to determine
whether psychosine modulated microglial production of TNF$. Microglia treated with
psychosine exhibited a measurable reduction in TNF$ production (Fig. 4-5B). Overall,
psychosine-treated microglia were significantly less cytotoxic to oligodendrocytes than
non-treated microglia in co-culture, whereas psychosine-treated microglia grown on TnC
displayed significantly greater toxicity to co-cultured oligodendrocytes and higher TNF"
production. These data suggest that psychosine can promote a potentially pathogenic
phenotype of microglia when in the presence of TnC. Also, these data suggest that
psychosine reduced the native toxicity of microglia to oligodendrocytes, but that the local
production of TnC in GLD overcomes and promotes psychosine-induced microglial
cytotoxicity to oligodendrocytes, potentially through modulating TNF" production from
microglia.
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Figure 4-5 Globoid cells grown on TnC are toxic to oligodendrocytes. Isolated
microglia treated with psychosine (+Psy), or grown on TnC and treated with psychosine
(+Psy+TnC), or vehicle for 7 consecutive days, were then co-cultured with
oligodendrocyte for 4 subsequent days. Oligodendrocyte cultures were about 50% MBP+
at the time of co-culture. (A) Analysis of cell death under each condition was measured by
LDH assay. Cytotoxicity is expressed as percent of full kill control (0.1% sterile Triton
X-100). Psychosine-induced globoid cells without TnC (black bar) had minimal toxicity in
co-culture to oligodendrocytes when compared to untreated microglia (gray bar),
whereas TnC-grown psychosine-treated microglia exhibited significant toxicity (striped
bar). (B) Levels of TNF" released from isolated microglia treated with psychosine,
TnC-grown microglia treated with psychosine, or vehicle control for 7 consecutive days
were measured by ELISA. Note that psychosine-treated microglia (black bar) exhibited
the least amount of TNF" release compared to untreated or TnC-exposed
psychosine-treated microglia (gray, striped bar, respectively). One way ANOVA, p<0.001;
where, * p<0.05; ** p<0.01; *** p<0.001. N=3/condition.
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IV-5 Discussion
In this study, we determined that TnC production was enhanced in twitcher mouse
and human GLD brain samples. We determined that microglial responses to psychosine
were enhanced by TnC, as measured by both increased MMP-3 expression and globoid
cell formation in vitro. These data suggest that localized accumulation of TnC may have
the potential to modify microglial responses to psychosine. The impact of this TnC
modulation was revealed by our investigation on the cytotoxicity of globoid cells toward
oligodendrocytes. We determined that globoid cells plated on TnC evoked a higher level
of cell death in co-culture with oligodendrocytes than globoid cells without TnC. Strikingly,
naïve microglia also showed significantly greater toxicity to oligodendrocytes than
psychosine-treated microglia, which actually reduced the native toxicity of microglia
toward oligodendrocytes. Together, these data suggest that by recapitulating the ECM
microenvironment of GLD, we dramatically influenced the cellular phenotype of microglia,
which may be an important consideration for modeling disease-like responses in cell
culture systems. Moreover, these findings support a more prominent and primary function
for microglia and globoid cells as putative direct inducers of myelin pathology in GLD.
Maladaptive changes in ECM composition have gained increasing interest for
their correlation and contribution to myelin pathologies. In this study, we determined that
TnC was differentially expressed in GLD. Tenascin-C has many known functions in
modulating cellular growth and maturation, and also the repulsion of cells via local
detachment (Jones and Jones, 2000). We hypothesized that TnC would alter microglial
responses to psychosine in accordance with these known functions, and determined that
microglia grown on TnC elicited a more robust increase in psychosine-induced MMP-3
expression and enhanced 'globoid-like' cell formation. In previous studies on traumatic
brain injury and Alzheimer’s disease, TnC expression has been closely associated with
both astrocytes and microglia (Dobbertin et al. , 2010, Nash et al., 2011, Smith and Hale,
1997, Wiese et al., 2012, Xie et al., 2013). Astrocytes have been identified as the
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common source of many ECM products including TnC and fibronectin. In our cell culture
system, the level of TnC was applied as a substrate on which the glial cells were cultured
since psychosine did not induce endogenous production of TnC from either the
astrocytes or microglia (Figure 4-6A). Indeed, our immunohistochemical analyses in the
twitcher brain revealed that TnC immunoreactivity did not always co-localized with
intensely labeled GFAP positive astrocytes (Figure 4-6C). Neurons have been proposed
to be a source of TnC in the CNS (Ferhat et al., 1996, Ferhat et al., 1996). Thus, we
examined whether psychosine induced TnC expression in neurons, using primary
neuronal culture. Here too, psychosine did not directly induce TnC expression in either
hippocampal or cortical neuron cultures (Figure 4-6B). However, in the twitcher brain,
TnC immunolabelling was co-localized with !-III tubulin positive neurons, suggesting a
possible neuronal relationship with TnC (Figure 4-6D). Thus, data indicate that
psychosine did not directly regulate TnC transcription by either non-myelinating glia or
neurons. Together, these point to possible inflammatory regulation of TnC by factors,
including TNF" and IL-1 (Nakoshi et al., 2008, Noda et al., 2000), which are greatly
upregulated in GLD brains (Kondo et al., 2011). Nevertheless, heightened TnC levels in
the CNS during this disease likely contribute to the sensitization of astrocytes and
microglia to psychosine, as demonstrated by the enhanced production of MMP-3 and
their toxicity to oligodendrocytes (Fig. 4-3).
In our previous work, we reported that psychosine transforms microglia into the
multinucleated phenotype with high phagocytic activity (Ijichi et al., 2013). In this study,
we extended these previous findings to explore the potential effect of psychosine-induced
globoid cells on oligodendrocytes. Interestingly, psychosine-induced globoid cells
exhibited a predominant M2 phenotype with reduced cytotoxicity to oligodendrocytes,
when compared to untreated microglia.
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Figure 4-6 Psychosine does not directly regulate TnC expression in glial or
neuronal cultures. (A) Mixed glial cultures grown on Laminin (Lm) or tenascin-c (TnC)
and (B) hippocampal (HippoN) or cortical (Cort N) neuronal cultures grown poly-L-lysine
were treated with psychosine (Psy) at (A)10uM 4hrs-7days or (B) 1 or 10uM 24hrs. Total
RNA was isolated and reverse-transcribed in cDNA, and TnC expression level was
analyzed using qRT-PCR. Note that in any of conditions, psychosine treatment did not
induce TnC expression regardless of concentrations or treatment time in glial or neuronal
cultures. Data represent Mean+/- SEM. N= 3-4/condition, except for cortical neuron
conditions (mean of triplicates from N=1). (C, D) TnC protein (green) was visualized using
immunohistochemistry along with cellular markers for astrocytes (GFAP, red, C) or
neurons (!III-Tubulin, red, D) in the dentate gyrus of P30 twitcher mice. 3-4 different
specimens were analyzed. Note that GFAP immunopositive staining did not co-localize
with TnC immunoreactivity (C). Some TnC+ plaques are co-localized in !III-Tubulin+
neurons (arrowheads, D), but not all neurons are co-localized with TnC immunoreactivity.
Data are representative images. Scale bar = 50µm.
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This suggests that globoid cells may be benign or potentially beneficial in GLD. However,
the effect of TnC on the microglial response to psychosine-induced globoid cells and this
effect on oligodendrocyte co-culture system were dramatic with a shift toward an
oligotoxic M1 phenotype. Our data also indicated that psychosine modulation of
microglial function correlated with and may be mediated by the inflammatory cytokine,
TNF". We hypothesize that TnC accumulation in GLD contributes to white matter
pathology via altering the microglial response to psychosine-induce demyelination. This
provides a new perspective on the role of globoid cells and the extracellular environment
in GLD. The mechanism(s) by which the combination of TnC and psychosine promote
microglial toxicity to oligodendrocytes is presently unclear. Previous studies in other
disease models have shown that altered ECM, associated with neuropathology, can
modify the production of growth factors such as cilliary neurotrophic factor, fibroblast
growth factor, epidermal growth factor, and tumor growth factor (Dobbertin et al., 2010,
Nash et al., 2011, Smith and Hale, 1997, Wiese et al., 2012, Xie et al., 2013). Future
studies are warranted to better understand how TnC-modified microglia, in association
with aberrant MMP-3 expression in GLD, contribute to the inflammatory environment of
the CNS in this disease.
An important question stemming from this study is: how does TnC alter
phenotype and response of microglia to psychosine? One possible mechanism is through
differential expression of ECM receptors on these cells. Several integrins are thought to
be TnC receptors, including $v, !1, and !2 families (Milner and Campbell, 2002). It was
reported that TnC binds to "v!3, "v!6, "9!1, and "8!1, which are distinct from the
integrin receptors for laminin, including "1!1 and "6!1 (Milner and Campbell, 2002).
Thus, the presence of TnC may stimulate microglia to express more TnC receptors, from
which downstream signaling may result in functionally different outcomes. Microglia have
been reported to basally express integrins $v and #1 (Milner and Campbell, 2003). While
altered integrin expression on microglia in GLD may result from psychosine levels in this
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disease, the elevated cytokines produced in the CNS during GLD may also contribute to
the activation of microglia (Kondo et al., 2011). In particular, the cytokines TGF#, TNF,
and IL-1#, which are known to be elevated in GLD, have also been reported to induce a
diversity of $ and # integrin expression on microglia (Milner and Campbell, 2003).
Interestingly, the ECM composition itself can induce changes in microglial integrin
expression (Milner and Campbell, 2003). Based on our findings in this report, further
analysis of integrin expression on microglia and their role in mediating the cellular
responses to psychosine in the presence of TnC would be expected to provide additional
mechanistic insights into the pathological activation of microglia in GLD.
It is important to point out that TnC is a putative substrate of MMP-3. The
concomitant increase of MMP-3 expression in GLD with the significant modulation of the
microglial response to psychosine on TnC suggests several potentially important
associations between TnC and MMP-3. For instance, we have determined that TnC
dramatically increased mmp-3 mRNA expression in glia (Figure 4-2). Previous work by
others has been implicated that MMP-3 enzymatically targets TnC and generates several
cleaved TnC products (Imai et al., 1994, Siri et al., 1995). Although there is no study yet
to show the binding capacity of cleaved TnC fragments or their signaling potentials, it is
possible that fragmented TnC may bind to different integrins from ones for full-length TnC,
or modulate signaling that results in microglial phenotypic changes. Future studies would
be required to further elucidate the involvement of integrins and possible TnC proteolysis
on cellular phenotype changes induced by TnC on microglia in response to psychosine.
Globoid cells found in vivo frequently contain tubulous inclusions and myelin
debris (Figols et al., 1992, Jesionek-Kupnicka et al., 1997), but their function in GLD had
been undetermined. Our detailed in vitro analyses and modeling indicate that the local
presence of TnC dramatically limits any potential beneficial function of globoid cells in
GLD. Our study now reports that globoid cells behave differently depending on their local
extracellular environment. Thus, GLD pathophysiology is likely a much more dynamic
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process than previously recognized. Indeed, cord stem cell and bone marrow
transplantations, while yielding encouraging but limited effectiveness, may be influenced
by altered ECM constituents in GLD. In particular, TnC may be a limiting factor for current
therapeutic strategies, as TnC-mediated effects on microglial cellular phenotype may
also impact cellular phenotype of transplanted cells. As mentioned above, TnC has
diverse functions on cellular growth/maturation and repulsion of cells (Jones and Jones,
2000). At sites of myelin lesions in MS, increased levels of TnC may have a beneficial
role to promote cell growth; yet it is possible that prolonged elevations of TnC may also
prevent the migration of progenitor cells necessary for mediating repair (Frost et al., 1996,
Garcion et al., 2001). It is worthwhile noting that TnC depositions in twitcher brain
exhibited a unique pattern of patchy clusters in multiple brain regions (data not shown).
Interestingly, some TnC+ clusters are positive for thioflavin-s, an amyloid marker (Smith
et al., 2014). Additionally, neuronal source would be consistent with the co-localization of
TnC foci that also stained for Thioflavin-s in the twitcher mouse brain. These findings are
also in agreement with our recent report on the development of intraneuronal inclusions
containing $-synuclein in GLD (Smith et al., 2014). Further analysis of GLD pathology is
needed to improve our understanding of the cellular source of TnC in GLD, and to further
characterize the composition of extracellular plaques characterized by TnC staining
patterns in this disease.
In summary, we have defined a primary pathogenic function for globoid cells in the
pathophysiology of GLD. The importance of the ECM microenvironment in GLD was also
highlighted by the enhanced transformation of microglia in response to psychosine when
in the presence of TnC. Further detailed analyses on the temporal and spatial functions of
TnC expression in the CNS are required to further elucidate the stage and full
significance of TnC to GLD pathology. Future consideration for whether this process
could be adopted to modify pathogenic microglial functions and how this understanding
may be therapeutically applied in GLD is necessary.
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Chapter Five
Summary of Conclusions, Discussion and Future Directions
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V-1 Summary and Conclusions
Globoid cells are a hallmark of GLD pathology. Despite their uniqueness, their
specific function and contribution to GLD pathogenesis has been largely overlooked.
Globoid cells have been thought to be a secondary consequence of chronic
demyelination. However, globoid cells can be observed prior to clinical disease onset and
demyelination (Martin et al., 1981) (Table 5-1). Additionally, uncontrolled, aberrant
microglial activity in GLD is thought to be a factor limiting the long-term efficacy of HSCT
for treating this disease (Pellegatta et al., 2006). Thus, investigating possible functions of
microglia and globoid cells was expected to provide new insights in the pathogenesis of
GLD.
Matrix metalloproteinases have been well characterized for their involvement in
a variety of neurodegenerative and demyelinating diseases; however, a role for these
proteases in a leukodystrophy had not been previously examined. We focused on MMP-3,
because it has been identified as a potent activator of microglia in a model of Parkinson’s
disease (Kim and Joh, 2006). Elevated MMP-3 has also been reported in multiple models
of demyelinating and neurodegenerative diseases (D'Souza et al., 2002, Jalal et al., 2012,
Kumnok et al., 2008, Rosenberg et al., 2001, Ulrich et al., 2006). Therefore, we
hypothesized that there is a potential association between MMP-3 and microglia/globoid
cells in the context of GLD pathology. Hence, the primary focus of this dissertation was to
investigate the contribution of microglia and globoid cells to GLD pathogenesis and to
examine the specific involvement of MMP-3 in the activation of microglia in GLD.
To this end, new models of globoid cell formation were developed to address
our questions. Using these models, the contribution of MMP-3 to the formation of globoid
cells (Chapter 3) and their function (Chapter 3 &4) was investigated. Also using this
model system, the role of the extracellular matrix (ECM) in the function of
GDL-associated microglia and globoid cells was determined.
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Table 5-1 Temporal comparisons of GLD abnormalities in the twitcher mice

References: 1) (Duchen et al., 1980), 2) (Pollanen and Brody, 1990), 3) (Nagara et al.,
1982), 4) (Takahashi and Suzuki, 1984), 5) (Taniike et al., 1999), 6) (Castelvetri et al.,
2011), 7) (Taniike and Suzuki, 1994), 8) (Ohno et al., 1993), 9) (Wu et al., 2000), 10)
(Tanaka et al., 1988), 11) (Jacobs et al., 1982)
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Our study is the first to demonstrate a role for MMPs in a leukodystrophy. Using
brains from GALC-deficient mice (twitcher mice), we determined that the expression of
MMP-3 gradually increased within the CNS of twitcher mice as their disease progressed
(Figure 3-1). Surprisingly, levels of MMP-2 and -9 were not increased in the CNS of
GLD-affected mice (Figure 5-1), despite their well-estabilshed association with CNS
inflammation (Benesova et al., 2009, Crocker et al., 2006, Hernandez-Guillamon et al.,
2012). This suggests that the predominant MMP involved in the pathogensis of GLD is
MMP-3.
To further characterize this apparent association between MMP-3 and GLD, a
novel model of globoid cell formation was developed. Globoid cells, the cell type
pathognomonic to GLD, were produced by exposing mixed glial cultures to psychosine.
This caused the microglia within the mixed glial cultures to transform into globoid-like
cells, characterized by multinucleation and a rounded morphology (Figure 3-5). This
phenomenon was consistent with two previous findings that demonstrated the ability of
psychosine to transform other cell types into multinucleated cells (Im et al., 2001,
Kanazawa

et

al.,

2000).

Moreover,

the

globoid-like

cells

produced

from

psychosine-exposed mixed glial cultures have a higher level of phagocytic activity as
compared to naïve (non-psychosine exposed) microglia (Figure 3-7). These results
complement previous reports describing that globoid cells found within the CNS of
twitcher mice possess a high degree of phagocytic activity as they invariably contain high
amounts of phagocytized materials (Itoh et al., 2002, Yunis and Lee, 1970).
Using this new model of globoid-like cell formation, the contribution of MMP-3
to globoid cell formation was investigated. First, using a pan-MMP inhibitor (GM6001), it
was demonstrated that psychosine-induced globoid cell formation was reduced,
suggesting a role of MMP in their formation (Figure 3-7). Next, the specific role of MMP-3
in globoid cell formation was investigated by using NNGH, a selective and potent inhibitor
of MMP-3. Indeed, a significant reduction of globoid cell formation was noted suggesting
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that the specific action of MMP-3 contribute to globoid cell formation (Figure 3-7). Finally,
mixed glial cultures were derived from MMP-3 knock out mice. When exposed to
psychosine, MMP-3 deficient cultures had lower levels of globoid cell formation as
compared to wild-type cultures (Figure 3-6). Overall, these data strongly suggests that
MMP-3 activity and globoid cell formation are linked.
The second part of my thesis studies focused on the role of the ECM as a
modulator of glial responses to psychosine. Cellular behaviors can be potently modulated
by the local environment, which consists of various types of ECM (Bandtlow and
Zimmermann, 2000, Franco and Muller, 2011, Liesi and Silver, 1988, Rogers et al., 1987,
Welser-Alves et al., 2011). Also, this idea is supported by studies reporting that the
composition of the ECM is altered in diseases such as multiple sclerosis (MS),
Alzheimer’s disease, focal cortical dysplasia, tumor, and subarachnoid hemorrhage
(Gutowski et al., 1999, Soares et al., 2012, Suzuki et al., 2010, Zamecnik et al., 2012,
Zamecnik et al., 2004). Thus, to better model the cellular environment of the GLD brain in
our culture systems, we began by investigating the ECM composition of twitcher mouse
brain. Our examination revealed that Tenascin-C (TnC), among the four ECM
constituents examined, was strongly expressed in twitcher brains, when compared with
age-matched wild-type mice (Figure 4-1). To examine the effect of TnC on microglial
responses to psychosine, glial cultures were established on TnC substrate, and then
challenged

by

psychosine

treatment.

We

determined

that

TnC

increased

psychosine-induced MMP-3 expression (Figure 4-3) and enhanced psychosine-induced
globoid cell formation (Figure 4-2). Interestingly, exposure of glia to TnC during globoid
cell induction by psychosine significantly altered the microglial phenotype, as measured
by oligodendrocyte death in our co-culture system. Overall, this strongly suggests that
TnC in GLD likely enhances microglial responses to psychosine and ultimately changes
microglial functionality in GLD toward a pathogenic phenotype.
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Figure 5-1 Expression levels of MMP-2 and -9 are not significantly elevated in the
twitcher brains. mRNA expression levels of MMP-2 and -9 in the brains of twitcher mice
(black bars) and age-matched wild-type controls (white bars) at P0 and P31 were
analyzed by qRT-PCR. Neither MMP-2 nor MMP-9 levels were significantly increased
compared to wild-type controls. Note that the increase of MMP-9 expression level in
twitcher mice at P0 was not statistically significant (P=0.127). N=3/genotype/age. (Ijichi &
Crocker, unpublished data)
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In other neurodegenerative and demyelinating disorders, upregulation of TnC has been
reported (Gutowski et al., 1999, Soares et al., 2012, Suzuki et al., 2010, Zamecnik et al.,
2012, Zamecnik et al., 2004); however, the factors governing TnC expression, as they
contribute to pathogenesis of these diseases has not been fully elucidated.

V-2 Discussion
V-2.1 In Vivo vs. In Vitro Globoid Cells
Globoid cells are the hallmark feature of GLD pathology, although their role in
GLD has long been ignored. Interestingly, these cells are among the earliest
characteristic changes in CNS tissue of GLD (Table 5-1). This lack of knowledge may
have been due to the assumption that the formation of multinucleated phagocytes, called
giant cells in other diseases, are typically considered as a consequence of pathology
rather than an initial pathogenic driving force (McNally and Anderson, 2011). Therefore,
there have been few studies investigating the mechanism by which globoid cells are
formed from phagocytes, particularly in the CNS of GLD. This dissertation focused on the
importance

of

globoid

cell

formation

in

the

CNS

and

demonstrated

that

psychosine-induced multinucleation of microglia in vitro exhibited higher levels of
phagocytic activity (Chapter 3). Indeed, globoid cells in twitcher brains frequently contain
PAS-positive debris, suggesting high levels of phagocytic activity. Globoid cells are also
found to be immunopositive for ferritin (a microglia marker) (Kaneko et al., 1989),
KP-1/CD68 (a monocyte marker), and some are also positive for vimentin (an
intermediate filament protein and marker of astrocytes and activated microglia)(Graeber
et al., 1988), HLA-DRa (an MHCII surface receptor), and TNF-" (Itoh et al., 2002), and
Iba-1 (a calcium binding protein used to identify microglia) (Kondo et al., 2011). Based on
the experiments in this dissertation, this collection of markers indicates that globoid cells
originate from microglia that develop a unique phenotype.
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There are several features of globoid cells that differ between in vivo and in
vitro. The average size of globoid cells found in human and murine GLD tissues range in
size from approximately 50µm to 200µm in diameter (Duchen et al., 1980, Norman et al.,
1961). However, in vitro globoid cells induced experimentally have an average diameter
of 15µm to 30µm (unpublished observation). In addition, one globoid cell in CNS tissue
can contain up to 20 nuclei (Norman et al., 1961); however, we routinely observed about
4 nuclei per globoid cell in vitro (Figure 3-5, 4-2). These differences between in vivo and
in vitro globoid cells may be explained by the cellular environment of microglia. Our
culture system significantly limits the available amount of secreted and cell-contacting
factors, cell types, dimensional space and time; thus, these limitations may be factors
underlying these discrepancies in size and complexity of in vivo versus in vitro globoid
cells.
In our studies, experimentally induced globoid cells were derived from wild-type
microglia. Wild-type glial cells express endogenous GALC, unlike cells from twitcher mice,
which lack functional GALC. Although exogenous psychosine application to wild-type
microglial cultures did not induce GALC expression (Figure 5-2), normal endogenous
GALC activity may have attenauted a more dramatic effect of psychosine on microglia.
This point could be addressed by comparing the number of psychosine-induced globoid
cells from microglia cultured from wildtype and twitcher mice. Analyses of size change,
polynucleation, cellular complexities, and even functionalities would serve to address the
question of whether globoid cell formation if further enhanced by the lack of GALC in the
culture. Nonetheless, our newly developed model of globoid–like cell production provides
a new system in which to study the process of globoid cell formation in GLD.
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V-2.2 MMP-3 and Globoid Cells in the Peripheral Systems
Several studies have reported the presence of globoid cells in the PNS, but to a
lesser extent than in the CNS (Kobayashi et al., 1985). Others reported no evidence of
globoid cells in peripheral systems (Wenger et al., 1999). These differing reports may
reflect the fact that there is currently no reliable means by which to distinguish between
CNS microglia and peripheral macrophages. To address this concern, this dissertation
studied the potential differences between microglia and macrophages with respect to
GLD pathology. Isolated microglia from the brain and macrophages from the peritoneal
cavity of wildtype mice allowed us to examine a possible difference between these types
of cells with respect to their response to psychosine treatment in vitro. Our study
demonstrated a clear difference in the response of microglia and macrophages to
psychosine. Microglia, as mentioned above, responded to psychosine with increased
MMP-3 expression and globoid cell formation, whereas macrophages exhibited no
psychosine-induced MMP-3 expression (Chapter 3); although, both populations of cells
responded robustly to LPS. Additionally, peripheral macrophages did not transform into
any multinucleated cells in response to psychosine treatment (Figure 5-3). This cellular
phenotypic difference was also supported by our observation that psychosine did not
enhance phagocytic activity in macrophages (Figure 5-3). To further examine whether
MMP-3 mRNA was upregulated in peripheral organs in GLD, as measured in CNS
tissues (Figure 3-1), MMP-3 expression level was also investigated in the spleen of
twitcher mice. Our qRT-PCR analysis determined that mRNA levels of MMP-3 did not
differ, when compared to wildtype spleen tissue (Figure 5-4). These data suggest that: (1)
microglia are the likely cell of origin for globoid cells in GLD; (2) MMP-3 is required for
psychosine-induced microglial transformation into globoid cells in response to
psychosine; and (3) macrophages and microglia are fundamentally distinct cell
populations in terms of their response to psychosine in GLD.
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Figure 5-2 Exogenous psychosine does not induce GALC expression in glial
culture. Wildtype mixed glial cultures were treated with psychosine or vehicle for 2, 4, or
20 hours and GALC expression levels were analyzed by qRT-PCR. Exogenous
psychosine application does not induce GALC mRNA expression in mixed glial culture at
any time point. (Ijichi & Crocker, unpublished data)
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Figure 5-3 Psychosine does not induce globoid cell formation and phagocytic
activity in peripheral macrophages. Peripheral macrophages isolated from peritoneal
cavity of wildtype mice were plated and treated with psychosine for 24 hours.
Macrophages were visualized and analyzed by immunocytochemistry using antibodies
against CD11b (red) and DAPI (blue) for multinucleation. Phagocytic activity of
macrophages was analyzed by FITC-labeled phagocytic bead (green) assay. Psychosine
treatment does not increase the number of globoid cells or phagocytic activity in
macrophages. N=3, 5 fields/conditions. Each field contains 50-70 DAPi+ nuclei. Scale
bars= 20µm (top), 50µm (bottom). (Ijichi & Crocker, unpublished data)
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Figure 5-4 Splenic tissue from twitcher mice does not have elevated MMP-3
expression. Splenic tissue was isolated from twitcher mice (Twi), twitcher mice treated
with bone marrow transplantation (BMT), and age-matched wildtype mice (WT), and
mRNA levels of MMP-3 were analyzed using qRT-PCR. MMP-3 level was not increased
in twitcher mice compared to wildtype. Note that BMT did not have an effect on MMP-3
expression level in the twitcher mouse spleen. (Ijichi & Crocker, unpublished data)

129

The microglial origin of globoid cells is also supported by the observation that globoid
cells are found in the CNS of both human and murine GLD prior to inflammation and
macrophage infiltration (Table 5-1)(Martin et al., 1981). Overall, our data indicate that
globoid cells originate from microglia, and thus, microglia play a prominent role in GLD
pathology.

V-2.3 Importance of ECM in Modeling Diseases
Cellular behavior is tightly regulated by the local microenvironment where cells
reside. Thus, local ECM molecules can be important mediators of cellular responses to
stimuli. Consistent with this, our study has demonstrated that TnC exerts a significant
impact on microglia and globoid cell function in response to psychosine (Chapter 4). The
enhanced expression of TnC in GLD led us to examine the effect of TnC on globoid cell
formation and we determined that TnC potently induced globoid cell formation. TnC also
enhanced cytotoxic effect of microglia toward oligodendrocytes in vitro (Figure 4-5),
whereas globoid cells formed on laminin were only mildly toxic to oligodendrocytes
(Figure 4-5). These results complement previous findings demonstrating that activated
microglia had negative effects on oligodendrocyte survival and proliferation via
mechanisms mediated by pro-inflammatory cytokines (Pasquini et al., 2007, Taylor et al.,
2010, Vartanian et al., 1995). Indeed, globoid cells in TnC-enriched cultures produced
significantly higher TNF-" expression than those grown on a laminin substrate (Figure
4-5). Levels of TNF-" released from microglia were also positively correlated with
oligodendrocyte death (Figure 4-5). Overall, these data suggest that the local ECM
microenvironment can markedly influence microglial functions in GLD.
Our results signify an important role of ECM composition in culture systems
when developing model for a disease. While pathological changes in secreted molecules,
including cytokines, chemokines and transmitters, are often reported and given
consideration in models, disease-specific ECM changes are often overlooked. As we
130

have demonstrated, ECM can be an important modulator of cellular response and
function. We propose that it is important to carefully consider and attempt to mimic the
ECM microenvironment in a disease-specific manner when investigating cellular
responses under any pathological conditions.

V-3 A Microglial Hypothesis of GLD pathogenesis: A working model and its future
directions
Results from this dissertation provide new evidence suggesting that the
activation of microglia leading to the formation of globoid cells is a primary event in GLD.
We were also the first to demonstrate a function for globoid cells by determining that
globoid cells can elicit cytotoxicity toward oligodendrocytes. These results suggest that
globoid cells in GLD can contribute directly to oligodendrocyte death and demyelination in
GLD. The psychosine hypothesis, originally described by Suzuki, proposed that GLD
pathogenesis is a cell-autonomous process driven by an intracellular accumulation of
psychosine within oligodendrocytes. However, many lines of evidence, from old and even
more recent studies, support our findings that GLD pathogenesis is a complex,
multifactorial process, wherein glial and neuronal abnormalities precede demyelination
and oligodendrocyte loss (Table 5-1). In particular, globoid cells are first observed in the
CNS of GLD before demyelination (Martin et al., 1981). From the results of this thesis, I
now hypothesize that aberrant microglial activity and globoid cell formation are primary
pathological events brought about directly in response to psychosine accumulation in
GLD. We have named this the “microglial hypothesis” of GLD (Figure 5-5).
The results in these studies support our microglial hypothesis by implicating
pathophysiological mechanisms of aberrant microglial activity in globoid cell formation
and demonstrating their contribution to demyelination to GLD pathogenesis. Key
elements of this mechanism include psychosine, microglia, globoid cells, MMP-3, and
TnC.
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Figure 5-5 Schematic flowchart of ‘conventional’ and ‘revised’ psychosine
hypothesis. Schematic drawing illustrates that the conventional psychosine hypothesis
(top) describes demyelination as a primary event and as an upstream event in GLD
pathogenesis. Revised psychosine hypothesis (bottom) depicts that psychosine
influences multiple cell types in the GLD brain and all contribute to demyelination. The
pathway in which psychosine induces globoid cell formation, leading to demyelination is
named “microglial hypothesis” (pink). Panels depicting demyelination and neuronal
damage adapted from www.mayo.edu and www.nature.com, respectively.
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In the following sections, I will discuss potential molecular mechanisms that could lead to
future research directions that may provide futher understanding and insights for GLD
pathogenesis, as outlined in this microglial hypothesis.

V-3.1 Contributions of MMP-3 in GLD Pathogenesis In Vivo
In our in vitro system, microglia transformed into multinucleated globoid cells in
response to psychosine. This phenomenon was blocked by either genetic ablation or
pharmacological inhibition of MMP-3. However, the mixed glial cultures used in these
studies were comprised of a limited number of cells, cell types, factors, time and space,
which may have been insufficient to adequately model the CNS tissue environment in
GLD. Nevertheless, our examinations of the effects of MMP-3 in GLD pathology provide a
new avenue to investigate the etiology of this disease.
One approach to further develop an understanding on the in vivo effect of
MMP-3 in GLD would be to cross-breed twitcher mice (GALCtwi/twi) with MMP-3 KO mice
(MMP-3-/-) to generate double-mutant mice. Progeny from these breedings would
generate twitcher mice that congenitally lack MMP-3 (GALCtwi/twi, MMP-3-/-). As MMP-3
would be absent throughout development in these double-mutant mice, the number of
globoid cells during fetal and perinatal period would be expected to be significantly lower
than MMP-3+/+ twitcher mice. This genetic approach to study MMP-3 in twitcher mice,
using this cross-breeding strategy, would also allow us to determine whether MMP-3
contributes to the limited lifespan of mice with GLD. Specifically, ablation of MMP-3 from
both CNS and non-CNS organs, such as astrocytes, peripheral immune cells and the
PNS, may reveal a novel global effect of MMP-3, related to improved survival and
reduced pathology. We recognize that our current limitation is that MMP-3 is not an only
factor driving the disease. In general, global MMP-3 KO mice also develop compensatory
changes in gene expression. For this reason, we would ideally target ablation in a specific
cell type, such as the astrocyte. However, any reduction in either pathology or symptoms
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in double mutant mice would serve as evidence to support the idea that MMP-3 is an
important mediator of GLD pathology.
Another strategy to examine the effect of MMP-3 on GLD pathogenesis in vivo
would be to administer a pharmacological inhibitor of MMP-3, such as NNGH, to twitcher
mice. Administration of MMP-3 specific chemical inhibitors into twitcher mice would be
expected to block MMP-3 and attenuate GLD pathology and disease course. Another
advantage of this approach would be to test whether symptomatic mice could benefit
from delayed treatments, modeling the clinical picture of this disease in human GLD.
Experimentally, MMP-3 inhibitors could also be injected directly into the CNS
parenchyma, to test whether brain levels of MMP-3 provide benefit. Currently, there are
broad-spectrum MMP inhibitors, for example batimastat, which are known to cross the
blood brain barrier (BBB) in animal models (Koutroulis et al., 2008, Mucha et al., 2007),
which could also be utilized. These pharmacological approaches would provide direct
translation to a potential clinical application and complement genetic approaches.
Chemical inhibitors of MMP-3 in twitcher mice would also allow us to examine the efficacy
of combined therapies, including MMP inhibition with HSCT, for instance. Overall,
analyses on the effects of MMP-3 inhibition in in vivo models would provide us with more
detailed insights into the contribution of MMP-3 in GLD pathogenesis, and support this
approach for potential therapeutic applications to treat this fatal disease. Doxycycline
hycate is a Food and Drug Administration (FDA)-approved MMP inhibitor that is readily
used to treat periodontal diseases (Sundararaj et al., 2013) and crosses the BBB. Thus,
MMP inhibition is a promising therapeutic approach to treat GLD.
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Figure 5-6 Schematic flowchart of potential molecular mechanisms of MMP-3
mediated globoid cell formation. Schematic drawing illustrates the potential molecular
mechanisms by which MMP-3 regulates globoid cell formation; 1) proteolysis of
substrates by MMP-3, 2) intracellular function of MMP-3, 3) proteolysis of TnC by MMP-3,
and 4) induction of integrins.
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V-3.2 Possible Mechanisms of MMP-3-mediated Globoid Cell Formation
One

principal

finding

of

our

study

was

that

MMP-3

mediates

psychosine-induced globoid cell formation. However, the molecular mechanisms
underlying how MMP-3 mediates microglial transformation to globoid cells remain elusive.
MMP-3 enzymatically targets many proteins (Table 2-2). Because of the proteolytic
nature of MMP-3, elevated expression and activity of MMP-3 by psychosine in GLD
would be expected to cleave molecular substrate(s), which would then regulate many
potential processes including multinucleation of microglia (Figure 5-6). Indeed, several
MMP-3 substrates, including TNF-", MMP-9 and EGF, have been associated with a
cytokinesis factor, CDK1, in hepatocytes (Serandour et al., 2005). Thus, globoid cell
formation may be mediated by MMP-3 proteolysis. To investigate this possibility, a
detailed proteomic profile of molecules expressed by microglia and/or produced during
globoid cell formation in vitro may be warranted. This examination would be expected to
reveal not only the MMP-3 substrates involved in the mechanism of globoid cell formation,
but may also provide novel targets to study their roles in globoid cell formation and
features.
Interestingly, a recent study by Eguchi et al. has suggested a novel intracellular
function of MMP-3. Their study demonstrated that nuclear MMP-3 protein bound to the
promoter enhancer sequences of connective tissue growth factor (CTGF) gene and
activated CTGF transcription in chondrocytes (Eguchi et al., 2008). Thus, it is possible
that intracellular MMP-3 in microglia may regulate transcription of target genes, which
may contribute to the failure of cytokinesis, culminating in globoid cell formation
(Kanazawa et al., 2000). Additionally, it has been proposed that MMP-3, when localized
to the nucleus, may alter the nuclear matrix, thus potentially contributing to genetic or
epigenetic defects in disease (Si-Tayeb et al., 2006). It is possible that multinucleation of
microglia in response to psychosine may be due to an altered nuclear matrix resulting
from increased intracellular MMP-3 activity (Figure 5-6). Together, increased MMP-3 in
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GLD may have nuclear localization and intracellular or transcriptional effects that
contribute to multinucleation of microglia in response to accumulated psychosine. To
address this possibility, a detailed localization analysis of intracellular MMP-3 within
microglia, in response to psychosine, would be essential. In addition, examination of the
changes in the microglial nuclear matrix may also reveal a possible aberrant intracellular
effect

induced

by

psychosine.

Furthermore,

transcriptome

analyses

of

psychosine-exposed microglia, and psychosine-induced globoid cells, may uncover a
gene activation profile that could then be used to identify novel key mediators of
microglial activation and pathology associated with GLD. Overall, examination of the
molecular and genetic profiles within psychosine-treated microglial and globoid cells
could provide new insight into GLD pathology.

V-3.3 TnC Contributions to GLD Pathogenesis In Vivo
This dissertation identified that local aberrant production of TnC modulates the
effects of psychosine on microglia in vitro (Chapter 4). Our in vitro studies indicate a need
to explore the effects of TnC on microglia in GLD using animal models. The genetic
crossing of twitcher mice (GALCtwi/twi) with TnC KO mice (TnC-/-) (Steindler et al., 1995) to
produce a double-mutant mouse (GALCtwi/twi, TnC-/-) may be one approach to address this
question. Cross-breeding of these two genetically modified mouse lines would generate
not only targeted genotypic mice (double mutant; GALCtwi/twi, TnC-/-) but also various
littermate controls, wildtype (GALC+/+, TnC+/+), twitcher mice (GALCtwi/twi, TnC+/+) and TnC
KO mice (GALC+/+, TnC-/-), that would be necessary to properly evaluate the outcomes of
survival, pathology and globoid cell formation. Genetic ablation of TnC in twitcher mice
would be expected to determine the effects of TnC on global cellular pathology in GLD
and an overall impact of TnC on GLD pathogenesis. Based on the data provided by our in
vitro study, a double mutant mouse would be expected to develop fewer globoid cells and
less M1 phenotype microglia; thus, less myelin pathology. These effects in double mutant
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mice would also be expected to improve their mobility and may also significantly extend
their lifespan. The effects of TnC in peripheral cell infiltration in GLD could also be tested
by application of HSCT in double mutant mice. As increased TnC has been associated
with vascular abnormality (Chinoy and Miller, 2006), peripheral cell trafficking in double
mutant mice treated with HSCT would be less. It is important to note that TnC KO mice
that lack TnC globally have been reported to develop minor behavioral abnormalities,
when challenged (Kiernan et al., 1999). If the minor abnormalities associated with global
TnC ablation significantly interfere with clinical phenotypes in double mutant mice, cell
type-specific conditional TnC KO mice could be generated, and then crossed with
twitcher mice. However, the cellular source of TnC in twitcher mouse brain would first
need to be determined. For instance a cell-specific TnC knockout mice could also be
produced using Cre-loxP technology. Using a yet to be developed TnC mouse line in
which a critical regualtory or coding region of TnC is flanked by loxP sites would enable
cell-specific deletion of TnC. Were these TnCfl/fl mice to then be crossed mice that
express the Cre-recombinase driven by a cell-specific promoter, such as a GFAP-Cre line,
the progeny would then have TnC specifically lost from their astrocytes (Garcia et al.,
2004). Cell-specific TnC KO mice could then be cross-bred with twitcher mice to generate
a triple mutant line for detailed study. Overall, findings from these mutant mice would be
expected to provide novel mechanistic insights to the contribution of TnC in GLD
pathogenesis.

V-3.4 TnC as an MMP-3 Proteolytic Target in GLD Pathology
TnC is a proteolytic substrate of multiple extracellular enzymes, including MMP-3. Thus, it
is possible that cleavage of TnC occurs during the pathogenesis of GLD. One likely
candidate for this proteolytic processing is MMP-3, which is known to be upregulated in
GLD. Several TnC isoforms are known to be cleaved by MMP-3 (Siri et al., 1995).
Cleavage of TnC and its potential for altered functions have been implicated in other
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pathological conditions, including periodontitis and Crohn’s disease (Ambort et al., 2010,
Ruggiero et al., 2013). This dissertation showed that there was an aberrantly high level of
TnC expression in the CNS of twitcher mice. One aspect of TnC biology that was not
addressed was whether observed plaques of TnC included cleaved TnC fragments
(Figure 5-6). To address this question, Western blotting analyses of brain homogenates
from twitcher mice could be useful. Indeed, our preliminary analysis showed that the CNS
tissue from twitcher mice contained a higher level of proteins at low molecular weights,
when compared to wildtype mice (Figure 5-7). However, the reliability and specificity of
the TnC antibody need to be confirmed using TnCKO brain tissue samples. TnC isoforms
may also be localized by immunohistochemistry in twitcher CNS tissue, which may lend
additional support to our ECM hypothesis describing microglial functions in GLD. Overall,
identification of TnC isoforms and their effects on cellular behaviors may be expected to
reveal additional pathophysiological mechanisms in GLD.

V-3.5 Integrins: TnC receptors in GLD Pathogenesis
A possible mechanism by which TnC may influence microglial
function is via their nteraction with integrins (Figure 5-6). Integrins comprise a family of
transmembrane heterodimers expressed by multiple cell types. Integrins are well-known
ECM receptors that are important for cell-cell contact, cellular migration and signaling
(Takada et al., 2007). TnC is known to bind to multiple integrins, including "4!1, "5!1,
"7!1, "9!1, "8!1, and "v!3 (Hauzenberger et al., 1999, Loike et al., 2001, Meiners and
Mercado, 2003, Milner and Campbell, 2002). It has been reported that microglia express
"v!3, "4!1 and "5!1 integrin subunits (Milner, 2009). However, levels of integrin
expression in the GLD brain have not yet been investigated. Future analyses of integrin
expression, the CNS cell types that express them and their regulation by psychosine may
provide potential integrin-mediated mechanisms underlying altered signaling leading to
globoid cell formation in GLD.
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Figure 5-7 Twitcher brains contain higher levels of small TnC fragments. Total
protein from brain homogenates of P20 and P31 twitcher mice and age-matched wildtype
controls were separated in polyacrylamide gel by size, and TnC fragments were
visualized by Western blot using an antibody against TnC (top). Red arrows indicate the
higher levels of small (low molecular weight) TnC fragments in the twitcher brains as
compared to wildtype brains. Bottom gel image shows that loaded amount of protein
samples between lanes was relatively consistent, determined by !-actin staining. (Ijichi &
Crocker, unpublished data)

140

TnC can also bind other ECM molecules, like fibronectin, which is also mediated by
interactions by integrins (Hauzenberger et al., 1999). In this way, altered TnC and/or
integrin expression may possibly disrupt the homeostatic support by ECM in the GLD
brain. Overall, identification of integrin involvement would be expected to shed light on
TnC-mediated pathophysiological mechanisms in GLD.

V-3.6 Contribution of Microglia in GLD Pathogenesis In Vivo
We determined that aberrant activity of microglia in response to psychosine
had a dramatic effect on oligodendrocyte survival. Surprisingly, we determined that
globoid cells derived on laminin were less toxic to oligodendrocyte than untreated
microglia, and globoid cells when grown on TnC reversed this beneficial effect. When
considered in the context of GLD pathology, the activation of microglia and globoid cell
formation have been found to precede other pathological findings, including
demyelination and oligodendrocyte death (Table 5-1). Thus, activation of microglia may
contribute importantly to pathology by driving the innate inflammatory process and even
contributing to oligodendrocyte death and demyelination. To examine the contribution of
microglia to GLD pathogenesis, experiments using transgenic mice in which microglia
can be selectively abolished could be performed. Twitcher mice could be cross-bred with
a transgenic mouse line that can selectively kill all CD11b+ cells in a ganciclovir-inducible
manner (CD11b-HSVTK) (Heppner et al., 2005). Treating double-mutant mice (GALCtwi/twi,
CD11b-HSVTK) with oral ganciclovir would effectively eliminate microglia and
macrophages in the twitcher mouse background. This strategy would allow us to control
the timing of microglial ablation by altering the initiation and duration of oral treatment. In
this way, we could examine how microglia contribute to the pathogenesis of GLD and the
potential for differential effects at different time points of preclinical and clinical disability in
twitcher mice. However, prenatal microglial ablation in prenatal or neonatal ganciclovir
treatment of CD11b-HSVTK mice and the possible impact on development are unknown.
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Another way to address the role of microglia in twitcher mice would be to
administer liposome-encapsulated clodronate (Kohl et al., 2003). Clodronate is an agent
selectively toxic to phagocytes (i.e., microglian and macrophages) in living animals, which
has been shown to successfully eliminate microglia in utero (Cunningham et al. , 2013).
In a previous study on a mouse model of ALS, when microglia were eliminated by
clodronate followed by HSCT, microglia were replaced with grafted hematopoietic-origin
cells, which resulted in reduced disease progression (Lee et al., 2012). This approach
could provide us with temporal control of microglial elimination, when used in conjunction
with the CD11b-HSVTK mouse and would be expected to establish the role microglia in
twitcher mice.

V-4 Therapeutic Applications of Our Findings
A current therapeutic option for GLD, HSCT, is effective only when
administered during the pre-symptomatic period of GLD (Duffner et al., 2009). The earlier
HSCT is provided to GLD patients, the more effective it is (Duffner et al., 2011, Wenger et
al., 2000). This fact strongly suggests that pathological mechanisms that hamper the
effect of HSCT emerge as the disease progresses. Very early stages of GLD
pathogenesis, which include astrocytic and microglial activation, may be effectively
altered by HSCT but timing for this intervention may be crucial. Indeed, aberrant
microglial activity has been discussed as a potential limiting factor for the efficacy of
HSCT in GLD (Pellegatta et al., 2006). To date, there are no therapeutic agents that
selectively target astrocytes and/or microglia. However, it may be possible to selectively
inhibit key factors in GLD pathogenesis, such as MMP-3, as suggested by our study.
Indeed, our study demonstrated that the level of MMP-3 in the brain of twitcher mice
treated with HSCT remained high (Figure 3-7), suggesting that high level of MMP-3 may
be a factor contributing to the limited efficacy of HSCT.
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As mentioned above, there are no MMP-3-specific inhibitors that can readily
cross the BBB. It is interesting to note that minocycline, a FDA-approved
tetracycline-class antibiotic, has been shown to inhibit MMP-3 in the brain (Garrido-Mesa
et al., 2013, Masocha et al., 2006). In a trypanosomiasis infection model, it was
demonstrated that systemic application of minocycline effectively inhibited MMP-3 and
had the benefit of preventing production of numerous pro-inflammatory cytokines,
including TNF-", IL-1!, and IL-6 (Masocha et al., 2006). Minocycline also reduced
numbers of active astrocytes and microglia in this model (Masocha et al., 2006).
Importantly, minocycline-treated twitcher mice from P5 exhibited significantly lower levels
of aforementioned pro-inflammatory cytokines and minocycline increased the lifespan of
twitcher mice by 21% (Luzi et al., 2009). Based on the report that minocycline can inhibit
MMP-3, it would expected that minocycline-treated twitcher mice would have lower
MMP-3 levels in their brains compared to untreated twitcher mice, and possibly less
globoid cell formation. This previous study, however, did not examine the potential of
minocycline as an adjunct therapy with HSCT in GLD. As minocycline counteracts
multiple inflammatory elements, including pro-inflammatory cytokine production, reactive
astrocytosis and microgliosis, it has also been proposed as a neuroprotectant (Chen et al.,
2011). Therapeutic uses of minocycline in GLD may hold promise and may be expected
to significantly impede the disease progression of GLD. Overall, the findings of this
dissertation have provided a new level to our understanding of GLD pathogenesis and
provided new therapeutic targets to treat GLD, a currently fatal and incurable disease.
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